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THE SURPRISING REACH OF FDA
REGULATION OF CANNABIS,
EVEN AFTER DESCHEDULING
SEAN M. O’CONNOR*
ERIKA LIETZAN**
As more states legalize cannabis, the push to “deschedule” it from the
Controlled Substances Act is gaining momentum. At the same time, the Food
and Drug Administration (FDA) recently approved the first conventional drug
containing a cannabinoid derived from cannabis—cannabidiol (CBD) for two
rare seizure disorders. This would all seem to bode well for proponents of full
federal legalization of medical cannabis. But some traditional providers are
wary of drug companies pulling medical cannabis into the regular small
molecule drug development system. The FDA’s focus on precise analytical
characterization and on individual active and inactive ingredients may be
fundamentally inconsistent with the “entourage effects” theory of medical
cannabis. Traditional providers may believe that descheduling cannabis would
free them to promote and distribute their products free of federal intervention,
both locally and nationally. Other producers appear to assume that descheduling
would facilitate a robust market in cannabis-based edibles and dietary
supplements. In fact, neither of these things is true. If cannabis were descheduled,
the FDA’s complex and comprehensive regulatory framework governing foods,
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drugs, and dietary supplements would preclude much of this anticipated
commerce. For example, any medical claims about cannabis would require the
seller to complete the rigorous new drug approval process, the cost of which will
be prohibitive for most current traditional providers. Likely also unexpected to
some, there is no pathway forward for conventional foods containing cannabis
constituents, with the (probably exclusive) exception of certain hemp seed
ingredients, if those foods cross state lines. And it will certainly come as a shock
to many that federal law already prohibits the sale of dietary supplements
containing CBD—including those already on the market as well as those made
from “hemp,” which has recently been descheduled under the 2018 Farm Bill.
This Article describes in detail the surprising reach of the FDA and then outlines
three modest, but legal, pathways forward for cannabis-based products in a
world where cannabis has been descheduled.
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INTRODUCTION
As a number of states have legalized cannabis—at least for state law
purposes—a quasi-licit above-ground industry has emerged.1 This
industry is enormous, with estimates into the billions of dollars of
annual revenues.2 Along with this economic opportunity, one of the
selling points of legalization for voters is that an illicit and often
dangerous underground industry will be transformed into a safe and
well-regulated one.3
Yet, “marihuana”—defined to include much of what is derived from
the plant Cannabis sativa L.4—is still illegal under the federal
Controlled Substances Act (CSA).5 “Marihuana” is expressly listed in
Schedule I of the CSA,6 which means there were government findings,
credible or not,7 that: (1) it “has a high potential for abuse”; (2) it “has
1. State Medical Marijuana Laws, NAT’L CONF. ST. LEGISLATURES (Oct. 17, 2018),
http://www.ncsl.org/research/health/state-medical-marijuana-laws.
2. See, e.g., Thomas Pellechia, Legal Cannabis Industry Poised for Big Growth, in North
America and Around the World, FORBES (Mar. 1, 2018), https://www.forbes.com/
sites/thomaspellechia/2018/03/01/double-digit-billions-puts-north-america-in-the-w
orldwide-cannabis-market-lead (estimating North American industry revenues in 2017
at $9.2 billion).
3. See, e.g., 2013 Wash. Legis. Serv. Ch. 3 § 1 (West) (“The people intend to stop
treating adult marijuana use as a crime and try a new approach that: . . . (3) Takes
marijuana out of the hands of illegal drug organizations and brings it under a tightly
regulated, state-licensed system similar to that for controlling hard alcohol.”).
4. 21 U.S.C. § 802(16) (2012). For further details on the origin and exact scope
of this definition, see infra Part II.
5. 21 U.S.C. §§ 801–904.
6. See § 812(c), Schedule I(c)(10).
7. Am. Coll. Physicians, Supporting Research into the Therapeutic Role of
Marijuana: An Addendum by the Health and Public Policy Committee 17 (2008)
(“Considering the evidence available today about the potential therapeutic benefits
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no currently accepted medical use in treatment in the United States”;
and (3) “[t]here is a lack of accepted safety” for use of the drug or
other substance under medical supervision.8 Tetrahydrocannabinols
(THC) and cannabimimetic agents (compounds that mimic the effects of
cannabinoids) are also listed in Schedule I.9 Manufacturing, distributing,
dispensing, or possessing with the intent to do any of the foregoing is
allowed under the CSA only for individuals who have been issued a so-called
“Schedule I license.”10 These licenses are rare and hard to come by.11
The Department of Justice (DOJ), and more specifically, the Drug
Enforcement Agency (DEA) generally enforce the CSA.12 Their
actions with regard to illicit trade in drugs are usually perceived to be
straightforward criminal prosecutions: “Miami Vice”- or “Cops”-style
drug busts.13 There is a misperception that such enforcement is not
available in states with recreational or medical marijuana laws, at least
with regard to state law-compliant cannabis enterprises.14 The reality

and risks associated with marijuana and its cannabinoids, ACP believes that it is time
to review the evidence to determine whether reclassification is appropriate.”).
8. § 812(b)(1)(A)–(C); see also infra Part II.
9. See § 812(c); § 812(d)(2)(A).
10. §§ 821–823; Synthetic Drugs, Real Danger: Hearing Before the Subcomm. on
Crime, Terrorism, Homeland Sec. & Investigations of the H. Comm. on the Judiciary,
114th Cong. 4 (2016) (statement of David Earl Nichols, Ph.D., Adjunct Professor of
Chemical Biology and Medicinal Chemistry at the University of North Carolina at
Chapel Hill, NC) (“Obtaining a Schedule I license is not a trivial matter . . . . [T]he
investigator must have a strong personal belief that something useful will be discovered
by their research that is of sufficient importance to justify the regulatory demands of a
Schedule I license. To wit, a researcher must submit an application to the DEA that
includes the investigator’s scientific credentials, the description of the laboratory, a
precise description of the work to be carried out, listing the specific substance to be
used, and a calculation of how much substance will be needed and for how long. If
the DEA determines that the . . . license is justified, there is then an inspection of the
storage facility . . . to ensure that the controlled substance cannot be easily
diverted . . . . Inventory and use must be documented, and there is a license fee for
most non-public institutions.”).
11. See NAT’L ACADS. SCIS. ENG’G & MED., THE HEALTH EFFECTS OF CANNABIS AND
CANNABINOIDS: THE CURRENT STATE OF EVIDENCE AND RECOMMENDATIONS FOR RESEARCH
378–84 (2017) [hereinafter THE HEALTH EFFECTS OF CANNABIS].
12. BRIAN YEH, CONG. RESEARCH SERV., RL34635, THE CONTROLLED SUBSTANCES
ACT: REGULATORY REQUIREMENTS 1 (2012).
13. See Sean M. O’Connor & Jason Liu, The Risks of Clouded Property Title for Cannabis
Business Owners, Investors, and Creditors, 3 TEX. A&M J. PROP. L. 67, 68 (2016).
14. See id. (“[B]ecause federal law does not distinguish between shadowy
underworld drug deals and the clean, well-lit places licensed and regulated under the
new state-legal regimes, all of the forfeiture rules apply equally to both. Accordingly,
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here again is further complicated by current DOJ policy and by an
annual congressional appropriations rider prohibiting the use of funds
for cannabis prosecution.15 Aside from cannabis drugs approved by
the Food and Drug Administration (FDA), and cannabis production
and research licensed by the National Institute of Drug Abuse (NIDA),
all cannabis production, distribution, or sale violate federal criminal
law under the CSA.
State decriminalization of medical marijuana (MMJ) in the 1990s
began flipping this dynamic.16 At the same time, even the federal
government was forced to provide cannabis to some patients under
“compassionate use” programs.17 Accordingly, the DOJ and the DEA
did not act as aggressively as they could have in relation to cooperatives
and dispensaries operating under first California’s, and then other
states’, MMJ quasi-legal frameworks.18 An uneasy partial truce was
established for patients who grew their own MMJ for personal use
because this was a grey area under the CSA as it did not involve
distributing or dispensing the substance to others, and the
“manufacturing” and possession was not for the purpose of distributing
or dispensing to others either.
This was the opening for cooperatives, and ultimately, dispensaries:
if a patient can grow cannabis for her own personal use, then she
should also be able to share resources for growing with other MMJ
patients. Accepting this premise, courts also had difficulty settling on
anything like a uniform minimum level of patient-member
participation, and so soon, effectively non-working members were
allowed.19 All that was needed was the minor formality of a member
card showing one had joined the co-op, perhaps with a doctor’s note
recommending cannabis to alleviate some symptoms.20

the façade of legitimacy and regularity rapidly attaching to the most well-intentioned
state-legal cannabis businesses is, of course, quite illusory.”).
15. See infra Part II.
16. See id. at 71–72.
17. See infra Part III.
18. See infra Part II.
19. See Alex Kreit, Reflections on Medical Marijuana Prosecutions and the Duty to Seek
Justice, 89 DENV. U. L. REV. 1027, 1041–44 (2012) (discussing various court decisions
on how much participation is required of a member of a marijuana cooperative).
20. See Gerald Caplan, Medical Marijuana: A Study of Unintended Consequences, 43
MCGEORGE L. REV. 127, 144 (“Routinely identifying individuals who are growing more
than the number of plants legally allowed, who purchased a fake recommendation or
forged one themselves . . . is impossible, except by happenstance.”). Thus, case law
soon established a free-speech right for doctors to recommend, but not necessarily
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With state MMJ laws enabling these quasi-licit cannabis enterprises—
effectively commercial businesses—and DOJ and DEA restraining their
enforcement efforts under the CSA, other federal regulatory agencies
began treating these operations as any other (licit) businesses.
Nevertheless, cannabis and illicit drug operations can violate a host of
other federal laws and regulations beyond the CSA—e.g., dumping
pollutants, dangerous work environments (to put it mildly), using
banned or improper pesticides, and discriminatory employment and
business practices.21
However, the respective federal agencies
enforcing these laws traditionally have not been on the front lines with
the DEA, busting down doors of derelict warehouses.22 To be clear,
many MMJ co-ops and dispensaries appear to be well-run and
compliant with laws and regulations. And some that were not fully

“prescribe,” cannabis to clients. E.g., Conant v. Walters, 309 F.3d 629, 639 (9th Cir.
2002) (“[W]hether a doctor-patient discussion of medical marijuana constitutes a
‘recommendation’ depends largely on the meaning the patient attributes to the
doctor’s words. This is not permissible under the First Amendment.”). Excellent
summaries of this history can be found elsewhere. See generally DOUGLAS A. BERMAN &
ALEX KREIT, MARIJUANA LAW AND POLICY (forthcoming 2019); ROBERT A. MIKOS,
MARIJUANA LAW, POLICY, AND AUTHORITY (2017); Kathleen Ferraiolo, From Killer Weed to
Popular Medicine: The Evolution of American Drug Control Policy, 1937–2000, 19 J. POL’Y.
HIST. 147 (2007).
21. Stephen Lee, Workplace Violations Found in Marijuana Sector, BLOOMBERG L.:
OCCUPATIONAL SAFETY (Aug. 27, 2015), https://www.bloomberglaw.com/document/
X60LREIK000000 (reporting on workplace hazards associated with the marijuana
industry); Bart Schaneman, Costly Employment-Related Lawsuits on the Rise in Cannabis
Industry as MJ Workforce Grows, MARIJUANA BUS. DAILY (Oct. 18, 2017),
https://mjbizdaily.com/costly-employment-related-lawsuits-rise-cannabis-industry-mjworkforce-grows (reporting on “an increasing number of lawsuits over everything from
wrongful termination and discrimination to sexual harassment”); Shannon Service,
Pot: Not so Green After All?, PBS: NEED TO KNOW (May 21, 2010), http://www.pbs.org
/wnet/need-to-know/environment/pot-not-so-green-after-all (discussing the marijuana
industry’s environmental impact, including diesel spills and toxic pesticides that wash
into rivers).
22. See Lee, supra note 21 (explaining that “because marijuana remains an illegal
narcotic at the federal level, the EPA hasn’t taken action, leaving growers in murky
legal terrain,” and reporting that the Occupational Safety and Health Administration
is collaborating with Colorado’s health department on “advisory efforts”). The
exception might be the Internal Revenue Service (IRS), which has had a surprisingly
prominent role taking down gangsters and criminals for tax evasion since the early
twentieth century. See, e.g., United States v. Hurley, 957 F.2d 1, 2, 7–8 (1st Cir. 1992)
(upholding a jury verdict that found two lawyers guilty of conspiracy to defraud the
Internal Revenue Service because they had helped a drug smuggler hide millions of
dollars earned from distributing marijuana and hashish).
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compliant may have been the result of good faith lack of knowledge,
especially given their largely unregulated status.
At the same time, MMJ regime enterprises were fairly restrained
affairs with little open advertising or public promotion. The physical
sites of dispensaries were generally nondescript, with little to indicate
what was going on inside other than the ubiquitous green crosses seen
in robust MMJ states like California, Oregon, and Washington.
Accordingly, federal agencies of all kinds took a hands-off approach to
these ventures, leaving regulation to the states.
Our focus here is on the FDA. Under MMJ regimes, whatever
medical or health claims were being made occurred either in semiprivate conversations in dispensaries, among users in person, or in
chat-room-type environments on the internet. With little evident
interstate activity—mandated, in fact, by the state MMJ laws
themselves—the FDA’s jurisdiction under the Federal Food, Drug, and
Cosmetic Act (FDCA)23 was limited. Enacted under the Commerce
Clause,24 the FDCA permits the FDA to regulate only products that
travel or have traveled in interstate commerce, as discussed in more
detail in Part III. However, with both recreational and medical
cannabis businesses emboldened by state legalization, overt marketing
and sales activities in interstate commerce prompted the FDA to take
enforcement action, also as reviewed in Part III. One of the Authors
has had significant discussions with the state-legal recreational and
medical industries and can report that FDA regulation is poorly
understood and largely ignored for the time being.25
At the same time, this grey market for medical cannabis under state
MMJ regimes was highly advantageous for those who wished “to do
good and do well” in the industry.26 While recent state regimes for
legal recreational cannabis have heavily taxed various levels of the
production value chain, state MMJ regimes generally did not tax
23. 21 U.S.C. §§ 301–399h (2012).
24. U.S. CONST. art. I, § 8, cl. 3 (“The Congress shall have Power . . . [t]o regulate
Commerce with foreign Nations, and among the several States, and with the Indian
Tribes . . . .”).
25. See Lee, supra note 21 (“Because growers, processors and sellers in states where
marijuana is now legal have operated outside the law for so long, they have learned to
ignore federal and state regulations . . . .”).
26. See Terra Carver, Executive Director, Humboldt County Growers Alliance, INFOCAST
(Oct. 3, 2018), https://infocastinc.com/market-insights/cannabis/terra-carverhumboldt-county-growers-alliance (commenting that “the combined medical and
adult-use [marijuana] market may be worth $5 billion by 2019 in California alone,”
and mentioning that cannabis use appears to displace opioid use to some extent).
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medical cannabis.27 Part of this was because no sales of goods were
supposed to be occurring: again, the idea was that all patients would
participate in a co-op-type structure to produce communally the product
they all used, or patients would produce solely for their personal medical
cannabis use.28 Nonetheless, with low tax, little to no regulations that
regular commercial businesses are subject to, and a growing influx of
essentially recreational users, the dispensaries did quite well.29 Further,
long-standing loyalty to producers and dispensaries that provided
consistent strains with perceived or quantifiable effects—for both
medical and recreational purposes—ensured stable customer bases.30
Unsurprisingly then, many of these enterprises were wary of—or
actively opposed—legalization efforts for recreational use.31 Correctly,
they sensed that legalization would bring full regulation and taxation,32
not to mention broad free-market competition and a commoditized
vice approach to cannabis (in which cannabis would be regulated and

27. See, e.g., Taxes Due on Marijuana, WASH. DEP’T OF REVENUE,
https://dor.wa.gov/print/46568 (last visited Feb. 5, 2019). But see Lisa Rough,
Cannabis Tax Rates: A State by State Guide, LEAFLY, https://www.leafly.com/news
/industry/marijuana-tax-rates-by-state (listing Alaska, California, Delaware, District of
Columbia, Maine, Massachusetts, New Hampshire, New Mexico, North Dakota,
Oregon, Vermont, and West Virginia among the states that did not tax medical
cannabis as of late 2017).
28. See, e.g., WASH. REV. CODE § 69.51A.085 (2011) (repealed 2016) (providing that
“qualifying patients” could participate in collective gardens for growing cannabis, but
prohibiting more than ten qualifying patients per garden along with the delivery of
cannabis to anyone other than the collective garden’s qualifying patients).
29. From Less than $100K to Millions of Dollars, Annual Marijuana Dispensary Revenues
Run the Gamut, MARIJUANA BUS. DAILY (Apr. 10, 2013), https://mjbizdaily.com/fromless-than-100k-to-millions-of-dollars-annual-marijuana-dispensary-revenues-run-thegamut (discussing the self-reported annual revenues of MMJ dispensaries, with 15%
reporting less than $100,000; 27% reporting between $100,000 and $250,000; 18%
reporting between $250,000 and $500,000; 15% reporting between $500,000 and $1
million; and 25% reporting over $1 million).
30. See, e.g., What Do Marijuana Strain Names Mean? Does it make a Difference?,
GROWNROGUE, https://www.grownrogue.com/meaning-marijuana-strain-names (last
visited Feb. 5, 2019) (describing how customers look for quality and consistency when
checking their preferred strains and dispensaries, often relying on characteristics such
as flower, aroma, taste, and how the strains make them feel).
31. Evan Puschak, Why the Medical Marijuana Industry Opposes Full Legalization,
MSNBC: THE LAST WORD WITH LAWRENCE O’DONNELL (July 29, 2013, 11:07 PM),
http://www.msnbc.com/the-last-word/why-the-medical-marijuana-industry-opposes.
32. See, e.g., 2013 Wash. Legis. Serv. Ch. 3 (I.M. 502) §§ 26–27 (West).
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sold similar to alcohol and tobacco).33 None of this would have been
particularly helpful to medical cannabis enterprises, although one could
argue that legalization at the federal level would remove the ongoing
threat of prosecution under the CSA. Some medical cannabis
proponents thus focused on rescheduling cannabis so that it would be
treated like a prescription drug, rather than a narcotic with “no currently
accepted medical use.”34 Rescheduling theoretically could have kept it
from becoming a commoditized vice substance, while also opening a path
to federally-compliant prescriptions under FDA and DEA regulations.
State legalization for recreational purposes has indeed not been
great for medical cannabis businesses. First, there has been a flood of
commercial cannabis businesses into states that have legalized
cannabis, which has been tempered only by limits on the number of
grower, processor, and retailer licenses that these states are willing to
grant.35 Second, in some states, medical cannabis businesses have had
to become licensed for the new regulated and taxed recreational
systems.36 Third, and most challengingly, the FDA has increased its
enforcement in light of widespread public advertisements and
promotions, including medical claims, by commercial medical
cannabis outfits.37 Unlike these commercial medical cannabis outfits,
the dispensaries had been very low-key and discrete in their public
advertising and promotions, largely because this was also a grey area
under state MMJ laws.38 With general legalization in various states
allowing for a higher and more explicit level of branding, advertising,
marketing, and promotion than was allowed in the medical cannabis

33. Vice Wars: Tobacco, Alcohol and the Rise of Big Marijuana, NBC NEWS (Nov. 22,
2014, 1:46 PM), https://www.nbcnews.com/storyline/legal-pot/vice-wars-tobaccoalcohol-rise-big-marijuana-n253801.
34. 21 U.S.C. § 812(b)(1)(B) (2012); see also Grace Wallack & John Hudak, Marijuana
Rescheduling: A Partial Prescription for Policy Change, 14 OHIO ST. J. CRIM. L. 207, 208 (2016)
(noting arguments that a Schedule change for marijuana might “better reflect[] the
medical, safety, chemical, and pharmacological realities of the substance”).
35. See, e.g., Marijuana Licensing, WASH. STATE LIQUOR & CANNABIS BD.,
https://lcb.wa.gov/mjlicense/marijuana-licensing (last visited Feb. 5, 2019).
36. See, e.g., id.
37. See infra Part III.
38. See THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 68–69, 72–73 (“Medical
cannabis law and policies vary greatly in terms of the regulations governing supply and
use . . . . Some states protect and regulate the operation of storefronts known as
dispensaries . . . . Some dispensaries openly advertise their wares and services to
patients at point of sale, with others aggressively promoting their business to the
general public.”).
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regimes, the race is now on to sell one’s expertise, services, and
product attributes in whatever way one can.
The end result may be the FDA cracking down hard—perhaps in
conjunction with state governments—on medical claims and any
positioning of cannabis products as medical without successful
completion of the arduous and expensive new drug application (NDA)
process.39 Further, given the high degree of reproductive variability of
cannabis, as indicated by new genetic tests being done on a range of
samples,40 it is unlikely that the psychoactive part of cannabis in its
natural state, and the way in which it is traditionally rolled and smoked,
would give anywhere near the predictable and quantifiable product
and clinical test results needed to satisfy the FDA under the NDA
process.41 While proponents of medical cannabis may assume that the
flower could simply be marketed as a dietary supplement outside the
new drug framework, dietary supplement options are quite limited.42
Nor is marketing of medical cannabis in food an easy alternative, given
the FDA’s complex framework for food regulation and its interaction
with the new drug framework.43
After all, there were very good reasons why Congress passed the Pure
Food and Drugs Act in 1906,44 and its successor, the FDCA, in 1938.45
Reformers at the turn of the last century and in the early decades of
the twenty-first century sought to protect consumers from tainted,
adulterated, toxic, mislabeled, or ineffective “patent medicines” and
proverbial snake oils.46 This is not to disparage or discredit medical
cannabis as a general matter, but rather to say that there is good reason
to require clinical proof that any particular product or process has the
actual therapeutic benefits that are claimed (i.e., that the product or
process is effective), and that it is safe enough for the indicated use. The
question of federal regulation of medical cannabis is thus complex.
This Article focuses only on regulation under the FDCA, in the event
that cannabis is descheduled from the CSA, and for certain products

39. See infra Section III.A.
40. See infra Part II.
41. See infra Section III.A.
42. See infra Section III.C.
43. See infra Section III.B.
44. Pub. L. No. 59-384, 34 Stat. 768 (1906).
45. Pub. L. No. 75-717, 52 Stat. 1040 (1938) (codified as amended at 21 U.S.C.
§§ 301–399h (2012)).
46. See Erika Lietzan, The Drug Innovation Paradox, 83 MO. L. REV. 39, 46–50 (2018)
(cautioning that “‘patent medicines’ . . . should not be confused with ‘patented’ drugs”).
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derived from the newly descheduled “hemp.”47 While some might
suspect that a Congress willing to deschedule cannabis would be
willing to amend the FDCA to allow the free-form expansion of
medical cannabis production, marketing, and sale that some
proponents and commentators advocate,48 this does not necessarily
follow. Indeed, FDA Commissioner Scott Gottlieb laid out the
compelling reasons why FDA should continue to regulate not only
hemp products, but any product containing substances classified as a
drug by the FDA—which includes THC and cannabidiol (CBD)—or
for which medical claims are made, regardless of their CSA status.49
The Article chooses descheduling over rescheduling because it calls
the relevant questions of FDA regulation into starker relief and
because it may be more politically feasible than conventional wisdom
holds—especially with both Democrats and Republicans now
espousing states’ rights.50 Further, the analysis for rescheduling is
effectively contained within that for descheduling. In particular, many
Democrats and progressives would like to see the federal government
allow state legal cannabis systems to expand with no threat of
intervention, even as President Trump has signaled a willingness to
allow the states to decide for themselves (with states’ rights long a
plank in Republican party politics).51
47. See supra notes 225–28, 406.
48. Frank Robison, Going Green: Legal Considerations for Marijuana Investors and
Entrepreneurs, 6 AM. U. BUS. L. REV. 57, 79–80 (2016) (“[T]he marijuana industry’s best,
perhaps only, hope to achieve commercial parity with other industries is for the federal
government to eliminate marijuana as a Schedule I controlled substance. This,
however, will alter the legal and commercial landscape altogether . . . .”).
49. Statement from FDA Commissioner Scott Gottlieb, M.D., on Signing of the
Agriculture Improvement Act and the agency’s regulation of products containing
cannabis and cannabis-derived compounds (Dec. 20, 2018) [hereinafter Statement on
Signing of the Agriculture Improvement Act], https://www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/ucm628988.htm?utm; see also infra Part III.
50. Tom Angell, Democrats Forming Marijuana Legalization Consensus, FORBES, Feb.
15, 2018, https://www.forbes.com/sites/tomangell/2018/02/15/democrats-formingconsensus-on-marijuana-legalization (noting support for marijuana legalization
among Democratic and Republican members of Congress and quoting Senate
Democratic Leader Chuck Schumer’s statement that “the States should continue to be
the labs of democracy when it comes to recreational & medical marijuana”).
51. See id.; Evan Halper, Trump Administration Abandons Crackdown on Legal
Marijuana, L.A. TIMES (Apr. 13, 2018), http://www.latimes.com/politics/la-na-polmarijuana-trump-20180413-story.html (reporting that “[t]he Trump administration
[wa]s abandoning a Justice Department threat to crack down on recreational
marijuana in states where it is legal,” and that Republican Senator Cory Gardner of
Colorado, who had been “incensed” by the Department’s threat, “said he was assured
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Some notes on terminology are warranted. First, this Article uses
“cannabis” to cover the plant and its products except where referring
to the defined legal category of “marihuana” under the CSA.52
“Marijuana” has unfortunate discriminatory and racial undertones to
many and is seen by some as imposed by anti-immigrant and,
pointedly, anti-Mexican activists in the early twentieth century.53
“Cannabis,” by contrast, is the older and more widely accepted name
of the plant, and indeed forms the basis of the scientific names of the
two major strains or species (speciation is contested): Cannabis sativa
L. and Cannabis indica Lam.54 Further, states, like Washington, with
advanced medical and recreational cannabis regimes have switched
over to “cannabis” as well.55

that the federal government would not interfere with his state’s marijuana industry
and that Trump would champion a new law that gives states the authority to set their
own pot policies”).
52. 21 U.S.C. § 802(16).
53. See Matt Thompson, The Mysterious History of ‘Marijuana,’ NAT’L PUB. RADIO:
CODE
SWITCH
(July
22,
2013,
11:46
AM),
https://www.npr.org/sections/codeswitch/2013/ 07/14/201981025/the-mysterioushistory-of-marijuana (“Numerous accounts say that ‘marijuana’ came into popular
usage in the U.S. in the early 20th century because anti-cannabis factions wanted to
underscore the drug’s ‘Mexican-ness.’ It was meant to play off of anti-immigrant
sentiments.”); see also Alex Halperin, Marijuana: Is it Time to Stop using a Word with Racist
Roots?,
GUARDIAN,
(Jan.
29,
2018),
https://www.thegu
ardian.com/society/2018/jan/29/marijuana-name-cannabis-racism
(“For
the
prohibitionists of nearly a century ago, the exotic-sounding word emphasized the
drug’s foreignness to white Americans and appealed to the xenophobia of the time.
As with other racist memes, a common refrain was that marijuana would lead to
miscegenation. Harry Anslinger, the bureaucrat who led the prohibition effort, is
credited as saying back then: ‘There are 100,000 total marijuana smokers in the US,
and most are Negroes, Hispanics, Filipinos and entertainers. Their Satanic music, jazz
and swing result from marijuana use. This marijuana causes white women to seek
sexual relations with Negroes, entertainers and any others.’”).
54. See Ethan B. Russo, Review, History of Cannabis and Its Preparations in Saga, Science,
and Sobriquet, 4 CHEMISTRY & BIODIVERSITY 1614, 1616–19 (2007) (discussing the taxonomy
of cannabis); Thompson, supra note 55 (“Throughout the 19th century, news reports and
medical journal articles almost always use the plant’s formal name, cannabis.”).
55. For example, in 2011, the Washington legislature amended its MMJ statute,
renaming the section “The Washington state medical use of cannabis act,” and
replacing the word marijuana with cannabis throughout the statute. See 2011 Wash.
Legis. Serv. Ch. 181 (West) (including amendments to Wash. Rev. Code § 69.51A.005
and § 69.51A.900). However, although the legislature has retained the statute’s title—
”the Washington state medical use of cannabis act”—in 2015, an amendment switched
cannabis back to marijuana throughout the statute.
See WASH. REV. CODE
§§ 69.51A.005–69.51A.900 (2015); 2015 Wash. Legis. Serv. Ch. 70 (West).
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Second, this Article uses “medical cannabis” to refer to growth,
production, processing, sale, and use of cannabis or its derivatives for
health or medical benefits. Similar to “cannabis,” we use “medical
marijuana” or “MMJ” only when referring to the legal, statutory
categories created under state laws.
Third, “descheduling” means congressional amendment of the CSA
to remove “marihuana”—or at least some parts of that broad statutory
term—from any of the restricted Schedules of controlled substances.
Descheduling should also include DEA action to remove medically
relevant components of cannabis, such as THC and CBD, as well as
synthetically-produced analogues, that it has placed in any of the
controlled substances Schedules under its statutory authority granted
under the CSA. Full descheduling would mean that (medical)
cannabis is no longer a controlled substance at any level.
Fourth, “rescheduling” means that Congress amends the CSA to
place “marihuana” into a less restrictive Schedule. Likewise, for full
rescheduling, the DEA would also move any medically relevant natural
or synthetic cannabis components that it has placed on Schedule I
down to the same or lower Schedule as “marihuana” would now
occupy. Rescheduling means that (medical) cannabis would still be a
controlled substance, but it would be easier to pursue clinical trials and
new drug approvals with compounds derived from the plant. Further,
over-the-counter (non-prescription) status for those drugs would at
least be theoretically possible (although unlikely).
Fifth, “traditional medical cannabis” means use of the plant in more
or less natural form with minimal processing. This includes not only
the familiar rolling and smoking of resinous flower or buds of the
plant, but also simple processes such as making butter, oils, or tinctures.
It can be contrasted with what might be called the pharmaceutical
approach in which a particular molecule is identified and then purified
or isolated, often through more sophisticated means.
Ultimately, we find only three pathways for “federal-legal” medical
cannabis after descheduling, should that occur. Importantly, this
includes CBD products that contain little to no THC and even those
derived from “hemp.” Many traditional medical cannabis practitioners
will be surprised and likely caught off guard by this. It will not be a
free-for-all wherein providers can say or do anything they want. At the
same time, these pathways are likely sound and provide a useful
roadmap for medical cannabis researchers and practitioners of all
stripes. The first pathway is “intrastate” product produced and
marketed or sold exclusively within a single state’s borders, which will
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be regulated primarily by state law. The second is small-molecule-drug
product following completion of a conventional new drug research
and development program and FDA approval of an NDA. The third is
to test and market, after a premarket submission to the FDA, an herbal
dietary supplement that does not include any ingredient or substance
currently approved as a drug or even in drug clinical trials—which
rules out any products containing THC or CBD. The relative
distribution among these pathways will turn on factors, such as perceived
or clinically measured efficacy, price, time to market, side effects, and
preferences within the patient and healthcare communities.56
This Article proceeds by giving a basic overview of the medical cannabis
industry and its products in Part I. The CSA’s treatment of “marihuana,”
including the mechanisms and effects of descheduling and rescheduling,
are covered in Part II. The FDA and the FDCA regulations relevant to
medical cannabis—and especially possible pathways to compliant
production, marketing, and distribution—are covered in Part III. Finally,
this Article sets out the pathways and discusses ways forward for medical
cannabis under full descheduling in Part IV.
I. HISTORY AND OVERVIEW OF THE MEDICAL CANNABIS INDUSTRY
Claims are made for medical applications of cannabis plants and
their parts going back thousands of years in different parts of the
world.57 The Cannabis sativa L. strain may have been one of the first
wild plants cultivated by humans.58 Early uses were through the raw
seeds, oils, and fibers,59 with other preparations following. There is
controversy over whether the various suspected cannabis uses and
references are to the same plant, however, or to different strains.60
Ailments treated included pain, migraine, fungal infections,
56. For instance, for less regulated herbal products that seem more “natural” to
consumers, or for finished pharmaceutical products known to have been tested in
randomized controlled clinical trials. See infra Conclusion.
57. See Russo, supra note 54, at 1621–41.
58. See id. at 1616 (noting that “sativa” was added to the name cannabis to
designate its status as “cultivated” as early as the 1500s).
59. See id. at 1626–27, 1630, 1636.
60. See id. at 1627, 1631 (endnotes omitted) (“Cannabis has over 50 synonyms in
India, and has been discussed in detail, along with its attendant controversy. Some
authorities have questioned whether bhang was a psychoactive at all, and others have
questioned whether references to cannabis in Indian literature are reliable prior to
the 11th century C.E . . . . Nyberg noted that the word bang, while still signifying
cannabis in contemporary Iran, has also been applied to other plants throughout
history.” (citations omitted)).
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psychological distress, anxiety or grief, ear infections, tumors,
abscesses, and more.61 There is debate over the constituent activeingredient components of the plants used in these ancient times, but
as a general matter, the selective breeding for cannabis containing
high levels of THC—the substance that produces the “high” from
cannabis use—is of a recent nature.62 Thus, older plants likely had a
more balanced profile across the various substances explained below
and would have produced different experiences from much of the
recreational cannabis sold today.63
Cannabis’s medical use is better documented in the Middle Ages
and up into the modern era in different parts of the world, than it was
for ancient use claims.64 However, with no knowledge of the
constituent molecules, physicians had little way of precisely developing
and administering cannabis-based remedies other than in the same
manner as all other materia medica herbal remedies of the time.65 Over
time, the intoxicating properties of cannabis also began creating some
concerns for particular social or religious groups, such as under
Muslim sharia law.66 There often seemed to be less focus on the
intoxicating aspects of cannabis in ancient and medieval use
references and more focus on the nutritive or medical properties of its
seeds and oil, than we might expected today when the focus is
primarily on the THC high.67 However, the Scythians and other
Central Asian groups seemed to have already been burning or heating
leaves, flowers, or seeds in open fires or on heated dishes to release
vapors that were intoxicating.68 We now know that heating is necessary

61.
62.
63.
64.

See id. at 1624–26.
See id. at 1619–20, 1627, 1631.
Id. at 1628–37.
See id.; Antonio Zuardi, History of Cannabis as Medicine: A Review, 28 BRAZ. J.
PSYCHIATRY 153, 153–55 (2006).
65. See Russo, supra note 54, at 1628; Zuardi, supra note 64, at 153, 156; see also
Materia medica, OXFORD ENGLISH DICTIONARY (3d ed. 2001) (defining materia medica as
“[t]he remedial substances and preparations used in the practice of medicine”).
66. See Russo, supra note 54, at 1627 (“[B]y this time, Egyptian medicine had
become Islamic medicine . . . . [W]hile many derided its psychoactive effects on the
basis of a ban on intoxicants in Muslim sharia law, a begrudging acknowledgement was
frequently made of its abundant medical attributes.”).
67. See generally id.
68. See Zuardi, supra note 64, at 154.
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to transform the relevant precursor chemicals from their natural state
in the plant into the form that induces a high in humans.69
Not surprisingly, substantial lore built up around medical,
recreational, and spiritual uses of cannabis.70 This lore continues to
provide some of the basis for today’s natural or herbal medical
cannabis industry.71 In part, this segment of the industry has been
bolstered by the continued interest in ancient and non-Western
holistic medicine that began in earnest in the late twentieth century.72
The benefits of this lore-based, medical cannabis attracted the
attention of Western-trained physicians and scientists as early as the
nineteenth century. For example, an Irish doctor working in Calcutta
in 1840 utilized the anti-convulsant properties of cannabis to treat
tetanus.73 Additionally, a French physician treated mental disorders
with cannabis by 1845.74 In 1851, the third edition of the United States
Pharmacopoeia75 (USP)—then simply a compendium of recognized
drugs—listed “extractum cannabis,” which it described as “[a]n
alcoholic extract of the dried tops of Cannabis sativa—variety Indica.”76
Subsequent editions explained how to prepare extracts and tinctures
of dried cannabis flowers.77 However, as mentioned above, antiMexican sentiment in the early twentieth century led to a

69. The scientific process is “decarboxylation,” during which a carboxyl group (COOH) is removed and replaced by a hydrogen atom (H). In the process, the plant
sheds CO2. In addition to heating, decarboxylation can be accomplished by other
means, including through premature aging by exposure to ultraviolet light. See, e.g.,
Stacie Carrier, The Process of Decarboxylation, CANABO MED. CLINIC (Oct. 20, 2017),
https://www.canabomedicalclinic.com/the-process-of-decarboxylation.
70. See Zuardi, supra note 64, at 154–55 (describing the medical and spiritual uses
of cannabis by various cultures).
71. See, e.g., Ethan Russo, Cannabis in India: Ancient Lore and Modern Medicine, in
CANNABINOIDS AS THERAPEUTICS 1, 11–12 (R. Mechoulam ed., 2005).
72. Sneha Mantri, History of Medicine: Holistic Medicine and the Western Medical
Tradition, 10 AM. MED. ASS’N J. ETHICS 177, 179 (2008).
73. See W.B. O’Shaughnessy, New Remedy for Tetanus and Other Convulsive Disorders,
23 BOS. MED. SURGICAL J. 153 (1840).
74. See Ethan Russo, Cognoscenti of Cannabis I: Jacques-Joseph Moreau, 1 CANNABIS
THERAPEUTICS 85, 86 (2001) (discussing the work of Moreau, including his 1845 book,
DU HACHISCH ET DE L’ALIENATION MENTALE: ETUDES PSYCHOLOGIQUES, which
documented his use of cannabis to treat mental illness).
75. NAT’L MED. CONVENTION, THE PHARMACOPOEIA OF THE UNITED STATES OF
AMERICA (Philadelphia, Lippincot, Grambo, & Co. 1851).
76. Id. at 50.
77. E.g., NAT’L CONVENTION FOR REVISING THE PHARMACOPOEIA, THE PHARMACOPOEIA OF
THE UNITED STATES OF AMERICA 145, 318 (Philadelphia, J.B. Lippincott & Co. 1864).
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demonization of “marihuana,” as the immigrants referred to it.78 This
story is complicated by the facts that the Mexican government was
already working to control it through criminal statutes and that the
peasants most likely to be fleeing to the United States following
upheaval caused by the Mexican Revolution of 1910 seemed the most
terrified by what the drug could do.79 Thus, while there is evidence of
news stories of the time focusing on “crazed” Mexicans committing
violent crimes and debauchery under the influence of substances using
terms we believe to correspond to strains or species of cannabis, there
were also stories of other minorities, suspect groups such as “jazz
musicians,” and other “undesirables,” engaged in such actions too.
Whatever the actual mix of motives, it is clear that “marihuana”
became a focal point of social, political, and legal concern in this
period, which led to legislation.
At the federal level, medical cannabis was regulated under the
minimalist provisions of the Pure Food and Drugs Act of 1906.80
Notably, Eli Lilly & Co. marketed a regulated cannabis formulation as
an antispasmodic, sedative, and narcotic.81 But it was not until the
Marihuana Tax Act of 193782 that cannabis was singled out as
something more pernicious than other herbal remedies of the time.83
Rapidly disappearing was media coverage of the medical benefits of
cannabis. Some individual states in fact were banning cannabis
outright, and most made it available under prescription only.84

78. See, e.g., Eric Schlosser, Reefer Madness, ATLANTIC (Aug. 1994),
https://www.theatlantic.com/magazine/archive/1994/08/reefer-madness/303476
(describing how Texas police officers claimed that marijuana caused a lust for blood
and incited violent crime while rumors also spread that Mexicans were distributing
“killer weed” to American schoolchildren).
79. See ERIC SCHLOSSER, REEFER MADNESS: SEX, DRUGS, AND CHEAP LABOR IN THE
AMERICAN BLACK MARKET 19 (2003); Schlosser, supra note 78.
80. Pure Food and Drugs Act, Pub. L. No. 59-384, § 8, 34 Stat. 768, 770 (1906)
(repealed by 21 U.S.C. § 1-5 (1940)) (deeming an article “misbranded” if the label
does not include the “quantity or proportion of any . . . cannabis indica, . . . or any
derivative or preparation of any such substances contained therein”), repealed by
Federal Food, Drug, and Cosmetic Act of 1938, Pub. L. No. 75-717, 52 Stat. 1040
(codified as amended at 21 U.S.C. §§ 301–399h (2012)).
81. See, e.g., ALISON MACK & JANET JOY, MARIJUANA AS MEDICINE?: THE SCIENCE BEYOND
THE CONTROVERSY 18 (2001) (reproducing images from 1913 Eli Lilly product labels).
82. Pub. L. No. 75-238, ch. 553, 50 Stat. 551 (1937).
83. Ferraiolo, supra note 20, at 148.
84. See id. at 153 (describing the Federal Bureau of Narcotics support for the
Uniform Narcotic Act, which made marijuana available only by prescription); see also,
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Nonetheless, cannabis research continued and major advances
towards identifying and isolating important constituents of the plant
took place in the 1930s and 1940s.85 Two key substances were isolated
from hemp oil: cannabinol (CBN) and CBD.86 The latter was present
in a mixture of two THC variants that induced “marihuana-like”
physiological results in dogs.87 The exact molecular structure of these
variants remained elusive, however. A single THC variant was soon
isolated from cannabis resin.88 But in many ways, THC was still a
predicted, and not fully realized, molecular construct.
By the 1940s, significant segments of the population had hardened
against “marihuana” for any use.89 Much of this resulted from the work
of the Federal Bureau of Narcotics, which, among other things,
released the low budget propaganda film, Reefer Madness,90 and
publicized the “marijuana menace” through allies in the newspaper
industry.91 In 1942, the United States Pharmacopeia Convention
removed cannabis from the twelfth edition of the USP, a compendium
now formally recognized under the FDCA of 1938.92 With this, the
medical cannabis industry moved underground.93 Few mainstream
researchers pursued it anymore. Unfortunately, this also sent the
traditional medical cannabis community back to the largely lore-based
trial and error practices it had used before the nineteenth century.94

e.g., 1913 Cal. Stat. 692, 697 §§ 8a–b (1913) (amending the California Poison Act of
1907 and making the possession of hemp or its derivatives a misdemeanor).
85. See Roger G. Pertwee, Cannabinoid Pharmacology: The First 66 Years, 147 BRIT. J.
PHARMACOLOGY S163, S163 (2006).
86. Id.
87. THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 46 (citing R. Adams et al.,
Structure of Cannabidiol, a Product Isolated from the Marihuana Extract of Minnesota Wild
Hemp, 62 J. AM. CHEM. SOC’Y 196 (1940); R. Adams et al., Conversion of Cannabidiol to a
Product with Marihuana Activity, 62 J. AM. CHEM. SOC’Y 2245 (1940)).
88. Id. (citing H.J. Wollner, Isolation of a Physiologically Active Tetrahydrocannibinol
from Cannabis sativa Resin, 64 J. AM. CHEM. SOC’Y 26 (1942)).
89. See Ferraiolo, supra note 20, at 153–54 (describing the public shift in perceptions
of drugs and marijuana, spearheaded by Anslinger, and the lack of marijuana defenders).
90. REEFER MADNESS (George A. Hirliman Productions 1938) (also screened under
different titles across the United States in the 1940s–1950s).
91. Ferraiolo, supra note 20, at 156.
92. NAT’L ACAD. SCI., MARIJUANA AND MEDICINE: ASSESSING THE SCIENCE BASE 16
(Janet E. Joy et al. eds., 1999) [hereinafter MARIJUANA AND MEDICINE]; THE HEALTH
EFFECTS OF CANNABIS, supra note 11, at 43.
93. Ferraiolo, supra note 20, at 154–55.
94. See supra notes 70–71 and accompanying text.
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The next set of major advances in cannabis research came in the
1960s and 1970s. Overshadowing them all was the discovery of the
elusive structure of the THC variant in cannabis that generates its
intoxicating effect.95 The development of nuclear magnetic resonance
imaging had enabled researchers to conclusively identify what became
known as 9-THC.96 But such new tools also led to the discovery of exact
molecular structures of other key cannabis substances including CBD,97
cannabichromene,99
cannabidivarin,100
cannabigerol
(CBG),98
101
102
The enactment of the CSA in
tetrahydrocannabivarin, and CBN.
1970—with its placement of “marihuana,” THC, and “cannabimimetic
agents” in Schedule I—erected serious barriers to research on cannabis.
Nonetheless, in the 1980s and 1990s, the mammalian cannabinoid
system came into view. The idea of cannabinoid receptors on cells was
postulated based on demonstrations of the selective binding to brain
membranes of synthetic molecules designed to mimic the actions of 9THC.103 A “receptor” is a protein, typically on the surface of a cell.104
Binding to a receptor triggers changes in the cell’s activity and, in this
case, causes psychological changes such as euphoria and shifts in sensory
perception.105 The actual existence of this first receptor, CB1, was

95. Pertwee, supra note 85, at S164.
96. THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 46 (citing Y. Gaoni and R.
Mechoulam, Isolation, Structure and Partial Synthesis of an Active Constituent of Hashish, 86
J. AM. CHEM. SOC’Y 1646 (1964)).
97. See Ethan B. Russo, Taming THC:
Potential Cannabis Synergy and
Phytocannabinoid-terpenoid Entourage Effects, 163 BRIT. J. PHARMACOLOGY 1344, 1345
(2011) (citing R. Mechoulam & Y. Shvo, Hashish—I: The Structure of Cannabidiol, 19
TETRAHEDRON 2073 (1963)).
98. Id. (citing Y. Gaoni & R. Mechoulam, The Structure and Function of Cannabigerol,
a New Hashish Constituent, 1 PROC. CHEMISTRY SOC’Y 82 (1964)).
99. Id. (citing Y. Gaoni & R. Mechoulam, Cannabichromene, a New Active Principle in
Hashish, 1 CHEMICAL COMM. 20 (1966)).
100. Id. (citing L. Vollner et al., Hashish. XX. Cannabidivarin, a New Hashish
Constituent, 3 TETRAHEDRON LETT. 145 (1969)).
101. Id. (citing E.W. Gill et al., Preliminary Experiments on the Chemistry and
Pharmacology of Cannabis, 228 NATURE 134 (1970)).
102. R.E. Musty et al., Interactions of 9-Tetrahydrocannibinol and Cannabinol in Man, in
2 THE PHARMACOLOGY OF MARIHUANA 559, 559–63 (M.C. Braude and S. Sarza, eds., 1976).
103. THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 46 (citing William A.
Devane et al., Determination and Characterization of a Cannabinoid Receptor in Rat Brain,
34 MOLECULAR PHARMACOLOGY 605 (1988)).
104. See Receptor, TABER’S CYCLOPEDIC MEDICAL DICTIONARY 1760 (19th ed. 2001).
105. See, e.g., MACK & JOY, supra note 81, at 58–59 (discussing potential psychological
changes and effects due to marijuana).
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corroborated in 1990.106 In 1993, a second receptor, CB2, was cloned and
identified.107 Endocannabinoids—cannabinoids produced by a mammal’s
own body—were also discovered, suggesting that endocannabinoid systems
are inherent to at least some mammals, and not merely a response to
external triggers such as 9-THC or CBD.108 This discovery also led to one
bold hypothesis that humans and cannabis co-evolved.109
The fascination with the dramatic effects of THC unfortunately led
to a near-exclusive research focus on that set of substances, and
particularly 9-THC.110 This may have also stemmed from the
dominant Western small molecule pharmaceutical approach in which
“active ingredients” are identified, isolated, purified, and concentrated
for therapeutic delivery, as other substances in source plants and other
natural materials are largely ignored.111 This approach has led to many
notable successes where modified concentrations of substances, or new
chemicals synthesized from them, provide much greater therapeutic
benefit than available from the naturally-occurring versions. For
example, acetylsalicylic acid, or aspirin, was synthesized in the midnineteenth century from substances that had been identified in willow
leaves and bark.112 The latter had been used therapeutically for
thousands of years.113 But this success can crowd out research on the
interactions and effects of the full range of chemicals—whether known
or considered “active” or “inactive” ingredients—in herbal remedies
106. THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 46 (citing Miles
Herkenham et al., Cannabinoid Receptor Localization in Brain, 87 PROC. NAT’L ACAD. SCI.
U.S. 1932 (1990); Lisa A. Matsudo et al., Structure of a Cannabinoid Receptor and
Functional Expression of the Cloned cDNA, 346 NATURE 561 (1990)).
107. Id. (citing Sean Munro et al., Molecular Characterization of a Peripheral Receptor for
Cannabinoids, 365 NATURE 61 (1993)).
108. See Russo, supra note 97, at 1354 (citing William A. Devane et al., Isolation and
Structure of a Brain Constituent that Binds to the Cannabinoid Receptor, 258 SCIENCE 1946
(1992); Raphael Mechoulam et al., Identification of an Endogenous 2-Monoglyceride, Present
in Canine Gut, that Binds to Cannabinoid Receptors, 50 BIOCHEMICAL PHARMACOLOGY 83
(1995); Takayuki Sugiura, 2-Arachidonoylglycerol: A Possible Endogenous Cannabinoid
Receptor Ligand in Brain, 215 BIOCHEMICAL BIOPHYSICAL RES. COMM. 89 (1995)).
109. See Russo, supra note 54, at 1614 (citing J.M. McPartland & G.W. Guy, The Evolution of
Cannabis and Coevolution with the Cannabinoid Receptor—A Hypothesis, in THE MEDICAL USE OF
CANNABIS AND CANNABINOIDS 71–101 (G.W. Guy, B.A. Whittle & P.J. Robson, eds., 2004)).
110. See Russo, supra note 97, at 1345.
111. See Si-Yuan Pan et al., New Perspectives on How to Discover Drugs from Herbal
Medicines: CAM’s Outstanding Contribution to Modern Therapeutics, 2013 EVIDENCE-BASED
COMPLEMENTARY & ALTERNATIVE MED. 1, 2–3 (2013).
112. Dawn Connelly, A History of Aspirin, PHARMACEUTICAL J. (Sep. 26, 2014), http
s://www.pharmaceutical-journal.com/news-and-analysis/infographics/a-history-of-aspirin.
113. Id.
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generally. In the traditional medical cannabis sector, and among some
researchers, this holistic approach to cannabis as an herbal remedy has
been called the “entourage effect.”114
This dichotomy between the small molecule pharmaceutical and
whole plant herbal approaches underlies the fundamental tension in
medical cannabis today. Drug companies generally seek to identify a
single active ingredient that can be developed into a drug product,
which in turn can be studied for safety and effectiveness in rigorously
controlled clinical trials for purposes of the FDA’s NDA process.115
This drug development model reflects the analytic framework in which
most of Western science and technology has proceeded for the past
few hundred years. Only by carefully isolating and testing a particular
phenomenon can we learn anything useful about it. This approach
has been focused to finer and finer levels of matter. Traditional
medical cannabis providers instead operate in a world in which not
only do they insist that preparations from whole portions of the
plant—such as the flower—are essential for therapeutic benefit, but
they also believe that different strains of cannabis produce
demonstrably different effects.116
This Article does not seek to resolve any of these debates, but rather
is intended to help all sides in the medical cannabis debates
understand how the FDA will likely approach the matter. This Article
also seeks to sketch three pathways in which we think medical cannabis

114. The term and concept “entourage effect” (sometimes “ensemble effect”) refers
to the synergy and interaction between multiple molecules and compounds within
cannabis and the interplay these chemicals have with one another when producing
effects on the body, as opposed to simply considering the effects of a single active
compound, like THC, in isolation. The term and concept were introduced to the
scientific literature by Ben-Shabat, Mechoulam, and others. See Shimon Ben-Shabat et
al., An Entourage Effect: Inactive Endogenous Fatty Acid Glycerol Esters Enhance 2-Arachidonoylglycerol Cannabinoid Activity, 353 EUROPEAN J. PHARMACOLOGY 23, 136 (1998); Raphael
Mechoulam & Shimon Ben-Shabat, From Gan-zi-gun-nu to Anandamide and 2-Arachidonoylglycerol: The Ongoing Story of Cannabis, 16 NAT. PRODUCT REP. 131, 136 (1999); see also
Russo, supra note 97, at 1344.
115. See infra Part III.
116. A similar set of perspectives that has been in the popular media recently
centers on the debate over “whole foods,” calories, and sugars in our diet. See generally,
e.g., MICHAEL POLLAN, THE OMNIVORE’S DILEMMA: A NATURAL HISTORY OF FOUR MEALS
(2007) (analyzing the ethos and processes behind three modes of food-chains:
“processed,” “organic,” and “neo-Paleolithic”). One side has taken the view that
“calories are calories” and “sugars are sugars.” The other side opines that the form of
our food, and its calories, and sugars, matters tremendously for metabolism, health,
and fitness. Both sides can cite some current scientific research.
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can proceed, compliant with FDA law, in the event descheduling
occurs. We set out these pathways in Parts III and IV, which arguably
fall on differing sides of this debate—or at least, they may appeal in
different ways depending on one’s place within that debate.
The remainder of this Part reviews the current state of scientific
understanding of cannabis, its constituents, and their effects on the
human body. Cannabis plants sit within the genus Cannabis and family
Cannabaceae.117 The latter includes the genera Cannabis and Humulus
(hops), which has led to interesting notes in the cannabis and beer
industries about similarities.118 Most of the taxonomic debate concerns
whether there are two or more species within the genus—usually
cannabis sativa and cannabis indica—or simply one (cannabis sativa) with
different strains, varietals, or subspecies.119 An alternate account finds
at least one other type as a possible species: Cannabis ruderalis Jan.120
In this schema: Cannabis sativa L. are “tall, branched plants for fiber,
seed, or psychoactive use”; Cannabis indica Lam. are “short, broadleafed plants” from the Indian subcontinent; and Cannabis ruderalis
Jan. are “short, unbranched ‘roadside’ plants usually weak in
cannabinoids.”121
Much of the uncertainty in classification appears to be from the
hardy proliferation of the plant, which has resulted in many varieties,
both cultivated and as found in the wild.122 Again, this Article does not
seek to resolve scientific or practitioner debates, but three points
suffice in summary. First, the wide and distinctive varieties of
cannabis—whether at a species level or lower—give ample grounds for
traditional medical cannabis practitioners to promote the importance

117. THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 44 (citing Mohammed
Kuddus et al., Cannabis sativa: An Ancient Wild Edible Plant of India, 25 EMIRATES J. FOOD
& AGRIC. 736, 737 (2013)).
118. Id.
119. Id. (citing Lucas Larsen, Botany: The Cultivation of Weed, 525 NATURE S4 (Sept.
24, 2015); ROBERT CLARKE & MARK MERLIN, CANNABIS: EVOLUTION AND ETHNOBOTANY
(1st ed. 2016); Karl W. Hillig, Genetic Evidence for Speciation of Cannabis (Cannabaceae),
52 GENETIC RESOURCES & CROP EVOLUTION 161 (2005); Ernest Small, Evolution and
Classification of Cannabis sativa (Marijuana, Hemp) in Relation to Human Utilization, 81
BOTANICAL REV. 189 (2015).
120. Russo, supra note 54, at 1616 (citing Richard Evans Schultes et al., Cannabis:
An Example of Taxonomic Neglect, 23 BOTANICAL MUSEUM LEAFLETS HARV. U. 337 (1974);
Loran C. Anderson, Leaf Variation Among Cannabis Species from a Controlled Garden, 28
BOTANICAL MUSEUM LEAFLETS HARV. U. 61 (1980)).
121. Id.
122. See, e.g., id.
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of strains and their entourage effects.123 In other words, the argument
is not just that certain key chemicals like THC vary among strains, but
also that many chemicals vary (i.e., that a compound may have the
same molecular structure but work differently in the body depending
on the varying other chemicals in the cannabis strain in which it
appears).124 Accordingly, from this view, using whole-plant derived
product is critical, rather than an isolated strain-specific constituent
like THC.125 Second, as companies like Phylos Bioscience sequence
the DNA of popular strains—and indeed seek to populate a “galaxy”
of certified types—it has become clear that much of what is being
passed as a particular strain in the traditional medical cannabis
industry is far from uniform or exact.126 And third, data generated by
these genomic sequencers should enable more definitive answers to
the classification debate in the near future.127
Across all cannabis plants, sophisticated traditional medical
cannabis practitioners and researchers identify three broad classes of
substances that may generate medical or health benefits:
cannabinoids; terpenoids; and flavonoids.128 The first class is the most
well-known as it contains THC and CBD. But significant confusion
exists, especially as to the “psychoactive” attributes of molecules within
this class.129 The problem likely stems from the fact that all
cannabinoids interact with the mammalian endocannabinoid system
and other parts of the central nervous system.130 Thus, all cannabinoids
are neurologically active. However, THC stands out as a cannabinoid
whose partial agonist binding to CB1 receptors causes the noted
psychological responses of euphoria, sensory perception shifts, and
other characteristics referred to as getting high or stoned.131 Trying to
distinguish synonymous terms like “psychoactive” and “psychotropic”

123. See infra notes 177–79 and accompanying text.
124. Id.
125. See infra note 179 and accompanying text.
126. See Why Phylos Certified?, PHYLOS, https://phylos.bio/phylos-certified (last
visited Feb. 5, 2019) (“Cannabis plants are currently sold under unreliable names (not
every “Blue Dream” is the same plant variety), meaning inconsistent experiences for
everyone—from farmers to consumers.”).
127. See supra notes 122–25 and accompanying text.
128. See THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 44 (citing AMERICAN
HERBAL PHARMACOPOEIA (2013)); Russo, supra note 97, at 1344.
129. See THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 47.
130. See id. at 46–48.
131. Id. at 51.
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does not help.132 Instead, this Article refers to all cannabinoids as
“neuro-active” and to THC as “psychoactive.” One further segmentation
of cannabinoids is important: “phytocannabinoids” are those produced
by plants through natural photosynthesis; “synthetic cannabinoids” are
those produced artificially; “cannabimimetic agents” are also produced
artificially but are designed to produce the results of a certain
cannabinoid (usually THC) and not necessarily replicate its exact
structure; and, as mentioned above, “endocannabinoids” are those
produced by the mammalian body through its own natural processes.133
The endocannabinoid system is now seen as “one of the key
regulatory mechanisms in the brain controlling multiple events such
as mood, pain, perception, learning and memory among others.”134
The system may also play protective and reparative roles in traumatic
brain injury and neurodegeneration.135 Mammalian bodies produce
endocannabinoids on-demand.136
At the same time, estimates of phytocannabinoids occurring in
cannabis range from sixty to more than 100.137 The two most
important at the moment, THC and CBD, are generated from the
common parent precursor CBG.138 To be accurate, the acid version of
each of these cannabinoids is expressed in cannabis itself (e.g., 9tetrahydrocannabinolic acid).139 In such form, they are inert for most
of the effects we associate them with. Ingesting in this form would not

132. These terms are nearly identical and trying to differentiate between them would
not help determine how chemicals like THC and CBD work differently on a molecular
level. Compare Psychoactive, MERRIAM WEBSTER (defining “psychoactive” as “affecting the
mind or behavior”), https://www.merriam-webster.com/dictionary/psychoactive (last
visited Feb. 5, 2019), with Psychotropic, MERRIAM WEBSTER (defining “psychotropic” as
“acting on the mind”), https://www.merriam-webster.com/dictionary/psychotropic
(last visited Feb. 5, 2019).
133. See generally Vincenzo di Marzo, Opinion, New Approaches and Challenges to
Targeting the Endocannabinoid System, 17 NATURE REVS.: DRUG DISCOVERY 623 (2018);
Debra A. Kendall & Guillermo A. Yudowski, Cannabinoid Receptors in the Central Nervous
System: Their Signaling and Roles in Disease, 10 FRONTIERS IN CELLULAR NEUROSCIENCE 1
(Jan. 2017); see also THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 44; Russo, supra
note 97, at 1344.
134. Kendall & Yudowski, supra note 133, at 3.
135. Id.
136. Id.
137. Russo, supra note 97, at 1346; THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 44.
138. Mei Wang et al., Decarboxylation Study of Acidic Cannabinoids: A Novel Approach
Using Ultra-High-Performance Supercritical Fluid Chromatography/Photodiode Array-Mass
Spectrometry, 1 CANNABIS & CANNABINOID RES. 262, 262 (2016).
139. Id. at 263.
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induce the desired effects. They must be decarboxylated first, which
in the case of traditional recreational and medical cannabis is generally
accomplished through heating, resulting in the forms of THC and
CBD that produce the sought-after effects.140
The two different sets of cannabinoid receptors on various cells
throughout the human body also play a key role in the effects of
cannabinoids. Cannabinoid binding to CB1 receptors can result in the
psychoactive mood and perceptions shifts associated with getting high,
as well as with therapeutic benefits.141 By contrast, CB2 receptors are
found predominantly within cells and tissues of the immune system
and the gut.142 Cannabinoids binding to them may regulate
inflammation, pain, and even neurodegeneration.143 Many of the
cannabinoids interact directly or indirectly with both CB1 and CB2
receptors.144 Even more complexly, cannabinoids like THC and CBD
can effectively interact with each other through the CB receptors.145
For example, CBD appears to modulate the stronger and more
negative effects of THC, such as anxiety.146 Notably, Sativex, approved
in the United Kingdom and elsewhere, but not in the United States,
contains both 9-THC and CBD.147

140. See Russo, supra note 97, at 1345.
141. See Kendall & Yudowski, supra note 133, at 1–2.
142. See, e.g., K.L. Wright et al., Cannabinoid CB2 Receptors in the Gastrointestinal Tract:
A Regulatory System in States of Inflammation, 153 BRIT. J. PHARMACOLOGY 263, 263 (2008).
143. Id.
144. See Kendall & Yudowski, supra note 133, at 4.
145. Id.
146. See Russo, supra note 97, at 1348. The mechanism and extent of this interaction
remains the subject of considerable ongoing research with results that have not yet
been reconciled. See, e.g., C. Klein et al., Cannabidiol Potentiates 9-Tetrahydrocannabinol
(THC) Behavioral Effects and Alters THC Pharmacokinetics During Acute and Chronic
Treatment in Adolescent Rats, 218 LIBERTAS ACADEMICA 443, 443 (2011) (finding that
pretreatment with CBD intensified all behavioral effects of THC including anxiety);
Daniel Thomas Malone et al., Cannabidiol Reverses the Reduction in Social Interaction
Produced by Low Dose 9-Tetrahydrocannabinol in Rats, 93 PHARMACOLOGY BIOCHEMISTRY
BEHAV. 91, 91 (2009) (finding that pretreatment with CBD reversed THC-induced
decreases in interactions).
147. Sativex is an oromucosal spray that, as noted, contains both 9-THC and
cannabidiol. The United Kingdom’s medicine regulator approved Sativex in June
2010 to improve symptoms related to muscle stiffness or spasm caused by multiple
sclerosis. See U.K. MEDS. & HEALTHCARE PRODS. REGULATORY AGENCY, PUBLIC
ASSESSMENT REPORT DECENTRALISED PROCEDURE: SATIVEX OROMUCOSAL SPRAY 2 (2014).
The drug is now approved in 25 countries but has not yet been approved in the United
States. Sativex®, GW PHARMACEUTICALS, https://www.gwpharm.com/healthcare-
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Terpenoids, the key components of essential oils, are synthesized in
cannabis as well.148 Cannabis contains over 200 terpenoids.149 It is
terpenoids and not cannabinoids that give cannabis its distinctive
aroma.150 While there is debate about the efficacy of terpenoids for
therapeutic uses, increased interest has correlated with studies showing
measurable benefits in this century.151 The primary terpenoids in
cannabis that may produce beneficial effects, alone or in conjunction
with a cannabinoid, are: Limonene, -Pinene, -Myrcene, Linalool, Carophyllene, Carophyllene Oxide, Nerolidol, and Phytol.152
Flavonoids are metabolites that play a role in pigmentation, UV
filtration, nitrogen fixation, and other functions in plants.153 They are
sometimes referred to as bioflavonoids.154 There appear to be twenty or
more flavonoids in cannabis.155 Those occurring only in cannabis have
been called “cannaflavins.”156 Flavonoids are pharmacologically active and
some in the medical cannabis community believe they work in concert with
terpenoids and other substances in cannabis plants.157 They are less wellstudied overall, in cannabis in particular, but have become a topic of
interest, especially among those who promote the entourage effect.158

professionals/sativex (last visited Feb. 5, 2019). This Article discuss other new drug
products derived from cannabis in Part IV.
148. Russo, supra note 97, at 1345, 1349 (noting that terpenoids were “previously
conceived as the quintessential fifth element, ‘life force’ or spirit . . . , and form the
largest group of plant chemicals”). For more detail on the role of terpenes in essential
oils, see Sangita Kumari et al., EssOilDB: A Database of Essential Oils Reflecting Terpene
Composition and Variability in the Plant Kingdom, 2014 DATABASE 1, 2 (Jan. 2014).
149. Russo, supra note 97, at 1349.
150. Id.
151. Id. at 1350–52 (citing studies that indicate terpenoids can act as sleep aids,
memory aids, anticonvulsants, antimalarials, and increase serotonin).
152. Id. at 1351.
153. Ulrike Mathesius, Flavonoid Functions in Plants and Their Interactions with Other
Organisms, 7 PLANTS 30, 30–31 (June 2018), https://www.ncbi.nlm.nih.gov/pmc/
articles/PMC6027123/pdf/plants-07-00030.pdf.
154. See, e.g., Drugs for Human Use Containing Rutin, Quercetin, Hesperidin, or
Bioflavonoids, 33 Fed. Reg. 818 (Jan. 23, 1968).
155. Patrick Bennett, What Are Cannabis Flavonoids and What Do They Do?, LEAFLY (Feb.
8, 2018), https://www.leafly.com/news/cannabis-101/what-are-marijuana-flavonoids.
156. Id.
157. See Angus Chen, Some of the Parts: Is Marijuana’s “Entourage Effect” Scientifically
Valid?, SCI. AM. (April 20, 2017), https://www.scientificamerican.com/article/someof-the-parts-is-marijuana-rsquo-s-ldquo-entourage-effect-rdquo-scientifically-valid.
158. Id.; see also supra note 114.
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At the same time, scientific researchers are not opposed to studying
other cannabis substances or even potential entourage effects,159 but
current supply issues severely limit such efforts.160 The Schedule I
status of much of the cannabis plant led the DEA and NIDA to restrict
licensed research to a strain of cannabis produced by the University of
Mississippi under contract with the federal government.161 This strain
is not particularly potent nor high quality from traditional medical
cannabis provider and user perspectives—even as it is deemed
“research grade” by the government—and is not one used by
dispensaries.162 Exacerbating this problem, NIDA research cannabis is
often harvested and stored in a freezer for years before being
distributed to researchers, further diminishing its potency (as well as
likely degrading other substances such as essential oils).163 But even if
this were a relevant strain and delivered fresh to researchers, the limit
to a single strain precludes exactly the kind of cross-strain comparisons
that traditional medical cannabis providers believe provides the core
basis for their practice.164 NIDA research cannabis also traditionally
was supplied only in plant form, precluding other important research
avenues that would consider the forms and modes of delivery, such as
conventional edible forms waxes for smoking or vaporizing, other
concentrates, oils that are sometimes ingested, and topicals).165
Changes initiated in 2016 are underway, however. NIDA began
working with the University of Mississippi to at least provide strains with
different concentrations of 9-THC and CBD.166 Yet, this facilitates
159. See, e.g., Russo, supra note 97, at 1349–52 (citing several studies involving
cannabis terpenoids).
160. See Chen, supra note 157.
161. See THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 382 (explaining that the
NIDA Drug Supply Program provides the only cannabis available for research);
Alexander W. Campbell, The Medical Marijuana Catch-22: How the Federal Monopoly on
Marijuana Research Unfairly Handicaps the Rescheduling Movement, 41 AM. J. L. & MED. 190,
200 (2015) (describing the oversight surrounding the marijuana manufacturer at the
University of Mississippi and the requirements researchers must meet to use marijuana
from there). In 2013, the First Circuit Court of Appeals upheld the DEA’s denial of a
license for a Massachusetts university professor to cultivate his own marijuana for medical
research on the grounds that he failed to demonstrate that current cannabis supply was
inadequate. See Craker v. DEA, 714 F.3d 17, 18–19, 29 (1st Cir. 2013).
162. THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 382.
163. Id. at 382–83.
164. See Chen, supra note 157 (describing how individual cannabis growers “have long
been crossing plants to develop distinctive strains that purportedly do different things”).
165. THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 383.
166. Id.
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primarily research focusing on characterizing the biological activity of
these two constituents, although it could also support research on the
current interest in the interaction of THC and CBD. More helpfully,
DEA also changed its policy to begin accepting applications for other
research-grade cannabis providers, which could result in a supply that
more closely matches that of private dispensaries.167 However, no
licenses have been granted as of publication. In the meantime, this
state of affairs appears to have driven some important medical
cannabis research overseas.168
Both pharmaceutical and whole flower medical cannabis
researchers have targeted a number of therapeutic fields. Some of
these fields have roots in ancient practice or in the nascent
pharmacological cannabis practices of the nineteenth and early
twentieth century (before cannabis “prohibition”).169 Pharmaceutical
approaches tend to orient around cannabinoids (especially THC and
CBD) and CB receptors because cannabinoids are seen as the primary
“active ingredients” available from cannabis.170 To be clear, the
pharmaceutical industry is not only developing drugs derived from
cannabis plant material, but also from synthetic cannabinoid products.171
Traditional medical cannabis practitioners and other researchers
tend to pursue illnesses that might benefit from the amount of
substances occurring in naturally-hybridized strains as delivered
through whole flower, oils, extracts, or concentrates, the latter of which
could reach pharmaceutical type levels of “active ingredients” such as
CBD.172 Further, not all traditional medical cannabis practitioners insist
on whole flower-based product. Some are fine advising pure THC
concentrates (albeit, of course, in some form that does not deliver 100%
THC to the patient). At the same time, formally-trained researchers
including Mowgli Holmes, at Phylos Bioscience, and Ethan Russo,
formerly at GW Pharmaceuticals, are among some of the strongest
167. Id. at 383–84 (citing Applications to Become Registered Under the Controlled
Substances Act to Manufacture Marijuana to Supply Researchers in the United States,
81 Fed. Reg. 53,846 (Aug. 12, 2016)).
168. See, e.g., Yardena Schwartz, The Holy Land of Medical Marijuana, U.S. NEWS &
WORLD REP. (Apr. 11, 2017), https://www.usnews.com/news/best-countries/articles
/2017-04-11/israel-is-a-global-leader-in-marijuana-research (illustrating how Israel has
become a prime location for cannabis research).
169. See supra Part I.
170. See Russo, supra note 97, at 1345, 1348.
171. See infra Section IV.B.1 (tracing the history of synthetic cannabis drug
development in the United States).
172. See supra notes 57–77 and accompanying text.
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proponents of entourage effect therapies.173 However, this does not
always mean whole flower-based product.
It can also mean
pharmaceutical products like Sativex, where the manufacturer
combines multiple substances for an overall desired effect and not just
a single active ingredient.174 Thus, there will likely be a continued focus
on multiple cannabinoid products first, especially from the
pharmaceutical side.175 Richer preparations including at least certain
terpenoids may follow. And of course, dietary supplement or whole
flower-derived product will contain the full complement of the
cannabinoids, terpenoids, and flavonoids in the cannabis strain’s profile.
II. CANNABIS AND “MARIHUANA”
UNDER THE CONTROLLED SUBSTANCES ACT
The CSA was enacted in 1970 as the cornerstone of a major push to
combat what was perceived by some as an epidemic of “recreational”
drug abuse, especially within the counterculture movement.176 It
consolidated various federal drug laws into a cohesive system of
regulations.177 The system created “Schedules,” or classifications, of
controlled substances with different levels of regulation.178 All
scheduled controlled substances are restricted in production and
distribution under registration and licensing requirements promulgated
by the Attorney General, ultimately delegated in large part to the

173. See Chen, supra note 157.
174. Id.
175. A recent report by the National Academies of Science, The Health Effects of
Cannabis and Cannabinoids, provides a useful list of the major health and disease areas
being pursued by researchers (although the reader should note the varying levels of
evidence for or against each: Chronic Pain; Cancer; Chemotherapy-Induced Nausea and
Vomiting; Anorexia and Weight Loss; Irritable Bowel Syndrome; Epilepsy; Spasticity
Associated with Multiple Sclerosis or Spinal Cord Injury; Tourette Syndrome;
Amyotrophic Lateral Sclerosis; Huntington’s Disease; Parkinson’s Disease; Dystonia;
Dementia; Glaucoma; Traumatic Brain Injury/Intracranial Hemorrhage; Addiction;
Anxiety; Depression; Sleep Disorders; Posttraumatic Stress Disorder; Schizophrenia and
Other Psychoses. See THE HEALTH EFFECTS OF CANNABIS, supra note 11, at xii.
176. See Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970,
Pub. L. No. 91-513, 84 Stat. 1236, 1242 (codified at 21 U.S.C. §§ 801–904 (2012)); see also
John Hudak, How Racism and Bias Criminalized Marijuana, WASH. POST (Apr. 28, 2014),
https://www.washingtonpost.com/news/in-theory/wp/2016/04/28/how-racism-and-bias
-criminalized-marijuana (arguing marijuana’s scheduling comes from President Nixon’s
contempt toward the counterculture movement and racial minorities).
177. See 84 Stat. at 1236–37.
178. 84 Stat. at 1247–52 (codified at 21 U.S.C. § 812 (2012)).
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DEA.179 The Attorney General—through the DOJ, DEA, and NIDA—
licenses producers, distributors, and retailers, as well as health care
providers who are able to write prescriptions for controlled
substances.180 The primary purpose of the CSA was to control
stimulants, depressants, and hallucinogens.181 The stated concern was
safety and the potential for addiction and abuse.182 Five Schedules
were included in the statute, in descending order of restrictiveness.183
Schedule I criteria are that the substance has “a high potential for
abuse,” “no currently accepted medical use in treatment in the United
States,” and “a lack of accepted safety for use of the drug or other
substance under medical supervision.”184 When initially enacted,
Schedule I included certain enumerated opiates, opium derivatives
(including heroin and morphine), and hallucinogens (including LSD,
“marihuana,“ tetrahydrocannibols, mescaline, peyote, and psilocybin).185
“Cannabimimetic agents” were later added to Schedule I and include “any
substance that is a cannabinoid receptor type 1 (CB1 receptor) agonist as
demonstrated by binding studies and functional assays within any of
[certain enumerated molecular structural classes].”186
Schedule II criteria also include “a high potential for abuse,” but the
substances have “a currently accepted medical use in treatment in the
United States or a currently accepted medical use with severe
restrictions.”187 The substances also have a risk of “severe psychological
or physical dependence” when abused.188 As initially set out, Schedule
II included both general classes of substances (including opium and
opiate generally, opium poppy and poppy straw, coca leaves and
preparations from them, and injectable liquid forms of
methamphetamines) and certain enumerated opiates (including
fentanyl and methadone).189
Schedule III loosened all three criteria.190 These substances have a
potential for abuse lower than those in Schedules I and II and a risk of
179.
180.
181.
182.
183.
184.
185.
186.
187.
188.
189.
190.

See 21 U.S.C. §§ 821–831.
See § 822; see also THE HEALTH EFFECTS OF CANNABIS, supra note 11, at 378–81.
H.R. REP. NO. 91-1444, pt. 1, at 6–7 (1970).
Id. at 1.
21 U.S.C. § 812.
§§ 812(b)(1)(A)–(C).
See Pub. L. No. 91-513, 84 Stat. 1236, 1248–49 (1970).
21 U.S.C. § 812(c), Schedule I(d)(2)(A).
§§ 812(b)(2)(A)–(B).
§ 812(b)(2)(C).
See 84 Stat. at 1250.
See 21 U.S.C. § 812(b)(3).

2019]THE SURPRISING REACH OF FDA REGULATION OF CANNABIS

853

only “moderate or low physical dependence or high psychological
dependence.”191 Initial classes of substances included stimulants
(amphetamine, phenmetrazine, non-injectable methamphetamine,
and methylphenidate), certain enumerated depressants, nalorphine,
and certain enumerated substances with quantified narcotic levels.192
Schedule IV lowered the abuse and risk factors further. These substances
have a low potential of abuse and limited physical or psychological
dependence relative to substances in Schedule III.193 A list of specific
substances, including phenobarbital, was included in the initial Schedule.194
Schedule V contains the lowest set of criteria. Abuse potential and
risk factors are set to a level below all Schedule IV substances.195 A
single class of substances that include no more than certain quantified
concentrations of narcotics along with other active medical ingredients
was included in the original act.196 An example would be cough
medicine with not more than 200 milligrams of codeine per 100
milliliters or per 100 grams of the overall substance.197
The definition of “marihuana” in the CSA was simply that which had
already been codified in federal statutes since the Marihuana Tax Act:
[A]ll parts of the plant Cannabis sativa L., whether growing or not; the
seeds thereof; the resin extracted from any part of such plant; and
every compound, manufacture, salt, derivative, mixture, or preparation
of such plant, its seeds or resin. Such term does not include the mature
stalks of such plant, fiber produced from such stalks, oil or cake made
from the seeds of such plant, any other compound, manufacture, salt,
derivative, mixture, or preparation of such mature stalks (except the
resin extracted therefrom), fiber, oil, or cake, or the sterilized seed of
such plant which is incapable of germination.198

But with the advances in chemical and genetic research on cannabis
taking place during the 1960s, the time was ripe for challenges as to
whether “Cannabis sativa L.” in fact included all kinds of cannabis in the
market. Fittingly, in a 1969 decision involving LSD and hallucinogenic
drug pioneer, Dr. Timothy Leary, the Supreme Court cautiously opined
in dicta that “it seems that there is only one species of marihuana,”
191. §§ 812(b)(3)(A), (C).
192. See 84 Stat. at 1251–52.
193. 21 U.S.C. §§ 812(b)(4)(A), (C).
194. See 84 Stat. at 1252.
195. 21 U.S.C. §§ 812(b)(5)(A), (C).
196. See 84 Stat. at 1252.
197. See id.
198. 84 Stat. at 1244 (codified at 21 U.S.C. § 802(16)); see also Marijuana Tax Act of
1937, Pub. L. No. 75-238, 50 Stat. 551 (codified at 26 U.S.C. § 4761(2)).
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although the case was decided under the earlier Marihuana Tax Act
statute and did not involve a direct challenge to the definition.199
A decision the next year in a Pennsylvania federal court also decided
under the earlier statute, expressly rejected the defendant’s argument
that “marihuana”—tied to Cannabis sativa L.—did not include
Cannabis “indicia.”200 In its examination of the legislative history of
marijuana law, the court quoted Henry J. Anslinger, the Commissioner
of Narcotics, when he spoke during congressional hearings on the
taxation of marijuana:
[M]arihuana is the same as Indian hemp, and is sometimes found as
a residual weed, and sometimes as the result of a dissemination of
birdseed. It is known as cannabin, cannabis Americana or cannabis
Sativa. Marihuana is the Mexican term for cannabis Indicia. We
seem to have adopted the Mexican terminology, and we call it
marihuana, which means good feeling.201

For Schedule I drugs and substances, the CSA prohibits their
manufacture, distribution, or dispensation, as well as their possession
with intent to manufacture, distribute, or dispense.202 Penalties
include not only fines and imprisonment,203 but also criminal and civil
forfeiture of property to the United States.204

199. Leary v. United States, 395 U.S. 6, 50 (1969) (citing lower court testimony of
Dr. Richard Schultes, Director, Harvard Botanic Museum).
200. United States v. Moore, 330 F. Supp. 684, 686–87 (E.D. Pa. 1970) (citing
Congressional legislative history, state court decisions, and scientific authorities for support).
201. Id. at 686 (quoting Taxation of Marihuana: Hearings Before the Comm. on Ways and
Means on H.R. 6385, 75th Cong. 18 (1937) (statement of H.J. Anslinger, Commissioner
of Narcotics)). It is unclear where Anslinger got the idea that “marihuana” meant “good
feeling.” The decision was affirmed by the U.S. Court of Appeals for the Third Circuit,
United States v. Moore, 446 F.2d 448 (3d Cir. 1971), and certiorari was denied by the
U.S. Supreme Court, Moore v. United States, 406 U.S. 909 (1972) (mem.). Subsequent
federal court decisions were consistent. See, e.g., United States v. Gaines, 489 F.2d 690,
690–91 (5th Cir. 1974) (affirming trial court’s refusal to instruct jury that the statutory
definition of marihuana only included Cannabis sativa L.); United States v. King, 485 F.2d
353, 360–61 (10th Cir. 1973) (holding a government chemist’s testimony amply
sufficient for prima facie case that the substance in defendant’s possession was marijuana
as defined in the statute, even though the chemist did not describe the marijuana as
Cannabis sativa L.); United States v. Rothberg, 351 F. Supp. 1115, 1118 (E.D.N.Y. 1972),
aff’d, 480 F.2d 534 (2d Cir. 1973) (rejecting defendants’ argument that government had
to prove the marijuana in question was Cannabis sativa L., rather than a different strain).
202. 21 U.S.C. § 841(a)(1) (2012).
203. § 841(b).
204. §§ 853(a), 881(a). Criminal forfeiture can occur where individuals have
violated CSA provisions punishable by more than one year in prison. § 853(a).
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The CSA specifically authorizes the Attorney General to add or
remove items from the Schedules, including moving items from one
Schedule to another.205 Any changes must be guided by the CSA’s
process, which includes requesting a scientific and medical evaluation
and recommendation from the Secretary of Health and Human
Services.206 Responsibility for the evaluation and recommendation has
been delegated, in turn, to the FDA.207 The FDA must consider certain
listed factors: the drug’s actual or relative potential for abuse, scientific
evidence of its pharmacological effect (if known), the state of current
scientific knowledge regarding the drug, the drug’s history and
current pattern of abuse, the scope (and duration and significance) of
abuse, its psychic or physiological dependence liability, the risk (if any)
it presents to public health, and whether it is an “immediate precursor”
of another controlled substance.208 The Secretary must recommend a
specific Schedule (or removal, if appropriate), and this
recommendation is binding as to scientific and medical matters.209
After the Secretary provides a recommendation, the Attorney General
must use formal rulemaking to issue a final decision.210 If the Secretary
recommends that a drug not be controlled, the Attorney General may
not control the drug.211 Where the United States is a signatory to a
treaty, convention, or protocol establishing controls over a particular
drug or substance, the Attorney General must add that drug or
substance to what is deemed the most appropriate Schedule.212 This is
particularly relevant where cannabis remains controlled under the
Single Convention on Narcotic Drugs.213 The FDA must alert the
Attorney General when a NDA involves a drug that has a “stimulant,
depressant, or hallucinogenic effect on the central nervous system,” and

205. § 811(a).
206. § 811(b).
207. See generally 21 C.F.R. § 1308; see also Controlled Substance Staff Functional Roles,
FDA, https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsand
Tobacco/CDER (last visited Feb. 5, 2019).
208. 21 U.S.C. §§ 811(b)–(c). A drug or substance that is an immediate precursor of
another listed drug or substance may be placed in the same or higher Schedule. § 811(e).
209. § 811(b).
210. § 811(a).
211. § 811(b).
212. § 811(d).
213. United Nations Single Convention on Narcotic Drugs, 1961, art. 28, Mar. 20,
1961, 18 U.S.T. 1407, 520 U.N.T.S. 240 (establishing an international treaty to regulate
drugs, including cannabis).
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the drug appears to have abuse potential.214 Any non-narcotic substance
approved by the FDA to be sold over the counter shall be excluded from
scheduling by regulation promulgated by the Attorney General.215
In 2009, in light of the increasing number of states enacting medical
marijuana laws, the DOJ issued a memo (the “Ogden Memo”) that
deprioritized prosecution of individuals engaged in medical cannabis
production, distribution, or use, provided they were compliant with
state laws and did not otherwise pose any enhanced risks.216 In the
wake of Colorado’s and Washington’s respective initiatives to statelegalize recreational cannabis, the DOJ took a cautious response.
Rather than taking any direct action against the states or officials
within them tasked with implementing the recreational systems, the
DOJ instead issued an internal guidance memo (the “Cole Memo”) to
U.S. attorneys.217 It recommended that U.S. attorneys use a set of drug
enforcement priorities in deciding where and how to allocate limited
government resources to cannabis prosecutions.218 The guidance was
particularly directed to attorneys in states with “robust” state cannabis
regulatory regimes.219 The eight priorities are:
(1) preventing the distribution of marijuana to minors;
(2) preventing revenue from the sale of marijuana from going to
criminal enterprises, gangs, and cartels;
(3) preventing the diversion of marijuana from states where it is
legal under state law in some form to other states;
(4) preventing state-authorized marijuana activity from being used
as a cover or pretext for the trafficking of other illegal drugs or other
illegal activity;
(5) preventing violence and the use of firearms in the cultivation
and distribution of marijuana;

214. § 811(f).
215. § 811(g)(1).
216. Memorandum from Deputy Attorney Gen. David W. Ogden on Investigations
& Prosecutions in States Authorizing the Medical Use of Marijuana to Selected United
States Attorneys (Oct. 19. 2009), https://www.justice.gov/sites/default/files/o
pa/legacy/2009/10/19/medical-marijuana.pdf.
217. Memorandum from Deputy Attorney Gen. James M. Cole on Guidance
Regarding Marijuana Enforcement to All United States Attorneys (Aug. 29, 2013)
[hereinafter Cole Memo], https://www.justice.gov/iso/opa/resources/30520138291
32756857467.pdf.
218. Id.
219. Id. (noting that a “robust” regulatory system would address the same priorities
the DOJ addresses in enforcement, including prohibiting access to minors and
preventing illicit trade that funds criminal enterprises).
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(6) preventing drugged driving and the exacerbation of other
adverse public health consequences associated with marijuana use;
(7) preventing the growing of marijuana on public lands and the
attendant public safety and environmental dangers posed by
marijuana production on public lands; and
(8) preventing marijuana possession or use on federal property.220

State regulatory regimes, such as that of Washington State, were set
up expressly to avoid tripping any of these eight prosecution priorities,
which also appeared in an earlier memo issued by Cole.221 However,
in 2018, Attorney General Sessions rescinded the Cole Memo and
other related guidance documents, and thus all participants in statelegal cannabis systems are now subject to the regular discretion of their
local U.S. Attorney to prosecute federal crimes.222 At the same time,
the so-called Rohrabacher-Blumenauer Amendment, an appropriations
bill rider that has been reapproved for the past few years,223 prohibits the
DOJ from using any congressionally-appropriated funds for cannabis
prosecutions for businesses or individuals operating under robust state
medical cannabis regulatory systems.224
Notwithstanding this
prohibition, the DOJ continued its prosecution of a California
dispensary until a federal judge recently rebuked the DOJ’s theory of
why its actions were not technically a use of appropriated funds.225 While
this ruling might seem to be a major victory for regulated cannabis
businesses, the DOJ’s willingness to go to court to protect its ability to
prosecute cannabis CSA violations, regardless of both the guidance of

220. Id.
221. See generally WASH. REV. CODE ANN. § 69.51A (West 2015).
222. See Memorandum from Attorney Gen. Jefferson B. Sessions, III on Marijuana
Enforcement to United States Attorneys (Jan. 4, 2018), https://www.justice.gov/opa/
press-release/file/1022196/download.
223. See Pub. L. No. 115-141, § 538, 132 Stat. 348 (2018); Pub. L. No. 115-31, § 537,
131 Stat. 135, 228 (2017); Pub. L. No. 114-112, § 542, 129 Stat. 2242, 2332 (2016); Pub.
L. No. 114-113, § 542, 129 Stat. 2242, 2332 (2015); Pub. L. No. 113-235, § 538, 128 Stat.
2130, 2217 (2014).
224. See Consolidated Appropriations Act, Pub. L. No. 115-141, § 538 (2018)
(providing that no funds from the Act may be used to prevent the states listed in the
Amendment from implementing their own laws legalizing, to whatever extent, the
medical use of cannabis).
225. United States v. Marin All. for Med. Marijuana, 139 F. Supp. 3d 1039, 1040,
1044 (N.D. Cal. 2015) (attacking the “contradiction inherent in the [DOJ’s] assertion
that enjoining any one medical marijuana dispensary . . . does not impede California’s
implementation of its medical marijuana laws”). The United States entered a notice
of appeal in December 2015 but moved to dismiss its appeal the following spring.
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the Cole Memo and the congressional appropriations bills, suggests that
the DOJ is not quite ready to give up cannabis enforcement.
In a much-publicized development, Congress “legalized” hemp in
2018 by changing the definitions of marihuana and THC in the CSA.226
First, this reveals the dubious position of those who assert hemp as some
kind of separate cousin species to cannabis. The Agriculture
Improvement Act227 effectively defines hemp as Cannabis sativa with
THC concentration of not more than 0.3 percent on a dry weight
basis.228 Second, the descheduling of “hemp” and Commissioner
Gottlieb’s response underscore this Article’s thesis that descheduling
cannabis will not result in the free production, marketing, and
distribution that proponents have claimed. Instead, the FDA will
continue to regulate any product containing ingredients such as THC and
CBD that are themselves currently regulated as drugs, as well as any
medical claims made by a producer of any products, regardless of whether
those products or their ingredients are scheduled under the CSA.
III. FDA REGULATION RELEVANT TO MEDICAL CANNABIS
The FDA regulates a wide variety of medical and consumer products
sold in the United States—not just foods and drugs, but also dietary
supplements, medical devices, cosmetics, and tobacco products.229
The agency’s authority to regulate an item is triggered when that item
satisfies a definition in the primary statute implemented by the agency,
the FDCA.230 For instance, if an item meets the definition of “drug” in
§ 201(g) the FDCA, the FDA has jurisdiction over the item and applies
its rules and policies relating to drugs.231
Two threshold points about the FDA’s jurisdiction are important to
understand. First, the statutory definitions for the various regulated
categories—such as “drug” and “dietary supplement”—do not always
align with common usage of the terms in question. Their meanings
have been fleshed out by the agency and courts, leading to rules that

226. See Agriculture Improvement Act of 2018, Pub. L. No. 115-334.
227. Pub. L. No. 115-334 (2018).
228. Id.
229. What Does FDA Regulate?, FDA, https://www.fda.gov/aboutfda/transparency/
basics/ucm194879.htm (last visited Feb. 5, 2019).
230. 21 U.S.C. §§ 301–399h (2012).
231. § 321(g)(1). Throughout this Article, statutory references in the text use the
provisions as numbered in the FDCA, rather than as numbered the U.S. Code. Section
201(g) of the FDCA is codified at 21 U.S.C. § 321(g).
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might not be evident from looking at the statute alone.232 And the
definitions do not take the same approach to classifying items. For
instance, one definition might consider the form of the item, another
the actual use of the item, and another the claims made about the
item.233 Complicating matters further, some definitions overlap. It is
possible for a single item to be both a cosmetic and a drug, for instance,
and regulated under both sets of authorities.234
Second, the FDA has authority only with respect to products shipped in
interstate commerce. Congress enacted the FDCA pursuant to its power
to regulate commerce among the states,235 and the statutory provisions
governing agency jurisdiction therefore focus on products that will be
shipped in interstate commerce as well as those that have already been
shipped in interstate commerce.236 The agency also takes the position
that it may regulate products containing components (such as
ingredients) previously shipped in interstate commerce, and the courts
have generally deferred to the agency on this point.237 Most medical
232. See, e.g., Meserey v. United States, 447 F. Supp. 548, 553 (D. Nev. 1977)
(explaining that “[r]egardless of the actual physical effect of the product, once it is
established that its intended use brings it within the drug definition, it will be deemed
a drug for purposes of the Act”); United States v. Frank, 189 F. 195, 199 (S.D. Ohio
1911) (“[I]f any substance or mixture is intended to be used for the cure, mitigation,
or prevention of disease of either man or other animals, it is nevertheless a drug
whether it is recognized in the Pharmacopoeia . . . or not.”).
233. See United States v. Hazel Bishop, Inc., 409 F.2d 734, 739 (2d Cir. 1969)
(“Regardless of the actual physical effect of a product, it will be deemed a drug for purposes
of the Act where the labeling and promotional claims intended to show uses that bring it
within the drug definition.”); Meserey, 447 F. Supp. at 553 (explaining that “[r]egardless of
the actual physical effect of the product,” once the product’s intended use is established as
one that falls within the statute, it will be deemed a drug covered by the FDCA).
234. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?), FDA, https://www.fda.gov/cosmetic
s/guidanceregulation/lawsregulations/ucm074201. (last visited Feb. 5, 2019) (“[A]
shampoo is a cosmetic because its intended use is to cleanse the hair. An antidandruff
treatment is a drug because its intended use is to treat dandruff. Consequently, an
antidandruff shampoo is both a cosmetic and a drug.”).
235. United States v. Walsh, 331 U.S. 432, 434 (1947) (“The Federal Food, Drug,
and Cosmetic Act rests upon the constitutional power resident in Congress to regulate
interstate commerce.”).
236. See, e.g., 21 U.S.C. § 331 (2012) (prohibiting certain acts, including the
introduction of misbranded or adulterated foods, drugs, devices, cosmetics, or tobacco
products into interstate commerce).
237. E.g., United States v. Regenerative Scis., LLC, 741 F.3d 1314, 1320–21, 1326
(D.C. Cir. 2014) (affirming the FDA’s regulatory authority over the stem cell mixture
at issue on the grounds that the mixture contained certain elements, specifically the
antibiotic doxycycline, that were transported through interstate commerce prior to
their incorporation into the mixture).
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treatments and consumer products travel in interstate commerce, so the
interstate commerce requirement generally does not meaningfully
constrain the FDA’s authority. After descheduling, however, some
cannabis-based products could be made, sold, and used only within the
borders of one state, without any component that traveled in interstate
commerce. In these cases, the FDA would have no jurisdiction.238
A product containing or derived from cannabis, or containing
components derived from cannabis, is most likely to be regulated by the
FDA as a drug, food or food additive, or dietary supplement. The
category will depend on the product. Because the product will contain
plant-derived ingredients, the FDA may also consider it a “botanical
product”—but this is a descriptive term, not a regulatory classification.239
Section II.A, discusses regulation of cannabis-based products as
drugs. Next, Section II.B and Section II.C explain how FDA would
regulate a food or a dietary supplement that contained cannabis or a
cannabis constituent. Section II.D considers the possibility that a
product comprising cannabis or derived from cannabis might fall into
a different FDA-regulated category or, indeed, outside the FDA’s
purview altogether due to the statutory requirement for interstate

238. Cf. Patricia J. Zettler, Pharmaceutical Federalism, 92 IND. L.J. 845, 879 (2017)
(“Because the FDA’s jurisdiction is limited to drugs that move in interstate commerce
(including drugs with components that move in interstate commerce), medical
marijuana laws could be written to avoid the FDA altogether by permitting only
wholly intrastate production and sale of marijuana.”). In this situation, however, state
laws might authorize (or prohibit) sale. As both Professor Zettler and Professor Noah
have pointed out, various state laws authorized the local production and sale of laetrile
for the treatment of cancer in the 1970s and 1980s, even though the FDA had not
approved the treatment. Id.; see also Lars Noah, State Affronts to Federal Primacy in the
Licensure of Pharmaceutical Products, 2016 MICH. ST. L. REV. 1, 22–23 (noting that after
the FDA “acted against [Laetrile] in the 1970s, numerous states legalized the use of
this purported treatment for cancer”). The interstate commerce limitation in the
FDCA has similarly prompted the FDA to stay its hand with respect to purely intrastate
sale of raw milk products. See Pub. Citizen v. Heckler, 653 F. Supp. 1229, 1235 (D.D.C.
1986) (explaining that the FDA declined to ban sales of raw milk because most raw
milk products were marketed exclusively in intrastate commerce and the agency did
not have adequate legal authority on the facts available at the time to prohibit
intrastate marketing of raw milk); Requirements Affecting Raw Milk for Human
Consumption in Interstate Commerce, 52 Fed. Reg. 29,509 (Aug. 10, 1987) (to be
codified at 21 C.F.R. pt. 131).
239. CDER Small Bus. & Indus. Assistance, Botanical Drug Review, FDA/CDER SBIA
CHRONICLES (Nov. 17, 2015), https://www.fda.gov/downloads/drugs/developm
entapprovalprocess/smallbusinessassistance/ucm472934.pdf (“Botanical products
may be classified as foods, dietary supplements, drugs, medical devices, or cosmetics,
depending on their ‘intended use.’”).
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commerce. Part IV continues the discussion of the current statutory
framework (as interpreted by the FDA) and the current regulatory
framework (as applied by the FDA) and, in places, note positions that
the FDA might take—without exploring whether this approach would
in the end withstand legal challenge.
A. Medical Cannabis as “Drug”
Explicit or implicit claims that a product containing cannabis (or a
cannabis constituent) could treat disease, or even simply affect the
functioning of the body, would turn that product into a “new drug”
that requires premarket approval from the FDA.240 The research
required to support premarket approval of a new drug is expensive and
time consuming,241 and some cannabis-based products could present
novel scientific and regulatory questions for the agency, potentially
slowing the process and adding risk. The agency has signaled its
support for cannabis-based drugs and may be flexible with regulatory
requirements in some situations, but there is no escaping the fact that
the cost of taking a cannabis-based product through the FDA’s new
drug approval paradigm could place this pathway out of reach for most
entities providing medical cannabis today.
1.

Regulation of medical cannabis under the FDA’s new drug authorities
Any product containing or made from cannabis would be deemed a
“drug” by the FDA if it were associated with medical claims.242 Section
201 of the FDCA defines a “drug” as any article (item) “intended for use
in the diagnosis, cure, mitigation, treatment, or prevention of disease in
man.”243 The term “drug” also includes any article “intended to affect
the structure or function of the body of man” (unless it is a food).244
Finally, anything intended as a “component” of a drug is also a drug.245
Under this definition, the FDA’s authority is triggered by the “intended

240. See United States v. Cruez, 144 F. Supp. 229, 230, 235 (D. Ill. 1956) (holding that
because the “defendant orally represented” that an herb tonic “was a remedy for treatment
of arthritis,” the tonic was considered a drug and subject to regulation under the FDCA).
241. News Release, Cost of Clinical Trials for New Drug FDA Approval are Fraction
of Total Tab, Johns Hopkins Bloomberg School of Public Health (Sept. 24, 2018)
(describing study findings that FDA clinical trials cost a median of $19 million dollars,
which makes up “one percent of the average total cost of developing a new drug”).
242. 21 U.S.C. § 321(g) (2012).
243. § 321(g)(1)(B).
244. § 321(g)(1)(C).
245. § 321(g)(1)(D).
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use” of an item. “Intended use” does not refer to the subjective intent
of the company selling the product, nor does it refer to the purchaser’s
intentions.246 Instead, intended use is measured objectively—generally
on the basis of the claims made by the persons legally responsible for
the product in interstate commerce.247 Thus, it usually turns on claims
made in labeling, advertising, and other promotion.248
Drug claims need not be explicit. If a company implies its product
can be used to treat disease, the FDA may conclude that the product is
a drug.249 And the term “disease” should be understood broadly. Any
claim relating to treatment of a medical condition—for instance,
easing the symptoms (such as muscle spasms) of multiple sclerosis,
reducing nausea associated with chemotherapy, increasing appetite in
patients with chronic illness such as HIV, or relieving pain and
inflammation of arthritis—will be viewed as a drug claim by the FDA.250
These claims turn the product into a drug even if the product does not
work as described.251
Any item is a “drug” for purposes of the FDA’s authority if it has the
requisite intended use.252 The agency’s drug authority will apply
246. See Nat’l Nutritional Foods Ass’n v. Mathews, 557 F.2d 325, 334 (2d Cir. 1977)
(“In determining whether an article is a ‘drug’ because of an intended therapeutic
use, the FDA is not bound by the manufacturer’s subjective claims of intent but can
find . . . intent on the basis of objective evidence.”).
247. 21 C.F.R. § 201.128 (2018) (stating that “intent is determined by such persons’
expressions or may be shown by the circumstances surrounding the distribution of the article”).
248. The claims need not be physically attached to the product (e.g., on the label).
See Kordel v. United States, 335 U.S. 345, 350 (1948) (finding that “[o]ne article or
thing is accompanied by another when it supplements or explains it”).
249. See, e.g., Patricia J. Zettler et al., Closing the Regulatory Gap for Synthetic Nicotine,
59 B.C. L. REV. 1933, 1944 (2018) (noting that the FDA regulates smoking cessation
aids as drugs based on the implied claims that they lower the risk of disease).
250. See United States v. Lane Labs–USA, Inc., 324 F. Supp. 2d 547, 569 (D.N.J.
2004) (finding that “through its promotional material . . . [the defendant] promoted
[its products] for the diagnosis, cure, mitigation, treatment, or prevention of diseases,
namely cancer and HIV/AIDS,” and making them drugs under the FDCA); United
States v. Cruez, 144 F. Supp. 229, 230, 235 (E.D. Ill. 1956) (holding that because the
“defendant orally represented” that its herb tonic “was a remedy for treatment of
arthritis,” it was considered a drug under the FDCA).
251. The definition of “drug” focuses on the item’s intended use, not its actual effect
in the body.
252. This is not to say, however, that anything intended to treat a disease is a drug.
FDA also regulates “devices,” which are similarly intended for use in the diagnosis,
cure, mitigation, treatment, or prevention of disease or intended to affect the structure
or function of the body. 21 U.S.C. §§ 321(h) (2012). Such an item will be a device,
rather than a drug, if (1) it is an “instrument, apparatus, implement, machine,
contrivance, implant, in vitro reagent, or other similar or related article,” (2) it does
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whether the product is composed of dried cannabis flower, derived
from a cannabinoid (or terpenoid or flavonoid), extracted from the
plant, or composed of synthetic compounds identical to (or similar to)
these botanically-derived alternatives. FDA authority will apply no
matter what form the product takes—whether it is sold in a tin like
chewing tobacco, sold dried for smoking, sold in an oil form for use
with a diffuser, or baked into a cookie. For instance, the FDA sent a
warning letter to General Mills in May 2009, concluding that because
the company promoted Cheerios® Toasted Whole Grain Oat Cereal
for lowering cholesterol and thus for treatment, mitigation, and
prevention of coronary heart disease, the breakfast cereal was also a
“drug” and would be regulated as a drug.253 Drug claims will establish
a drug’s intended use and turn the item into a drug, for FDA purposes.
“Drug” status under the FDA framework would trigger a variety of
regulatory requirements. For instance the manufacturer would be
required to comply with “current good manufacturing practices”
(cGMP).254 The FDA’s cGMP regulations impose requirements relating
to the creation and training of a quality control unit, design and features
of any buildings and facilities used, design and maintenance of
equipment used, production and process controls, and recordkeeping,
among other things.255 Failure to comply with current cGMP would
render the product adulterated and could expose the company to
enforcement action, including criminal prosecution.256
Also, the FDA would have jurisdiction over the product’s “labeling,”
meaning any “written, printed, or graphic materials” associated with
the product.257 If the agency concluded the product could be sold over
the counter,258 the manufacturer would need to comply with the

not “achieve its primary intended purpose through chemical action within or on the
body,” and (3) it is “not dependent upon being metabolized for the achievement of its
primary intended purpose.” Id.
253. Warning Letter from FDA to General Mills (May 5, 2009),
http://wayback.archive-it.org/7993/20170112195733/http://www.fda.gov/ICECI/E
nforcementActions/WarningLetters/2009/ucm162943.htm.
254. 21 U.S.C. § 351(a) (2012) (deeming a drug “adulterated” if “the methods used
in, or the facilities or controls used for, its manufacture, processing, packing, or
holding do not conform to or are not operated and administered in conformity with
current good manufacturing practice”).
255. See generally 21 C.F.R. pt. 211 (2018).
256. See 21 U.S.C. § 331(a), § 332, § 333.
257. § 321(m) (defining labeling as “all labels and other written, printed, or graphic matter
(1) upon any article or any of its containers or wrappers, or (2) accompanying such article”).
258. See infra Section III.C.
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agency’s nonprescription drug labeling regulations and, among other
things, generally include a “Drug Facts” panel on the outside
container.259 If the FDA instead concluded that prescriptions would be
needed, the company would need to comply with the agency’s
prescription drug labeling rules.260 The agency could also take
enforcement action if any labeling—written, printed, or graphic
materials—were “false or misleading in any particular.” This would
include taking action if the labeling omitted material information,
such as the consequences from customary or usual use of the
product.261 Again, these rules would apply simply because the product
bore a medical claim and therefore became a “drug”—no matter what
form the product took.
The FDA would almost certainly also deem a cannabis drug to be a
“new drug,” which is a separate statutory category requiring premarket
approval. A drug is a “new drug” unless two things are true: (1) it is
“generally recognized, among experts qualified by scientific training
and experience to evaluate the safety and effectiveness of drugs, as safe
and effective for use under the conditions prescribed, recommended,
or suggested in the labeling thereof,” and (2) it has been marketed for
a material time and to a material extent under those conditions.262
Conventionally, this is referred to as being “generally recognized . . . as
safe and effective” or “GRASE.”263 The FDA determines whether each
product is GRASE, conducting the inquiry product by product, rather
than active ingredient by active ingredient.264 And the inquiry is
specific to the conditions described in that product’s labeling—its
intended use, as well as its route of administration, dosage form, and
strength.265 In other words, the specific drug product (not cannabis
itself, or cannabis for a particular type of use, such as pain relief) must
be GRASE. If it is not, the product is a new drug, which means it cannot
be shipped in interstate commerce without either (1) an approved NDA,

259. See 21 C.F.R. § 201.66(c).
260. See infra Section III.A.3.
261. 21 U.S.C. §§ 321(n), 352(a).
262. § 321(p).
263. Id.
264. See United States v. Generix Drug Corp., 460 U.S. 453, 459 (1983) (concluding that the
term “drug” refers to “entire drug products, complete with active and inactive ingredients”).
265. 21 U.S.C. § 321(p) (defining a drug as a new drug if it is not GRASE “under
the conditions prescribed, recommended, or suggested in the labeling thereof”).
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which permits commercial marketing, or (2) effective investigational
new drug application (IND), which permits testing in humans.266
The FDA has consistently treated cannabis-based drugs as “new
drugs” under the FDCA. For instance, in the 1970s, the agency
permitted INDs for the use of cannabis to treat a variety of ailments,
including refractory glaucoma and anorexia associated with AIDS.267
Although the IND regulatory mechanism normally governs clinical
trials, the INDs permitted here were for compassionate use programs.
Unlike clinical trials, these programs were not intended to generate
information for purposes of new drug approval. They were instead
designed primarily to permit treatment of a patient’s disease or
condition.268 While these early “treatment INDs” are no longer active,
the FDA has since permitted dozens of INDs for true clinical trials of
cannabis and cannabis-based products.269 In addition, the FDA has
approved three NDAs for synthetic cannabinoids as well as one NDA
for a naturally derived cannabinoid drug product.270
In view of these precedents, the FDA would likely conclude that any
drug containing or derived from cannabis is a new drug.271 Although

266. § 355(a).
267. MACK & JOY, supra note 81, at 159–61.
268. The government established the program initially to settle a civil lawsuit
brought by Robert Randall, who sought cannabis for treatment of his glaucoma. The
government eventually agreed to supply medical cannabis—in cigarette form—to
several other people through the same mechanism. Kuromiya v. United States, 78 F.
Supp. 2d 367, 368 (E.D. Pa. 1999); see also Moira Gibbons, The Cannabis Conundrum:
Medication v. Regulation, 24 HEALTH LAW. 1, 5 (2011). The National Institute on Drug
Abuse (NIDA), part of the National Institutes of Health (NIH), cultivated and
distributed the cannabis. MACK & JOY, supra note 81, at 160.
269. The program shut down in 1991, but the government continued to supply the
thirteen patients that it had approved by that time. Kuromiya, 78 F. Supp. 2d at 370; MACK
& JOY, supra note 81, at 160. For a discussion of current clinical trials, see infra Section IV.B.
270. See infra Section IV.A.
271. In November 2017, the FDA received a citizen petition asking it to confirm
that cannabis and THC are not only drugs but also new drugs—that is, not generally
recognized as safe and effective. See Drug Watch Int’l, Inc. Citizen Petition, No. FDA2017-P-6692 (Nov. 21, 2017), https://www.regulations.gov/document?D=FDA-2017-P6692-0001. The petition relies on the fact that, at the time of its filing, the FDA had
approved three synthetic cannabinoid drugs under the new drug provisions. Id. at 4.
On July 2, 2018, the FDA denied the citizen petition, refusing to issue a “negative
monograph specifically stating that unapproved new OTC marijuana and THC
products are not GRAS/E and [] subject to” regulation, but nonetheless finding that
“these products are ‘new drugs’” under the FDCA. Response from FDA to Drug Watch
Int’l, Inc., No. FDA-2017-P-6692-0042 (July 2, 2018), https://www.regulations.gov/
document?D=FDA-2017-P-6692-0042.
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a drug may be exempt from the FDA’s new drug authorities, it is
unlikely that either exemption would cover a drug containing or
derived from cannabis.272 First, a particular product might be deemed
GRASE and therefore not a new drug. Since the 1960s, however, the
FDA has interpreted the GRASE exemption to require “the same
quantity and quality of scientific evidence that is required to obtain
approval of an application for the product.”273 The Supreme Court has
accepted the FDA’s approach, reasoning that any other approach would
deprive the agency of jurisdiction over a drug that, if it were subject to
the agency’s jurisdiction, could not be marketed.274 And again, the new
drug inquiry is product by product and specific to the conditions of use
described in the labeling. Extensive published research on medical
cannabis uses, broadly speaking, will not satisfy the standard. The
agency would expect “substantial evidence” that a particular product was
safe and effective for a particular use.275 In this case, the manufacturer
might as well seek approval of a marketing application.
Second, a product might be “grandfathered,” and therefore not a
new drug. Under the original grandfather clause, a drug product on
the market before passage of the FDCA in 1938 was not a “new drug”
if “its labeling contained the same representations concerning the
conditions of its use.”276 When Congress amended the statute in 1962
to require that new drug applications contain effectiveness data, it
extended the grandfather clause, exempting any drug that was
excluded prior to 1962, so long as its composition and labeling did not
change.277 In effect, a drug that is not GRASE is nevertheless exempt
from the new drug provisions if it was regulated under the Pure Food
and Drugs Act of 1906 and if its labeling at the time contained the same
representations as now concerning the conditions of its use. It would
be exceptionally difficult for a company to satisfy the documentation

272. It would still be a “drug” subject to the agency’s drug regulations, including (as
noted) current good manufacturing practice and labeling requirements, and probably
prescription status.
273. 21 C.F.R. § 314.200(e)(1) (2018). This Article describes this evidentiary
burden in the next Subpart.
274. See Weinberger v. Hynson, Westcott & Dunning, Inc., 412 U.S. 609, 631 (1973)
(“[W]e cannot construe § 201(p) to deprive FDA of jurisdiction over a drug which, if
subject to FDA regulation, could not be marketed because it had not passed the
[FDA’s] ‘substantial evidence’ test.”).
275. Id. at 617–19.
276. 21 U.S.C. § 321(p) (2012).
277. Drug Amendments Act of 1962, Pub. L. No. 87-781, § 107(c), 76 Stat. 780, 789.
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requirements that the FDA has put in place for grandfather status.278
The agency requires evidence of “past and present quantitative
formulas, labeling, and evidence of marketing.”279 And, like GRASE
status, grandfather status is product-specific.280 The FDA has rejected
arguments about cannabis products to date based on the sufficiency of
the evidence presented.281
278. See 21 C.F.R. § 314.200(e)(2) (providing that “[a] contention that a drug
product is exempt” under § 201(p) of the act or the § 107(c) amendments must be
supported by sufficient evidence).
279. Id.
280. The FDA will not make decisions about grandfathering on a class-wide basis.
See, e.g., Response from FDA to Alston & Bird LLP, No. FDA-2012-P-0189 (Nov. 12,
2015), https://www.regulations.gov/document?D=FDA-2012-P-0189-0006 (denying
petition to confirm grandfather status of cocaine hydrochloride, noting disagreement
with petitioner’s premise “that a determination as to whether drug products are
exempt from the new drug safety and effectiveness requirements . . . by virtue of the
1938 grandfather clause can or should be made on a class-wide (i.e., non-productspecific) basis,” and adding that “determinations with respect to ‘grandfather’ status
are made on a product-specific basis”).
281. In 2000, the FDA rejected a petition arguing that various products prepared
from “home-grown cannabis” were exempt from the “new drug” authorities under the
grandfather clause. See Klopper & Mikuriya Citizen Petition, No. FDA-1999-P-2922
(formerly Docket No. 99-1865/CP1) (May 21, 1999). The petitioners had described
specific formulations, uses, and labeling on the market prior to the 1938 statute,
including formulations marketed by Parke, Davis, & Company (which included
“pressed flowering tops” sold by the ounce) for analgesic purposes, spasmodic
disorders, and neuralgia; extracts sold by Eli Lilly & Company as analgesics and for
migraines; “flowering top of the female plant” sold by Merck to increase the appetite;
and the “dried flowering tops of the female plant” sold by Squibb for epilepsy. Id. The
agency denied the petition because the petitioners had not presented evidence that
the drug products for which they sought grandfather status were “the same drug
products that were marketed” prior to 1938. Response from FDA to Klopper &
Mikuriya, No. FDA-1999-P-2922 (Dec. 29, 2000). A grandfather argument must be
supported by (among other things) an “exact quantitative formulation of the drug
(both active and inactive ingredients).” Id. It must also be supported by documents
to show that the labeling has not changed. The FDA also took the position that
because cannabis is a controlled substance and must bear a “C” designation in the
labeling, the labeling has changed sufficiently to revoke grandfather status. If cannabis
were descheduled, the FDA could not deny grandfather status on this ground.
A still-pending petition submitted in 2011 attempts to overcome the
documentation hurdles with respect to two additional products: bulk cannabis (in
pressed, loose leaf, sifted, grounded, or powdered forms) and cannabis in tincture or
liquid form as manufactured and labeled by the Lloyd Brothers Corporation. See
Mikuriya & McPike Citizen Petition, No. FDA-2011-P-0671 (Sept. 9, 2011),
https://www.regulations.gov/document?D=FDA-2011-P-0671-0001. The petitioners
provide details about the Lloyd Brothers distilling process, details about the company’s
marketing time line, and copies of the labels showing the percentage of alcohol present. Id.
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A company need not petition the agency asking for confirmation
that its product is GRASE or grandfathered. Instead, it may reach this
conclusion on the basis of evidence in its possession and proceed to
market. If the company is correct, the product is a drug subject to the
FDA’s drug authorities. But the FDA is likely to disagree with this
assessment for a drug containing or derived from cannabis, and a
company that erred would face enforcement action—up to and
including criminal prosecution.282 The Authors therefore assume that
any commercial product containing or derived from cannabis that is
intended for a medical use will require an approved NDA.283
2.

Pathway to market under the new drug authorities
An NDA must describe the product, including its composition and
how it is made, and demonstrate that the product is safe and effective
when used as described in its labeling.284 An applicant describes the
product and manufacturing process in the “[c]hemistry,
manufacturing, and controls” (“CMC”) section of the NDA, and it
substantiates the product’s safety and effectiveness with preclinical
(animal and laboratory) and clinical (human) data.285

282. 21 U.S.C. § 333(a) (2012).
283. There is another possibility: new drug status and enforcement discretion
because the cannabis is undetectable. The National Drug Code Directory on the
FDA’s website lists numerous marketed homeopathic drugs that list cannabis sativa as
an ingredient. See National Drug Code Directory, FDA, https://www.accessdata.fda.gov/
scripts/cder/ndc (last visited Feb. 5, 2019). Home Sweet Homeopathics, for instance,
appears to market a homeopathic medicine for migraine containing “cannabis sativa
30c.” Id. (select “labeler” from the drop down menu; then search for “Home Sweet
Homeopathics”). BioEnergetics, Inc. appears to market a homeopathic medicine for
allergies containing cannabis sativa pollen. Id. (select “labeler” from the drop down
menu; then search for “BioEnergetics, Inc.”). The practice of homeopathy assumes
that disease symptoms can be cured by small doses of substances that would cause
similar symptoms in healthy people. The cannabis in a homeopathic product labeled
as containing diluted cannabis is likely to be undetectable. Homeopathic medicines
are nevertheless “drugs” and, indeed, likely all “new drugs” that require preapproval.
The FDA has historically exercised enforcement discretion, unless safety issues arose.
See generally FDA, DRUG PRODUCTS LABELED AS HOMEOPATHIC: GUIDANCE FOR FDA STAFF
AND INDUSTRY (2017), https://www.fda.gov/downloads/drugs/guidancecompliance
regulatoryinformation/guidances/ucm589373.pdf; CPG Sec. 400.400 Conditions Under
Which Homeopathic Drugs May be Marketed, FDA, https://www.fda.gov/iceci/com
pliancemanuals/compliancepolicyguidancemanual/ucm074360.htm (last updated
Mar. 20, 2015). It is unlikely to exercise this discretion if the cannabis-derived active
ingredient can be detectable.
284. 21 C.F.R. § 314.50(d)(1).
285. § 314.50(d)(1), 314.50(d)(5)(iv).
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Some new drugs containing, or derived from, cannabis would qualify
as botanical drugs, in which case they might benefit from the agency’s
emerging and more flexible approach to botanical NDAs.286 The FDA
has published guidance to encourage the development of botanical
drugs,287 and in 2003 it created a Botanical Review Team (BRT) to
assist in review of botanical NDAs.288 The guidance describes greater
flexibility with respect to some application requirements, and the BRT
appears to be pivotal in ensuring the agency exercises this flexibility.289
Using this more flexible approach, the FDA has now approved two
botanical drugs: Veregen (sinecatchins) for the treatment of genital
and perianal warts, and Mytesi (crofelemer) for the symptomatic relief
of non-infectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy.290
286. A botanical NDA proposes a drug containing plant-derived ingredients.
According to agency officials, interest in botanical drugs has been increasing. Between
1982 and 2007, the agency received more than 350 requests to conduct clinical trials
and requests for meetings about clinical trials. Shaw T. Chen et al., New Therapies from
Old Medicines, 26 NATURE BIOTECH. 1077, 1077 (Oct. 2008).
287. See generally FDA, BOTANICAL DRUG DEVELOPMENT: GUIDANCE FOR INDUSTRY
(2016) [hereinafter BOTANICAL GUIDANCE].
288. A reviewer from the BRT provides a “pharmacognosy review” which, among
other things, evaluates the identity of the plant used in the botanical drug product,
evaluates the applicant’s raw material characterization and control, and evaluates
previous human experience with the botanical product. The botanical NDA is
otherwise reviewed by the same FDA scientific staff within the Office of New Drug
Products (OND) as any other NDA. Chen, supra note 286, at 1077–78. See generally
FDA, CTR. DRUG EVALUATION & RES., OFFICE OF PHARM. QUALITY, MAPP 5210.9 REV 1,
MANUAL OF POLICIES AND PROCEDURES: REVIEW OF BOTANICAL DRUG PRODUCTS (2016)
[hereinafter REVIEW OF BOTANICAL DRUG PRODUCTS].
289. See REVIEW OF BOTANICAL DRUG PRODUCTS, supra note 288, at 9 (discussing the BRT’s role).
290. FDA, CTR. FOR DRUG EVALUATION & RES., APPROVAL PACKAGE FOR: APPLICATION
NO. 202292ORIG1S000 (2012) [hereinafter FULYZAQ APPROVAL PACKAGE],
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202292Orig1s000Appr
ov.pdf (approving Fulyzaq); FDA, CTR. FOR DRUG EVALUATION & RES., APPROVAL
PACKAGE FOR: APPLICATION NO. 21-902 (2006) [hereinafter VEREGEN APPROVAL
PACKAGE], https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021902s000_
approv.pdf (approving Veregen). The names of these products have changed since
their initial approval. In June 2007, FDA approved a supplemental NDA to reflect a
change in the nonproprietary name for Veregens from kunecatechins to sinecatchins.
See FDA, CTR. FOR DRUG EVALUATION & RES., APPROVAL OF NDA 21-902/S-001, (June 1,
2007),
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/021902s
001ltr.pdf. In March 2018, FDA approved a supplemental NDA to reflect a change in
the proprietary name of Fulyzaq to Mytesi. See FDA, CTR. FOR DRUG EVALUATION &
RES., APPROVAL OF NDA 202292/S-006 (Mar. 6, 2018), https://www.accessdata.fda.gov/
drugsatfda_docs/appletter/2018/202292Orig1s006ltr.pdf. The text of this Article
uses the current names rather than the names at the time of initial approval.

870

AMERICAN UNIVERSITY LAW REVIEW

[Vol. 68:823

FDA officials cite the agency’s work on botanical drug development
as evidence that the agency “actively” supports the development of
drugs from cannabis.291 But there are two reasons to be cautious. First,
the botanical NDA framework does not apply to drugs containing
highly-purified substances simply derived from naturally occurring
sources.292 Many commonly-used drugs contain active ingredients
derived from plant sources and subsequently are highly processed and
purified.293 The FDA gives the example of paclitaxel, originally derived
from an extract of the yew tree.294 The agency does not consider these
botanical drugs, and they do not benefit from the flexibility enjoyed by
the companies that developed Veregen and Mytesi.295 Likewise, a
highly processed and purified drug derived from an extract of the
cannabis plant does not enjoy the same flexibility that attaches to drugs
the FDA deems botanical. As a result, the traditional new drug
development and approval paradigm described below will apply to
some drug products derived from cannabis.296 The more flexible
291. Douglas C. Throckmorton, Meeting Presentation, FDA Regulation of Marijuana:
Past Actions, Future Plans (April 12, 2016), https://www.fda.gov/downloads/AboutFD
A/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM498077.pdf.
292. BOTANICAL GUIDANCE, supra note 287, at 1.
293. See Kate Wong, Mother Nature’s Medicine Cabinet, SCIENTIFIC AMERICAN (Apr. 9, 2001),
https://www.scientificamerican.com/article/mother-natures-medicine-c (providing commons
examples such as aspirin).
294. BOTANICAL GUIDANCE, supra note 287, at 2. Paclitaxel was originally made from the
bark of Taxus brevifolia, the Pacific yew tree. Success Story: Taxol, NATIONAL CANCER INST.,
https://dtp.cancer.gov/timeline/flash/success_stories/S2_taxol.htm. Eventually a
starting material could be extracted from other Taxus trees, including the common
Taxus baccata (European yew). Id. This starting material was collected from plants
cultivated in public and private parks and gardens as well as plantations in Europe.
E.g., FDA, CTR. FOR DRUG EVALUATION & RES., NDA 20-262/S-026, ENVIRONMENTAL
ASSESSMENT AND FINDING OF NO SIGNIFICANT IMPACT FOR TAXOL (PACLITAXEL) INJECTION
(Nov. 6, 1997), https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020262
s026s027s028_taxol_chemr_EA_phrmr.pdf.
295. Veregen is made from the dried leaves of Camellia sinensis, a green tea plant,
grown on specific farms. FDA, CTR FOR DRUG EVALUATION & RES., APPLICATION NO. 21902, BOTANICAL REVIEW (Sept. 15, 2006) [hereinafter VEREGEN BOTANICAL REVIEW],
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021902s000_botanicalr.
pdf. The drug substance in Mytesi—crofelemer—is extracted from Croton lechleri, also
known as dragon’s blood or tree’s blood, harvested from the wild in South America.
FDA, CTR FOR DRUG EVALUATION & RES., APPLICATION NO. 202292ORIG1S000, SUMMARY
REVIEW (Dec. 14, 2012) [hereinafter FULYZAQ SUMMARY REVIEW], https://www.acce
ssdata.fda.gov/drugsatfda_docs/nda/2012/202292Orig1s000SumR.pdf.
296. As this Article discusses in Part IV, the FDA recently approved a drug
containing a highly purified extract of cannabis, and although the agency did not
deem the drug a botanical, it invited the BRT to participate in review of the
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approach to development and approval of botanical drugs—also
described below—may apply to others.
Second, agency documents relating to approval of Veregen and
Mytesi illustrate that although the FDA may be willing to take a more
flexible approach with respect to certain portions of the NDA, there is
a potential for significant disputes between the BRT and the usual
reviewers in the Office of New Drug.297 This disagreement may require
resolution by agency leadership. The need for leadership involvement
could make it risky to count on the exercise of flexibility for a cannabisbased botanical NDA and important to engage with the agency early
regarding plans to file a botanical NDA.
a. Chemistry, manufacturing, and controls
The CMC section must describe and provide data on the
composition, manufacture, and specifications of both the drug
substance (active ingredient) and the finished drug product (that is,
in its final form for the patient).298 Describing the active ingredient
means describing its physical and chemical characteristics and its
stability; explaining how it is made (or isolated and purified, for
instance); describing the controls used during manufacturing; and
laying out the specifics that are needed to ensure its identity, strength,
quality, and purity.299 Describing the product also includes listing the
components used in its manufacture (and identifying their
manufacturer and specifications), describing the manufacturing
procedures and in-process controls used, and laying out the
specifications needed to ensure the product’s strength, quality, purity,
potency, and bioavailability.300
The primary challenges for a botanical NDA are uncertainty about
the botanical drug’s active constituents, heterogeneity of the drug
substance, and inconsistency from batch-to-batch.301 These issues will
complicate preparation and review of the CMC section of the NDA.302

application. See EPIDIOLEX PRODUCT QUALITY REVIEW(S), infra note 571. But it does
not appear from the review documents that the applicant needed, or that the FDA
exercised, the same sort of flexibility with respect to application requirements as it
applied when approving Veregen and Mytesi.
297. FULYZAQ SUMMARY REVIEW, supra note 295; VEREGEN APPROVAL PACKAGE, supra note 290.
298. 21 C.F.R. § 314.50(d)(1)(i)(2018).
299. § 314.50(d)(1).
300. § 314.50(d)(1)(ii)(a).
301. BOTANICAL GUIDANCE, supra note 287, at 4.
302. 21 C.F.R. § 314.50(d)(1)(i).
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The FDA’s guidance document indicates that “therapeutic consistency”
can be supported using a totality of the evidence approach,” if the
applicant submits information relating to the botanical raw material,
quality control through chemical testing and manufacturing control,
and biological assays or even clinical data.303 Quality control of the drug
substance may consider factors such as strength by dry weight, chemical
identification of active constituents (if known) or chemical constituents,
quantification of active constituents (if known) or chemical
constituents, and tests for residual pesticides.304 A biological assay
would need to reflect the drug’s known or intended mechanism of
action.305 If the active constituents are not known or quantifiable, it
may be important to develop an assay to assess batch potency and
activity relative to a reference standard.306 The chemistry section
should also include a thorough review of past human experience with
the raw materials and known constituents.307
The application of a “totality of the evidence” for botanical drugs
means that some drugs that would not pass a traditional CMC review
may survive review with the support of the Botanical Review Team.308
The primary chemistry reviewer in the Office of New Drugs
considering Mytesi, for instance, concluded that issues relating to the
identity, strength, purity, and quality of the drug substance and drug
product precluded approval.309 The botanical reviewer, by way of
contrast, argued that these concerns stemmed from a “strict reading”
of the regulations and definitions of “identity,” “active ingredient,” and
“purity” from a “pure small molecule drug perspective.”310 He argued
that the regulations should be interpreted in a way that would
303. Id.; see also Botanical Drug Review, supra note 239, at 2 (noting that the FDA will
use a “totality of the evidence” approach, in order to overcome limitations in the ability
to characterize the active ingredient (or mixture) and in order to respond to concerns
about heterogeneity and batch-to-batch variability). Describing the raw material
includes explaining the agricultural and collection practices used. BOTANICAL
GUIDANCE, supra note 287, at 4.
304. BOTANICAL GUIDANCE, supra note 287, at 10–11.
305. Id. at 4.
306. Id. at 10.
307. Id. at 7–8.
308. Botanical Drug Review, supra note 239 (indicating that the CMC documentation
for a botanical drug may be different from that for a synthetic or highly purified drug).
309. FULYZAQ SUMMARY REVIEW, supra note 295, at 4; see also FDA, CTR. FOR DRUG
EVALUATION AND RES., MEMORANDUM: BOTANICAL SECONDARY REVIEW OF NDA 202292
8–11 (2012), https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202292Or
ig1s000BotanicalR.pdf.
310. FULYZAQ SUMMARY REVIEW, supra note 295, at 2.
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“accommodate the complex nature of botanical drug substance.”311
For example, he wrote, “the ‘identity’ of botanicals must include, in
addition to the standard chemical analyses, the source of raw materials
and other non-CMC data—e.g., identification of species, geographic
location of harvesting, processing, and bioassay, if available.”312 The
Division Deputy Director agreed with the botanical reviewer’s view that
“botanical new drugs can rarely have CMC specifications as precise as
those of pure chemical drugs,” and “it is especially difficult to
determine for botanical drugs with unknown number and identities of
active ingredients (such as crofelemer) whether the future marketing
batches will have the same therapeutic effects as that observed in
clinical trials.”313 Ultimately, the Director of the Center for Drug
Evaluation and Research made the call, concluding—possibly in light
of the “urgent need” for the product, which was intended for
treatment of diarrhea in patients with HIV/AIDS—that “all of the
CMC characterization” was not needed.314 This history suggests that
the agency’s willingness to be flexible in any particular case may
depend a great deal on the views of a single botanical reviewer. It could
also depend on the support of agency leadership, who may focus on
broader questions of public health.
b. Preclinical and clinical data
An NDA also contains several sections establishing the product’s
safety and effectiveness.315 Generating the data in these sections
requires a stepwise process beginning with laboratory and animal
studies, (“preclinical” or “nonclinical” research), followed by several
phases of human (“clinical”) trials that culminate in pivotal trials
establishing effectiveness.316

311. Id.
312. Id. The botanical reviewer played a key role in pushing the agency’s thinking
further. For instance, he proposed a variety of ways to address uncertainty about batchto-batch variability that did not appear in the 2004 version of the guidance document
then in effect. These included “pre-CMC” steps (such as controlling collection of raw
materials to eco-geographic regions with good agricultural and collection practices)
and “post-CMC” evidence (such as clinical evidence that therapeutic effect is not
affected by batch-to-batch variation). Id. at 4–5.
313. Id. at 4.
314. Id. at 12.
315. 21 C.F.R. § 314.50(d)(2)–(5)(2018).
316. FULZYAQ SUMMARY REVIEW, supra note 295, at 5–6.
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The general goal of preclinical research is to collect the data
necessary to support the safety of early clinical trials.317 In practice, the
FDA expects both pharmacology tests, which consider how the drug
works on various physiological systems and how the body processes the
drug, and toxicology tests, which assess the drug’s short-term and longterm adverse effects.318 The applicant submits its preclinical data in an
IND. The amount of newly generated preclinical data needed for a
botanical IND will depend on the human experience with the
botanical drug to date.319 But the FDA expects rigorous data on the
nonclinical pharmacology and toxicology of the precise drug
substance being developed, which means that anecdotal reports about
the safety and effectiveness of cannabis—even if based on decades of
illicit use or even reports of lawful medical use prior to enactment of
the CSA—will not suffice. These data could reduce the amount of
nonclinical testing required by the FDA, but they will not replace it.320
After the FDA permits an IND to go into effect, the company may
conduct human testing.321 The agency expects the pre-approval
clinical testing process to advance through stages, from small groups
of healthy volunteers, at the outset, to large multi-site trials in patients,
designed and executed to provide statistically robust proof of safety
and efficacy.322 The agency’s regulations describe three phases of
trials, but marching through three sequential, non-overlapping phases
of testing is not required and may not always be the most effective or
efficient way to proceed.323 The final pivotal trials are designed to
317. Id. at 9.
318. 21 C.F.R. § 312.23.
319. Id.
320. The recently-enacted 21st Century Cures Act does not change this. See generally
Pub. L. No. 114-255, 130 Stat. 1033 (2016). Congress directed the FDA to evaluate the
potential use of “real world evidence” in approval decisions, but only in decisions to
approve new indications for already approved drugs. See 130 Stat. at 1096–98.
Moreover, this new provision of the statute does not alter the standard of approval,
including the “substantial evidence” standard. Id.
321. The Drug Development Process, Step 3: Clinical Research, FDA, https://www.fda.gov
/forpatients/approvals/drugs/ucm405622 (last visited Feb. 5, 2019).
322. Id.
323. § 312.21. Phase 1 trials generally involve administering the investigational
drug to a very small number of healthy individuals primarily to gather safety data, such
as safe dosage for future tests. A company might use patients rather than healthy
volunteers, however, if the drug is very potent or toxic and use in healthy volunteers would
raise ethical issues. Phase 2 trials are designed to gather additional short-term safety data
and dose range findings, but also effectiveness data. They usually involve a small number
of patients, perhaps as many as several hundred. Phase 3 studies are designed to determine
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establish that the drug satisfies the statutory approval standard:
“substantial evidence” of effectiveness.324 Substantial evidence means
evidence consisting of “adequate and well-controlled” clinical trials, on
the basis of which qualified experts could “fairly and responsibly”
conclude that the drug has the effect claimed.325
The FDA’s regulations flesh out the characteristics of an “adequate
and well-controlled” trial.326 Such a trial has a protocol with a clear
statement of objectives and a summary of the proposed method of
analysis.327 It should use a design that permits a valid comparison with
a control to provide a quantitative assessment of the drug’s effect, and
the effect should be measured in a way that is well-defined and
reliable.328 Subjects should be selected in a way that ensures they have
the disease or condition being studied, and they should be assigned to
treatment and control groups in a way that minimizes bias and ensures
the arms are comparable.329 Additional measures should be taken to
minimize bias on the part of the subjects as well as other participants
in the trial, such as the investigators conducting the trial.330 Finally,
the study report should include an appropriate statistical analysis of
the results, sufficient to assess the drug’s effects.331

whether the drug is safe and effective for the target indication and to more precisely
identify any drug-related adverse effects. They typically involve several hundred to several
thousand patients and multiple sites, often in multiple countries. Id.
324. 21 U.S.C. § 355(f) (2012).
325. § 355(d). The FDA generally expects two adequate and well-controlled trials,
however, Congress amended the FDCA in 1997 to confirm that the agency may
approve a drug on the basis of one, combined with “confirmatory evidence.” See Food
and Drug Modernization Act of 1997, Pub. L. No. 105-115, 111 Stat. 2296, 2313.
326. See 21 C.F.R. § 314.126; see also Lietzan, supra note 46, at 51–54 (2018).
327. § 314.126(b)(1).
328. § 314.126(b)(2).
329. § 314.126(b)(3).
330. § 314.126(b)(4).
331. § 314.126(b)(7). The gold standard approach is a randomized, double-blind,
placebo-controlled hypothesis-testing trial pursuant to a written protocol with a
prespecified data analysis plan. E.g., John Concato et al., Randomized, Controlled Trials,
Observational Studies, and the Hierarchy of Research Designs, 342 NEW ENGLAND J. MED. 1887
(2000); Laura E. Bothwell et al., Assessing the Gold Standard—Lessons from the History of
RCTs, 374 NEW ENGLAND J. MED. 2175 (2016). That said, the substantial evidence
standard can be surprisingly flexible when circumstances necessitate flexibility. The
FDA has approved new drugs on the basis of a single trial, on the basis of a single study
in fewer than 10 patients, on the basis of studies without blinding or controls, and—
indeed—without any efficacy testing in humans. See, e.g., Frank J. Sasinowski &
Alexander J. Varond, FDA’s Flexibility in Subpart H Approvals: Assessing Quantum of
Effectiveness Evidence, 71 FOOD & DRUG L.J. 135, 139–41 (2016) (studying nineteen
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The clinical data requirements for approval of a botanical drug do
not differ from the clinical data requirements for a non-botanical
drug.332 Phase 3 trials of a botanical drug, including a drug containing
cannabis, would have the same purpose and design requirements as
any other phase 3 trials. Clinical development of botanical drugs does,
however, face some special issues, and clinical development of a
cannabis-based botanical drug would face these issues.
First, a botanical drug substance can differ in its characteristics over
the course of a drug development program.333 For instance, changes
in the agricultural and collection practices for the raw material, or
changes in the manufacturing process as result of process optimization,
may lead to changes in drug substance composition.334 Preclinical and
clinical testing results that use earlier versions of the drug substance
generally cannot be used in a marketing application without
“bridging” studies that compare the versions.335
Second, a botanical drug substance may vary in chemical
composition from batch-to-batch. The FDA will expect an applicant to
explore the impact of batch-to-batch variability on the therapeutic
effect of the botanical drug product and, in particular, to support an
argument that expected variations will not cause a meaningful
difference in therapeutic effect.336 The agency has suggested using
multiple batches in phase 3 trials, which may help an applicant
understand (1) which variations are clinically relevant and (2) if they
are clinically relevant, the range of variability that can be tolerated to
maintain the product’s identity, safety, and efficacy.337
Third, depending on the route of administration and therapeutic
goal, it may be difficult to design an adequately blinded clinical trial
with objective endpoints.338 In some cases, it may be necessary to use a
botanical in the control drug in order to mask the presence (or

approvals granted by the FDA through its accelerated approval process for diseases
and illnesses other than cancer and AIDS).
332. See, e.g., VEREGEN BOTANICAL REVIEW, supra note 295, at 2 (2006) (“For clinical
data to support marketing approval, there should be no difference between botanical
and non-botanical drugs.”).
333. Other drugs evolve during development, but the FDA has flagged this as an
issue for botanical drugs in particular.
334. BOTANICAL GUIDANCE, supra note 287, at 6.
335. Id.
336. Id. at 15–16.
337. Id.
338. Id. at 12.
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absence) of the active drug.339 Senior leadership at the agency has also
questioned whether blinding is possible if an investigational cannabisbased drug is administered through combustion (smoking) and have
expressed concern about the subjectivity of the endpoints needed for
many therapeutic goals of cannabis-based products.340 Subjective
endpoints can reduce the reliability of positive results from a trial and
can lead the FDA to reject marketing applications.341
Finally, there is an open question of whether and how the FDA’s
combination drug regulation will apply.342 Under this regulation, the
sponsor of a drug product containing two active components must
demonstrate that each component makes a contribution to the total
effect that the combination is represented to have.343 Traditionally, if
both ingredients are directed to the same sign or symptom, the FDA
expects a “factorial” study, which demonstrates that the combination
has a larger treatment effect than either active ingredient alone.344 The
agency has proposed to consider fresh or physically processed material
derived from a single part of a single species of a plant as a single
botanical raw material.345 Thus a botanical drug product derived from
a single part of a plant would not be subject to the fixed combination
drug regulation.346 In contrast, a botanical product composed of
multiple and easily separable parts of a single species of plant (e.g.,
flowers and bark of a woody plant) would continue to be subject to the
combination drug requirements.347 The agency has proposed waiving
this regulation for a traditional botanical drug composed of multiple
raw materials in a fixed ratio, at least if there are so many active
ingredients that factorial studies to assess the contribution of each
would be infeasible.348 Other botanical drug products would be

339. Id.
340. See Marijuana Trials Should Aim for Higher Standard: Superiority to Marinol, FDA’s
Temple Suggests, PINK SHEET (Feb. 24, 1997).
341. FDA, GUIDANCE FOR INDUSTRY, INVESTIGATORS, AND REVIEWERS: EXPLORATORY
IND STUDIES 11 (2006).
342. See generally 21 C.F.R. § 300.50 (2018).
343. § 300.50(a).
344. Fixed-Combination and Co-Packaged Drugs: Applications for Approval and
Combinations of Active Ingredients Under Consideration for Inclusion in the Overthe-Counter Monograph, 80 Fed. Reg. 79,776, 79,785 (Dec. 23, 2015) (to be codified
at 21 C.F.R. pts. 300, 330, and 610).
345. Id. at 79,780.
346. Botanical Drug Review, supra note 239, at 2.
347. Id.
348. 80 Fed. Reg. at 79,787.
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deemed fixed combination drugs even though derived from a single
botanical raw substance.349
c. Route of administration
State-regulated medical cannabis today is mostly inhaled (vaporized
or combusted), although increasing amounts are administered orally
(for instance, in gel caps and oils) or even topically.350 A company
developing a medical cannabis product for FDA approval could in
theory consider any route of administration. A drug’s route of
administration can affect its dosing as well as its safety and
effectiveness;351 however, the route of administration will dictate some
data requirements.352 As discussed in Section IV.A, the four approved
cannabinoid drugs are administered orally.353 Other routes of
administration may face additional hurdles at the agency.
The prospects for inhaled products, in particular, are unclear.
Generally, inhaled drug products fall into three categories: metered
dose inhalers, dry powder inhalers, and nebulizers.354 Some ongoing
medical cannabis clinical research involves inhaled products; many
involve combustion (smoking), but at least one involves a metered
dose inhaler.355 But the agency has expressed skepticism. When
discussing medical cannabis, FDA leadership recently indicated the
349. Id. at 79,781.
350. Mary Barna Bridgeman & Daniel T. Abazia, Medicinal Cannabis: History, Pharmacology,
and Implications for the Acute Care Setting, 42 PHARMACY & THERAPEUTICS 180, 183 (2017).
351. This is known to be true of cannabis in particular. Id. (“The method of
administration can impact the onset, intensity, and duration of psychoactive effects;
effects on organ systems; and the addictive potential and negative consequences
associated with use.”).
352. If a drug is meant to be inhaled, for instance, the FDA requires inhalation
toxicity studies and may require carcinogenicity studies. FDA, NONCLINICAL SAFETY
EVALUATION OF REFORMULATED DRUG PRODUCTS AND PRODUCTS INTENDED FOR
ADMINISTRATION BY AN ALTERNATE ROUTE: GUIDANCE FOR INDUSTRY AND REVIEW STAFF 6
(2015).
353. See infra Section IV.A.
354. Shuguang Hou et al., Practical, Regulatory and Clinical Considerations for
Development of Inhalation Drug Products, 10 ASIAN J. PHARM. SCI. 490, 491, 495–96 (2015)
(defining metered dose inhalers as a suspension- or solution-based formulation of
drugs propelled by hydrofluoroalkane propellants; dry powder inhalers as “a blend of
micronized drug powder with larger carrier particles”; and nebulizers as a drug
“formulated in aqueous solution or suspension, which is atomized into fine droplets
via an external nebulization source”).
355. NCT02729623, The Pharmacokinetics, Safety, and Ease of Use of a Portable MeteredDose Cannabis Inhaler, CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/
NCT02729623 (last updated July 25, 2016).
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agency prefers that inhaled drugs be intended to treat the lungs.356
Most drugs approved for delivery through the lungs are intended to
treat the lungs in some fashion.357 The agency’s resistance to
inhalation could be overcome, however, with solid data on the
effectiveness of this route of administration—such as evidence that
inhalation leads to more consistent dosing than oral delivery.358
Inhalation by combustion would face a higher hurdle. Agency
officials have consistently expressed skepticism that combustion of
cannabis would allow delivery of a consistent dose.359 The FDA would
expect an applicant to address the risk of pulmonary cancer and other
respiratory tract diseases, such as chronic obstructive pulmonary disease,
particularly if the combustible product were intended for chronic use.
This could entail long-term safety studies before approval, and—
depending on the intended use—some findings might preclude

356. Brenda Sandburg, Gottlieb on Medical Marijuana: Smoking is Not Effective Way to
Deliver API, PINK SHEET (Apr. 19, 2018), https://pink.pharmaintelligence.
informa.com/PS122944/Gottlieb-On-Medical-Marijuana-Smoking-Is-Not-EffectiveWay-To-Deliver-API (quoting Scott Gottlieb, the Commissioner of Food and Drugs, as
saying, “We generally would prefer not to deliver drugs through the lung unless we
were treating the lung in some fashion”).
357. Id. For instance, Proventil-HFA (albuterol sulfate) and Flovent (fluticasone
propionate) are marketed in pressurized metered dose inhalers for treatment of
bronchospasm and asthma, respectively. Shuguang, supra note 354, at 493. Tobi
Podhaler (tobramycin) is marketed as a powder for inhalation, which a patient selfadministers for management of cystic fibrosis with Pseudomonas aeruginosa, using a
proprietary device. Id. at 493, 497. AstraZeneca markets Pulmicort Respules
(budesonide) for asthma in a suspension (liquid) for use with a nebulizer, which turns
the liquid into a mist for inhalation into the lungs. Id. at 493.
358. Some research suggests that inhaled THC reaches its peak level in the body
“nearly instantaneously” due to direct absorption by the capillaries in the lungs,
leading to more consistent levels of the drug than an oral formulation. MACK & JOY,
supra note 81, at 143, 203.
359. Researching the Potential Medical Benefits and Risks of Marijuana, FDA (2016)
[hereinafter Researching Marijuana], https://www.fda.gov/newsevents/testimony/
ucm511057 (“When the Institute of Medicine (IOM) reviewed the clinical use of
marijuana, it identified the problems associated with obtaining consistent dosing using
smoked products and recommended that clinical trials involving marijuana should be
conducted with the goal of developing safe, alternative delivery systems . . . .”);
Sandburg, supra note 356 (quoting Commissioner Gottlieb that “the best way to deliver
an active pharmaceutical ingredient is in a measured dose in a form where you can
purify the ingredient and you know what you are getting and you can demonstrate
dose effect and you can provide a reliable treatment to a patient,” which “generally is
probably not going to come from something that is smoked”).
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approval.360 Although the FDA permits numerous clinical trials of smoked
cannabis for medical conditions, the agency’s view seems to be that “the
purpose of clinical trials of smoked cannabis would not be to develop
cannabis as a licensed drug but rather to serve as a first step toward the
development of non-smoked rapid-onset cannabinoid delivery systems.”361
Cannabis-based drugs presented in dosage forms that are not
intended for inhalation (especially combustion) are less likely to raise
complex regulatory issues and less likely to meet resistance from the
agency. But each route of administration and dosage form will present
issues for consideration. Topically administered drugs in solution or
gel form, for instance, may present safety issues if physical contact with
others can transfer the active ingredient.362 Concerns about transfer
could lead to additional premarket testing requirements and, if
appropriate, special safety controls after approval.363 The agency’s

360. See Ethan Russo et al., Current Status and Future of Cannabis Research, CLINICAL
RESEARCHER 58, 59 (Apr. 2015) (“Meanwhile, although cannabis smoking may not be
epidemiologically linked to lung cancer, it is responsible for chronic cough, sputum,
and cytological changes, which render smoked cannabis an impossible candidate for
approval as a prescription product in most jurisdictions.”). Because the approval
decision requires benefits and risks to be considered together, it is likely that even
these risks would be acceptable to the agency for some uses.
361. Researching Marijuana, supra note 359. If the agency permitted an inhalable
cannabis-based product, the product might be considered a “combination product”
(combining a drug and device). The phrase “combination product” includes a drug
and device that are physically combined and produced as a single entity (such as a
patch that delivers an active ingredient), as well as a drug and device that are packaged
together (such as a nebulizer and suspension). 21 C.F.R. § 3.2(e) (2018). In this case,
the company would need to consider both drug and medical device regulatory issues.
As a practical matter, the analysis is unlikely to change. A combination product’s
“primary mode of action”—the single mode of action that provides its most important
therapeutic action—dictates which part of the FDA will review the premarket
submission. 21 U.S.C. § 353(g)(1)(C) (2012). The Center for Drug Evaluation and
Research (CDER) would almost certainly take the lead on premarket review of a
cannabis-derived drug product. Combination products are typically regulated under
the marketing authorization associated with the component that provides the primary
mode of action, meaning that this product would probably still require only an NDA.
See 21 U.S.C. § 353(g)(1)(D). In some cases, though, the agency will require a second
premarket submission tied to the second constituent part. An alternative in this case
would be to use a device that the FDA has already approved or cleared for the market.
362. See, e.g., MEDICATION GUIDE: ANDROGEL (2016), https://www.rxabbvie
.com/pdf/androgel1_62_medguide.pdf (advising users to wash their hands “right
away” after application).
363. For instance, testosterone in gel form is approved for treatment of men with a
testosterone deficiency but it can rub off on women and children, causing early
puberty in a child. Companies developing topical testosterone products are generally
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guidance documents and precedents are key to understanding what
might be required in any particular case, but it is safe to say that orally
administered products in traditional dosage forms (tablet, capsule, and
solution) are the least likely to face unexpected regulatory hurdles.
3.

Approval and risk management
Approval of a new drug represents the FDA’s conclusion that the
benefits of the drug outweigh its risks when the drug is used in
accordance with its approved labeling.364 The agency would make
several additional risk management decisions when approving a
cannabis-based drug.
First, the FDA would likely designate a cannabis-derived drug
product as a prescription product. Prescription status is required for
any drug that is “not safe for use except under the supervision of”
licensed prescribers because of its “toxicity or other potentiality for
harmful effect, or the method of its use, or the collateral measures
necessary to its use.”365 Although the FDA considers these and related
factors when deciding whether to switch a drug from prescription to
nonprescription status,366 as a practical matter, almost every new drug

required to conduct transfer studies, and the drugs are approved with special risk
management measures. For instance, Androgel® (testosterone) is distributed with a
“Medication Guide” that instructs patients to apply the drug to areas of their shoulders,
upper arms, and abdomen that will be covered by a t-shirt and to wash their hands
immediately. See id.
364. See 21 C.F.R. § 314.50(d)(5)(viii) (requiring NDAs to discuss “why the benefits
exceed the risks under the conditions stated in the labeling”); see also United States v.
Rutherford, 442 U.S. 544, 555 (1979) (“[T]he [FDA] generally considers a drug safe
when the expected therapeutic gain justifies the risk entailed by its use.”); FDA,
CRITICAL PATH OPPORTUNITIES REPORT R-8 (March 2006), http://wayback.archiveit.org/7993/20180125142845/https://www.fda.gov/downloads/ScienceResearch/Sp
ecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/UCM077254.p
df (suggesting approval once “uncertainty” about benefit-risk balance has been
“reduced to an acceptable level”).
365. 21 U.S.C. § 353(b). If cannabis and THC were rescheduled rather than
descheduled, the CSA would require that the product be sold only on prescription.
See 21 C.F.R. § 1306.11 (requiring a written prescription for the distribution of any
Schedule II substance); § 1306.21 (requiring a prescription for the distribution of any
Schedule III, IV, or V substance).
366. The FDA considers a variety of factors, such as the ability of patients to selfdiagnose and follow treatment instructions, public health considerations, such as
whether a prescription requirement would be an impediment to timely treatment in
emergency situations, and possibly even social policy. See generally Peter Barton Hutt,
A Legal Framework for Future Decisions on Transferring Drugs from Prescription to
Nonprescription Status, 37 FOOD DRUG COSM. L.J. 427 (1982).
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is first approved today as a prescription drug.367 The agency might also
be reluctant to permit a cannabis-based drug to be available over the
counter if others are limited to prescription status—particularly if the
prescription products are intended for treatment of serious conditions
and generally require a physician’s involvement. Some active
ingredients are available in both prescription and nonprescription
form,368 but the possibility that patients needing medical attention
might self-treat with the nonprescription cannabis-based product
would give the agency pause.
Second, as a prescription drug, a cannabis-based drug—whether
edible, inhaled, ingested, or applied topically—would require FDAapproved labeling for prescribers. Agency regulations specify the
format and content of this labeling, which is meant to summarize and
distill the safety and effectiveness information in the marketing
application so that prescribers can make informed judgments about
treatment.369 In addition to information about the preclinical and
clinical studies supporting approval, the labeling must describe the
overall adverse reaction profile of the drug based on the entire safety
database, as well as clinically significant adverse reactions and other
safety hazards.370 The labeling must present information about “drug
abuse” and “dependence,” even if the drug is not controlled, describe
clinically significant interactions with other prescription medicines (as
well as nonprescription drugs, foods, and dietary supplements), discuss
use in special populations such as pregnant and breastfeeding women,
and advise about the signs and symptoms of overdose and
recommended treatment of overdose.371
Third, in some cases, the FDA might decide that the risks associated
with the product require the adoption of special risk management
measures. The agency could, for example, require the company to
distribute patient labeling, a “Medication Guide,” explaining the key
risks associated with the drug and any special measures that should be
taken (such as avoiding driving and consumption of alcohol) when
using the drug.372 If the FDA concludes that the drug’s benefits
367. Id. at 428.
368. Examples include ibuprofen and fluticasone propionate.
369. See 21 C.F.R. § 201.57; Requirements on Content and Format of Labeling for
Human Prescription Drug and Biological Products, 71 Fed. Reg. 3,922 (Jan. 24, 2006)
(to be codified at 21 C.F.R. pts. 201, 314, and 601).
370. 71 Fed. Reg. at 3,922.
371. Id. at 3,994.
372. 21 C.F.R. §§ 208.1, 208.20.
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outweigh its risks only with special risk management measures in place,
it will require the company to implement a “risk evaluation and
mitigation strategy.”373 In particular, if necessary to mitigate a specific
serious risk listed in the drug’s labeling, the agency can impose use and
distribution restrictions.374 These might include limiting the drug to
prescribers with special training or requiring that all patients be
entered in a registry.375 Particularly if the agency had concerns about
dependence or misuse of a cannabis-based drug product, it might
impose access restrictions. Descheduling of cannabis, THC, and
cannabimimetics would not preclude this.
Nevertheless, the risks and benefits of a new drug are never fully
understood at the time of approval. This would be true of any
cannabis-based new drug product, despite the long history of medical
and non-medical use of cannabis.376 The FDA’s concern is the safety
and effectiveness of the particular dosage form, strength, patient
population, and use at issue. Risk management, which includes
monitoring and responding to risk, is therefore the dominant feature
of postmarket regulation of new drugs.377 The FDA may require a
company to conduct postmarket testing, as a condition of approval, to
assess known risks or even to assess signals that emerged during
premarket testing.378 Both approved botanical drugs were subject to
postmarket testing obligations.379 And regardless of whether the
agency imposed postmarket testing as a condition of approval, any
company that held an approved NDA for a cannabis-based drug
product would be required to evaluate and report any adverse events
of which it became aware.380 These reports, in turn, could lead to

373. Risk Evaluation and Mitigation Strategies (REMS), FDA, https://www.fda
.gov/Drugs/DrugSafety/REMS/default.htm (last updated Feb. 2, 2018).
374. 21 U.S.C. § 355-1(f)(3) (2012).
375. §§ 355-1(f)(3)(A), (F).
376. Russo, supra note 54, at 1614.
377. 21 U.S.C. § 355-1.
378. See § 355(o)(3).
379. For instance, the FDA required Salix Pharmaceuticals, which holds the NDA
for Mytesi, to conduct two rodent carcinogenicity studies. See FDA, CTR. DRUG
EVALUATION & RES., NDA APPROVAL: NDA 202292, https://www.accessdata.fda.gov/
drugsatfda_docs/appletter/2012/202292Orig1s000ltr.pdf (last visited Feb. 5, 2019).
The company also committed to an in vitro and an in vivo study in humans to further
explore the pharmacodynamics of crofelemer, as well as additional analytical work and
additional work on its bioassays. Id.
380. See 21 C.F.R. § 314.80 (2018).
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labeling changes or more significant requirements, such as new studies
or access restrictions.381
The Poison Prevention Packaging Act of 1970 (PPPA)382 would also
apply to cannabis-derived drug products and might require the
manufacturer to adopt special packaging.383 The PPPA applies to any
food or drug customarily produced or distributed for sale for
consumption or use by individuals in or about the household.384 The
Consumer Product Safety Commission’s implementing regulations
require that any prescription drug intended for oral administration be
packaged in accordance with its “special packaging” standards.385 The
general idea is that the packaging must be reasonably convenient for
adults to open and yet designed so that young children cannot easily
obtain the contents.386 Thus, the company would have to use packaging
that provided a specified degree of child resistance, confirmed using
testing procedures also specified in the regulations.387 At the same time,
the packaging would need to satisfy “ease of adult opening” standards,
which must be similarly tested in both senior adults and younger adults
according to the agency’s testing standards.388
4. Consequences of using the new drug pathway
The new drug research and development process is notoriously
expensive and risky. For a new chemical entity, it can take ten to twelve
years and cost more than $1 billion.389 Prior and longstanding use of
cannabis for medical and non-medical purposes may reduce some of
the risk, for instance, by identifying promising uses and suggesting the
appropriate dosing. Also, the agency’s flexibility with botanical NDAs
may reduce some of the cost, where it applies. Pursuing new drug
approval for medical cannabis after descheduling could, however, still
cost hundreds of millions of dollars. This will put the process out of
381. 21 U.S.C. §§ 355(o)(3)–(4); 21 C.F.R. § 201.57(c)(6)(i).
382. Pub. L. No. 91-601, 84 Stat. 1670 (codified at 15 U.S.C. §§ 1471–77).
383. § 1472.
384. § 1471(2).
385. 16 C.F.R. § 1700.14(a)(10).
386. § 1700.14.
387. §§ 1700.15, 1700.20.
388. § 1700.15.
389. Joseph A. DiMasi et al., Innovation in the Pharmaceutical Industry: New Estimates of
R&D Costs, 47 J. HEALTH ECON. 20, 25–27 (2016) (estimating average out-of-pocket cost
per approved compound of $1.4 billion and total preapproval cost of $2.56 billion); Erika
Lietzan, The Myths of Data Exclusivity, 20 LEWIS & CLARK L. REV. 91, 107–08 (2016)
(discussing range of estimates for the length of time and cost of developing a new drug).
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reach for most entities currently providing medical cannabis.390 Yet
avoiding the new drug approval process is not an option; medical
claims on any product in interstate commerce will trigger the FDA’s
new drug authorities and require an approved NDA.391
Even well-established biopharmaceutical companies might eschew
development of cannabis-based products. It is not clear a cannabisbased product would enjoy enough exclusivity in the market for a
company to recoup its investment and earn a profit. U.S. law provides
exclusivity (as an incentive for new drug research) through two
mechanisms—patent protection and regulatory exclusivity—but the
value of these for cannabis-based drugs is unclear.392 Patent protection
would preclude any other company from making, using, or selling the
patented invention for a fixed period of time.393 But a company could
not patent the cannabis plant itself, and it may not be possible to patent
the medical uses of cannabis that have been known for years.394 It may
be possible to patent genetically engineered cannabis plants, methods
of cultivating the plants, and methods of manufacturing cannabisbased products. Newer methods of treatment and delivery devices,
among other things, may also be patentable.395 And regulatory
exclusivity will prevent submission, or in some cases approval, of other
applications at the FDA for a fixed period of time.396 Patent protection
and regulatory exclusivity could motivate the larger companies to invest
390. See Alex Halperin, What Will Rescheduling Marijuana Mean for the Pot Industry?,
ROLLING STONE (Apr. 20, 2016), https://www.rollingstone.com/culture/culturenews/what-will-rescheduling-marijuana-mean-for-the-pot-industry-203124 (“If the
federal government determines that medical marijuana must be subjected to FDA
approval, companies would have to enter a process that can take years to complete and
cost more than $1 billion per product. Few, if any, cannabis companies in the U.S.
have the resources for that, which might open the door for Big Pharma to muscle in
and take over the business.”).
391. See supra Section III.A.1.
392. Lietzan, supra note 46, at 56 (2018).
393. See 21 U.S.C. §§ 355(c)(3)(E), 355(j)(5)(F).
394. See 35 U.S.C. § 102(a)(1) (preventing a person from obtaining a patent if the
product was “described in printed publication, or in public use, or otherwise available
to the public” before the patent was filed).
395. See generally Gretchen L. Temeles et al., IP Protection and the Cannabis Industry:
Strategies and Trends, LEGAL INTELLIGENCER (April 2, 2018, 2:10 PM),
https://www.law.com/thelegalintelligencer/2018/04/02/ip-protection-and-the-cann
abis-industry-strategies-and-trends (describing cannabis-related patents to date).
396. E.g., 21 U.S.C. § 355(j)(5)(F)(ii) (prohibiting submission of a generic drug
application for five years after approval of a new chemical entity, meaning an active
moiety not previously approved in an NDA); 21 U.S.C. § 360cc (providing seven years
of “orphan drug” exclusivity for drugs approved for treatment of rare diseases).
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in the research and development needed for approval of a cannabisbased product. These companies could, however, be concerned about
competition from cannabis-based products that are labeled for other
conditions or, indeed, that are marketed without medical claims at all.
Without a reasonable assurance of actual exclusivity in the marketplace,
these companies might pursue other projects instead.
B. Medical Cannabis as (or in) Food
Cannabis as it is currently sold and used is unlikely to qualify as food
in itself, and an extract from cannabis presented as a single-ingredient
product would similarly not qualify. Rather than focusing on intended
use as it does for drugs, the FDCA defines food by its actual use. Food,
thus, is any “article[] used for food or drink for man.”397 The FDA
interprets this to mean any item consumed primarily “for taste, aroma,
or nutritional value.”398
Arguably, neither cannabis nor a single-ingredient cannabis extract
product would satisfy this test. There is, however, some evidence that
cannabis seeds, leaves, and other parts of the plant were historically
eaten as food, whether by themselves or in combination with other
foodstuffs.399 Seed cakes were popular in the ancient world, and oil
seems to have been consumed just like other plant oils.400 Further,
these uses would not have decarboxylated the THC or CBD contained
in the raw plant materials (unless the foods were cooked or baked),
which means the strongest and most notable effects of cannabis were
probably not obtained.401 This suggests that ancient populations may
have valued cannabis components for their nutritive value. If true seed
cakes and other cannabis-based foods were re-introduced to the
market and consumed primarily for their nutritive value, as was
apparently the case in the ancient world, the FDA might apply its food
authorities.402 Among other things, the food would be adulterated if it

397. 21 U.S.C. § 321(f)(1).
398. Nutrilab, Inc. v. Schweiker, 547 F. Supp. 880, 883 (N.D. Ill. 1982), aff’d, 713
F.2d 335 (7th Cir. 1983).
399. See supra Section I.B.
400. See e.g., Zuardi, supra note 64, at 154.
401. Id. at 154, 156.
402. For instance, as discussed in note 430, the agency permits the use of hulled hemp
seed, hemp seed protein powder, and hemp seed oil in certain foods, provided these
ingredients meet certain specifications. In some cases, however, there is a risk the FDA
would resist the characterization as food (or a food ingredient) and deem the product
an unlawfully marketed dietary supplement, for reasons discussed in Section IV.B.
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was “ordinarily . . . injurious” to health or if it contained a pesticide
residue that exceeded an established tolerance, or for which no
tolerance had been established.403
As discussed in this part, however, there are also substantial
impediments to simply adding cannabis, or an extract from cannabis,
to a conventional food such as a cookie, candy, or beverage. These
impediments include the rule that foods cannot contain new drugs
(the drug exclusion rule) and the fact that, as a single ingredient
among many, cannabis (and a cannabis constituent) would probably
be deemed a “food additive” requiring premarket approval.
1.

The drug exclusion rule: the 301(ll) problem
It is unlawful to include either dronabinol (9-THC) or CBD in a
conventional food because these substances now appear in products
regulated as new drugs.404 As discussed later in this Article, the FDA
has approved two NDAs for dronabinol and an NDA for CBD.405
Under the drug exclusion rule of § 301(ll) of the FDCA, a food
containing a substance that is an active ingredient of an approved drug
product—or an active ingredient of a product in clinical trials that
have been made public—cannot be shipped in interstate commerce.406
Although there are ways to avoid the drug exclusion rule, these are not
promising for cannabis-based foods.
403. 21 U.S.C. §§ 342(a)(1)–(2), 348(a) (2012). Pesticide issues could be significant.
There are no pesticides approved for use on cannabis plants. Jenna H. Bishop, Note,
Weeding the Garden of Pesticide Regulation: When the Marijuana Industry Goes Unchecked, 65
DRAKE L. REV. 224, 226 (2017). At the same time, studies “overwhelmingly reveal that
growers are choosing to use unapproved and unregulated pesticides.” Id. But these
problems are not insurmountable. Indeed, the responsible segments of the industry are
well aware that pesticide issues need to be addressed for all cannabis products, not just
those that might be positioned as conventional food.
404. Even if there were no drug exclusion, the FDA might take the position that
intentionally adding dronabinol or CBD to a food product in amounts known to affect
the body constitutes evidence that the product is intended to address disease or affect
the structure or function of the body. Cf. Zettler, supra note 249, at 1965 (discussing
a warning letter to distributor of “Magic Power Coffee,” which contained an analogue
of sildenafil, the active ingredient of Viagra).
405. See infra Section IV.B.1.
406. 21 U.S.C. § 331(ll). The FDA focuses on the whether the food is or contains a
substance that is the same active moiety as the new drug in question. The source of
the substance does not matter. Thus, for instance, the rule applies even if the
substance derives from a plant classified as “hemp” and exempt from the Controlled
Substances Act pursuant section 12619 of the Agriculture Improvement Act of 2018,
Pub. L. 115-334 (amending 21 U.S.C. §§ 802(16), 812(c)). See Statement on Signing
of the Agriculture Improvement Act, supra note 49.
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First, § 301(ll) contains an exception for a substance marketed in
food before the drug in question was approved or the trials started.407
But the agency requires that the substance be overtly marketed in the
food, for instance with references in the label.408 The FDA would
probably refuse to consider marketing in violation of federal law,
including the CSA.409 Moreover, the FDA has already concluded that
“THC” and CBD must be excluded from foods in interstate
commerce.410 That said, it has invited evidence and arguments to the
contrary.411 In addition, its claim about “THC” may be overbroad. The
agency has approved products containing dronabinol, which is a
synthetic 9-THC, but cannabis also contains several variants of 8THC.412 These are also referred to as “THC” but may not be barred by
the drug exclusion rule.
Second, the drug exclusion rule “precludes only the specific active
ingredients already present in new drugs.”413 “A company can avoid the
drug exclusion by adding a different cannabinoid (or terpenoid or
flavonoid) from cannabis—rather than dronabinol or CBD—to its
food.”414 But it will be important to do so overtly—“calling out the precise
cannabinoid in the food label”—as soon as possible after descheduling.415
“As soon as one of these other cannabinoids is the subject of a publicly
known clinical trial, it will be too late to add it to a food.”416

407. § 331(ll)(1).
408. E.g., FDA, DIETARY SUPPLEMENTS: NEW DIETARY INGREDIENT NOTIFICATIONS AND
RELATED ISSUES: GUIDANCE FOR INDUSTRY 44 (2016) [hereafter NDI GUIDANCE]; FDA
Response to Biostratum, Inc., No. FDA-2005-P-0259 (formerly Docket No. 2005P0305/CP1) (Jan. 12, 2009), https://www.regulations.gov/document?D=FDA-2005-P0259-0004 (explaining that the “relevant inquiry” for determining whether a substance
prohibited by the drug exclusion rule is whether a company was also marketing the
substance alone as a food or dietary “by . . . making claims about the [substance] or
otherwise highlighting its presence in the product”).
409. Alice Mead, The Legal Status of Cannabis (Marijuana) and Cannabidiol (CBD)
Under U.S. Law, 70 EPILEPSY & BEHAVIOR 288, 290 (2017).
410. FDA and Marijuana: Questions and Answers, FDA (June 25, 2018), https://www.
fda.gov/newsevents/publichealthfocus/ucm421168 [hereafter Marijuana Q&A].
411. Id.
412. See MARIJUANA AND MEDICINE, supra note 92, at 24–25.
413. Erika Lietzan, Cannabis and the Often Overlooked Drug Exclusion Rule, OBJECTIVE
INTENT BLOG (Sep. 18, 2018), https://objectiveintent.blog/2018/09/19/cannabisand-the-often-overlooked-drug-exclusion-rule.
414. Id.
415. Id.
416. Id.
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Third, a company might be able to “avoid the drug exclusion rule by
manufacturing and selling conventional food products with
dronabinol or CBD purely within the confines of a single state.”417 To
be sure, the FDA has asserted jurisdiction over medical treatments
involving substances prepared purely on premises or within a state
when it can identify a component (raw material) that had been
shipped in interstate commerce.418 But doing so rests on the phrasing
of an enforcement provision that would not apply here. The FDA
generally proceeds under § 301(k) of the statute, which prohibits
misbranding or adulteration after an item has been shipped in
interstate commerce.419 But § 301(ll) is drafted differently, prohibiting
interstate shipment of a food after addition of a new drug.420 It is not
clear that the FDA could act under § 301(ll) with respect to a food
made with dronabinol or CBD and sold within the same state, even if
it contained a component (which is also a “food”)—such as flour—that
had been shipped in interstate commerce.
2.

Regulation as a food additive: the 402(a) problem
Even if a company avoided the drug exclusion rule (for instance, by
adding a new cannabinoid, terpenoid, or flavonoid to its food), it
would still need to grapple with the FDA’s food additive rules.
Generally speaking, every ingredient in a food sold in interstate
commerce is a food additive, subject to preapproval requirements,
unless an exception applies.421 The FDCA defines “food additive” as
“any substance the intended use of which results or may reasonably be
expected to result, directly or indirectly, in its becoming a component

417. Id.
418. See United States v. Regenerative Scis. LLC, 741 F.3d 1314, 1320–21 (D.C. Cir.
2014); see also Complaint for Permanent Injunction, United States v. California Stem
Cell Treatment Ctr., No. 5:18-CV-1005 (C.D. Cal. 2018), 2018 WL 2144859; Warning
Letter from FDA to Dr. Drew Varano (Apr. 5, 2010), https://wayback.archiveit.org/7993/20170112062943/http://www.fda.gov/ICECI/EnforcementActions/Wa
rningLetters/2010/ucm207651.htm.
419. See 21 U.S.C. § 331(k) (2012) (prohibiting any act with respect to a food or
drug that (1) is done while the article is held for sale after shipment in interstate
commerce and (2) renders the article adulterated or misbranded).
420. See § 331(ll) (preventing the introduction into interstate commerce of a food
to which a drug has already been added).
421. See § 321(s) (providing exceptions for substances that are generally recognized
as safe, as well as certain pesticide chemicals, color additives, new animal drugs, and
dietary supplements).
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or otherwise affecting the characteristics of any food.”422 Even food itself
becomes a food additive if it is used as a component in another food.
A company wishing to add a non-excluded cannabis constituent (other
than dronabinol or CBD) to a conventional food would need to obtain
approval of a food additive petition unless it determined that an
exception applied.423 A petition, in turn, must contain information about
the additive itself (its “chemical identity and composition”), information
about the manufacturing process and facility, and the controls used to
ensure that the additive’s composition is consistent.424 It must also
contain data on the technical effects of the food additive, as well as data
from safety studies.425 Generating these data and securing the FDA’s
approval of a food additive petition can take six years or longer.426
The key exception carves out a substance “generally recognized,
among experts qualified by scientific training and experience to
evaluate its safety, as having been adequately shown . . . to be safe
under the conditions of its intended use.”427 Put another way, if the
cannabis constituent were generally recognized as safe (GRAS) under
the specific conditions of use intended, meaning safe at a particular
level in a particular type of food, it would not be considered a food
additive. A company could determine on its own that a particular
cannabis constituent was GRAS for use in the particular food the
company marketed.428 Federal law does not require a company to seek
the FDA’s approval, or even the agency’s agreement, that the product is

422. Id.
423. See § 348(b); see also Determining the Regulatory Status of a Food Ingredient, FDA,
https://www.fda.gov/food/ingredientspackaginglabeling/foodadditivesingredients/
ucm228269 (last updated Sept. 20, 2018).
424. See 21 C.F.R. § 171.1(b) (2018).
425. Id.
426. Inst. of Med.: Food Forum, Enhancing the Regulatory Decision-Making
Approval Process for Direct Food Ingredient Technologies 2, 29 n.230 (1999).
427. 21 U.S.C. § 321(s).
428. A substance is GRAS if shown safe using “scientific procedures” or, if it was used
in food before January 1, 1958, shown safe “through experience based on common use
in food.” 21 C.F.R. § 170.30(a). The FDA interprets this to require “common knowledge
throughout the scientific community knowledgeable about the safety of substances
directly or indirectly added to food that there is reasonable certainty that the substance
is not harmful under the conditions of its intended use.” Id.
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GRAS.429 But if the agency disagreed with the company’s judgment call,430
the ingredient would be an unapproved food additive, which would mean
the conventional food containing this ingredient was adulterated under
§ 402(a) of the FDCA.431 A company that shipped or received the food in
interstate commerce could face enforcement action, up to and including
criminal prosecution.432 Even if the food itself was not shipped in
interstate commerce, the FDA could take enforcement action if another
ingredient was shipped in interstate commerce.433
3.

No claims could be made
If a company avoided the drug exclusion issue and § 402(a), it might
be able to add a cannabis constituent to a conventional food. But

429. The FDA has created a formal process for voluntary GRAS notifications. See
generally 21 C.F.R. §§ 170.203–170.285. This does not result in regulatory certainty; the
agency will typically respond only that it has “no questions at this time.”
430. The agency has published various lists of substances it recognizes as GRAS.
Although the lists are not meant to be exhaustive, they do not include cannabis. See
21 C.F.R. pts. 182, 184, 186. In December 2018, however, the FDA issued three “no
questions” letters in connection with voluntary GRAS notifications relating to the use
of hulled hemp seed, hemp seed protein powder, and hemp seed oil in various foods.
Hemp seeds are the seeds of the Cannabis sativa plant, and the specific ingredients that
were the subject of the GRAS notifications contained only trace amounts of THC and
CBD. See FDA Responds to Three GRAS Notices for Hemp Seed-Derived Ingredients for Use in
Human Food, FDA (Dec. 20, 2018), https://www.fda.gov/Food/NewsEvents/Con
stituentUpdates/ucm628910 (describing the FDA’s response to GRAS Notice Nos.
GRN 000765, 000771, 000778). As a result, these constituents can be marketed in the
specified foods without food additive approval.
431. Section 402(a) of the FDCA deems a food adulterated if it contains a food
additive that is unsafe within the meaning of 21 U.S.C. § 348. See 21 U.S.C.
§ 342(a)(2)(C)(i); see also § 348 (declaring a food additive unsafe unless it complies
with a food additive regulation).
432. See §§ 331(a), (c). To be sure, the FDA has not acted against foods containing
cannabis that are sold in recreational cannabis law states. As mentioned above, this is
probably because the sales are illegal under the CSA in the first instance. Robert J.
MacCoun & Michelle M. Mello, Half-Baked—The Retail Promotion of Marijuana Edibles, 372
NEW ENG. J. MED. 989, 990 (2015); see also Paul R. Larkin, Marijuana Edibles and “Gummy
Bears,” 66 BUFF. L. REV. 313, 349–56, 359 (2018) (discussing three reasons the FDA may
have refrained from acting, including that the agency chose to avoid getting embroiled
in disputes over the proper role of the federal government with respect to state cannabis
laws and an overly broad reading of the Rohrabacher-Blumenauer Amendment).
433. The agency would reason that the food—for instance, a cookie—was
adulterated by the addition of an unapproved food additive subsequent to the
interstate shipment of one of its components—the flour. See 21 U.S.C. § 331(k); see
also Complaint for Permanent Injunction ¶ 13, 15, 47–49, 55, United States v. Cal.
Stem Cell Treatment Ctr., No. 5:18-CV-1005, (C.D. Cal. 2018), 2018 WL 2144859.
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federal law would not permit the company to make any claims about
the food relating to the presence of the cannabinoid.
First, the FDA would not permit a “structure/function” claim (such
as “helps maintain a calm disposition”) relating to the cannabis
constituent. While the agency freely permits structure/function claims
on dietary supplements,434 it permits these claims on conventional
foods only if the claimed effect is achieved through the “nutritive
value” of the food or nutrient.435 In a related context, the agency
defines “nutritive value” to mean the item’s “value in sustaining human
existence by such processes as promoting growth, replacing loss of
essential nutrients, or providing energy.”436 Thus although the FDA
will permit structure/function claims referring to the role of wellknown nutrients such as calcium and vitamin C, it would probably not
permit a structure/function claim relating to non-nutritive effects of
cannabis constituents.437
It might be possible to make a
structure/function claim for a food containing cannabis constituents with
nutritive value (such as seeds and leaves in a hemp cake), but the FDA
would permit only claims about effects related to the nutritive benefit.
Second, the FDA would not permit any claim relating to the
treatment, prevention, or cure of a disease, such as cancer. A disease
claim will always turn a substance into a drug and usually also trigger
the requirement to hold an approved NDA.438 It would not matter that
the commercial product was presented to consumers as a conventional
food. A product can fall into more than one regulatory category and
be regulated under both sets of rules at the same time.439 A
conventional food containing cannabis, with a disease claim relating
to the cannabis, would be regulated as both a food and a drug.
Third, even though there is a special exception for “health claims”
on foods and dietary supplements, the FDA would probably not permit
a health claim on a conventional food based on the presence of a

434. See supra Section IV.B.
435. Food Labeling; Requirements for Nutrient Content Claims, Health Claims,
and Statements of Nutritional Support for Dietary Supplements, 62 Fed. Reg. 49,859,
48960 (Sept. 23, 1997) (to be codified at 21 C.F.R. pt. 101).
436. 21 C.F.R. § 101.14(a)(3) (2018).
437. It might be possible to challenge the FDA’s approach to structure/function
claims on conventional foods as inconsistent with the statute, but exploring this
argument is beyond the scope of this Article.
438. See supra notes 250, 288 and accompanying text.
439. See, e.g., supra note 240 and accompanying text.
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cannabis constituent in this food.440 A health claim characterizes the
relationship of a substance to a disease or health-related condition.441
The agency’s regulations provide that a health claim must satisfy
certain basic eligibility requirements before it can even be
considered.442 A typical health claim for a conventional food relates to
decreased dietary level of a substance (such as lower saturated fat).443
For example, the agency has authorized “diets low in sodium may
reduce the risk of high blood pressure, a disease associated with many
factors” on a food that satisfies the agency’s nutrient content
requirements for “low sodium” food.444 If a health claim is based on the
presence of a substance other than decreased dietary levels, the substance
must be used in the conventional food for a traditional food purpose.445
440. Moreover, the agency’s permission is necessary. There are three ways this can
happen. First, the agency may expressly authorize a claim, in a regulation, if it finds
that the claim is supported by the “totality of publicly available scientific evidence” and
that there is “significant scientific agreement” among qualified experts that the claim
is supported by this evidence. 21 U.S.C. § 343(r)(3)(B); 21 C.F.R. § 101.14(c).
Second, a series of First Amendment rulings require the agency to exercise
enforcement discretion with respect to claims that do not rise to this statutory
standard, if appropriate disclaimers have been added. E.g., Pearson v. Shalala, 164
F.3d 650, 653–54, 657 (D.C. Cir. 1999). The FDA expects a company to submit a
petition for a qualified health claim, however, with the scientific data supporting the
proposed claim. See Guidance for Industry: Interim Procedures for Qualified Health Claims
in the Labeling of Conventional Human Food and Human Dietary Supplements, FDA (July
2003), https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegu
latoryInformation/LabelingNutrition/ucm053832.htm#intro. Third, another federal
agency with responsibility for human nutrition research or for protecting public health
might publish an authoritative statement concerning the relationship between the
substance and a disease or health-related condition. The FDA has the opportunity to
modify or even prohibit a claim published by another agency. See Guidance for Industry:
Notification of a Health Claim or Nutrient Content Claim Based on an Authoritative Statement
of a Scientific Body, FDA (June 11, 1998) [hereinafter Health Claim Guidance],
https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInf
ormation/LabelingNutrition/ucm056975.
441. 21 U.S.C. § 343(r)(1)(B). The FDA defines a “disease or health-related
condition” in this context as “damage to an organ, part, structure, or system of the
body such that it does not function properly (e.g., cardiovascular disease), or a state of
health leading to such dysfunctioning (e.g., hypertension).” 21 C.F.R. § 101.14(a)(5).
442. See Health Claim Guidance, supra note 440.
443. 21. C.F.R. § 101.14(b)(2).
444. § 101.74.
445. § 101.14(b)(3) (“The substance must . . . contribute taste, aroma, or nutritive
value, or any other technical effect listed in § 170.3(o) of this chapter, to the food and
must retain that attribute when consumed at levels that are necessary to justify a claim”);
see also Food Labeling; General Requirements for Health Claims for Food, 58 Fed. Reg.
2,478, 2,499 (Jan. 6, 1993) (to be codified at 21 C.F.R. pts. 20 and 101). Permitted
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In effect, the substance must contribute taste, aroma, or nutritive value.446
The FDA probably would not permit a health claim on conventional food
based on the presence of a cannabinoid because the cannabinoid would
not be serving one of these traditional food purposes. It is conceivable
the agency would permit a health claim about another cannabis
constituent grounded in the nutritive value of that constituent.
4.

Risk of the FDA invoking new drug authorities
The path forward for a food containing a cannabis constituent
requires solving the drug exclusion issue (for instance, by ensuring the
food contains only constituents that have not been studied or approved
in new drugs, which excludes at least dronabinol and CBD), avoiding
§ 402(a) (through approval of a food additive petition or a GRAS
determination), and making no claims relating to the medical benefits
of cannabis in the food (though perhaps making health claims tied to
nutritive benefits, with the agency’s permission). But there would still
be a non-trivial risk that the FDA would classify the product as a drug.
The FDA’s regulations state that a product’s intended use is
determined by the expressions of the person legally responsible for its
labeling, but it may also be shown “by the circumstances surrounding
the distribution of the article.”447 These include the circumstance that
the item is, with this person’s knowledge, “offered and used for a
purpose for which it is neither labeled nor advertised.”448 In 1980, the
United States Court of Appeals for the D.C. Circuit added that the
intended use of a product is determined “from its label, accompanying
labeling, promotional claims, advertising, and any other relevant
source.”449 The full impact of the language in the regulation and court
decision is unsettled. But the FDA concluded that balloons filled with
nitrous oxide (laughing gas) and distributed in the parking lot of a
rock concert at RFK Stadium were “drugs” even though the sellers
made no claims about the intended use of the balloons.450 A federal

“technical effects” in food include use as an anti-caking agent, curing or pickling agent,
emulsifier, or leavening agent, among other things. 21 C.F.R. § 170.3(o).
446. 21 C.F.R. § 101.14(b)(3). Nutritive value, in this context, means “value in
sustaining human existence by such processes as promoting growth, replacing loss of
essential nutrients, or providing energy.” § 101.14(a)(3).
447. § 201.128.
448. Id.
449. Action on Smoking & Health v. Harris, 655 F.2d 236, 239 (D.C. Cir. 1980)
(emphasis added) (quoting Hanson v. United States, 417 F. Supp. 30, 35 (D. Minn 1976)).
450. United States v. Travia, 180 F. Supp. 2d 115, 116, 118–19 (D.C. Cir. 2001).
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district court agreed with the FDA that the balloons were intended to
affect the structure or function of the body, reasoning that “the sellers
did not need to label or advertise their product, as the environment
provided the necessary information between buyer and seller.”451 If
the agency were concerned about the safety of conventional foods
containing cannabis constituents, it might invoke this theory and argue
that the products were drugs. This would, in turn, trigger the agency’s
new drug authorities and render the products illegal. But it would be
a controversial position for the agency to take.
If a company managed to move forward with a conventional food
containing a cannabis constituent, the agency’s regulations and
policies relating to food would apply.452 In addition to the pesticide
residue issue already flagged, these would include a variety of
affirmative labeling requirements.453
For example, unless an
exemption applied, the company would need to provide nutrition
information in the form of a “Nutrition Facts” box.454 In addition, the
agency’s many regulations implementing the FDA Food Safety
Modernization Act455 would also apply. Thus, among other things, unless
an exemption applied, the company would need to establish and

451. Id. at 119.
452. These rules therefore apply to any foods containing the hemp seed derived
food ingredients for which FDA issued GRAS response letters in December 2018. See
supra note 430.
453. See 21 U.S.C. §§ 343(i)(1)–(2), 343(q). Products marketed as imitations of
well-known products that do not themselves contain cannabis or one of its constituents
would likely draw warning letters, on the theory that the labeling was misleading,
particularly if children were the primary consumers of the imitated products. § 343(a).
Examples might include “Rasta Reeses” (packaged to resemble Reese’s Peanut Butter
Cups), “Keef Kat” (KitKat), and “Buddafinger” (Butterfinger), all currently on the
market. See MacCoun, supra note 432, at 990. The FDA recently took action against
vendors of e-cigarette liquids that were labeled to look like children’s juices and
candies, on the theory that the products were misbranded, because their labeling
and/or advertising was false or misleading—in that they imitated other products. E.g.,
Warning Letter from FDA to NEwhere Inc. d/b/a Mad Hatter Juice (May 1, 2018),
https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm618146.
454. 21 U.S.C. § 343(q)(1); Food Labeling; Serving Sizes of Foods that Can
Reasonably be Consumed at One Eating Occasion; Dual-Column Labeling; Updating,
Modifying, and Establishing Certain Reference Amounts Customarily Consumed;
Serving Size for Breath Mints; and Technical Amendments, 81 Fed. Reg. 34,000,
34,000 (May 27, 2016) (to be codified at 21 C.F.R. pt. 101). Numerous exemptions
apply, including for foods produced by very small businesses, food sold in small
packages, and foods served in restaurants (including bakeries) for immediate
consumption on the premises. 21 C.F.R. § 101.9(j).
455. Pub. L. No. 111-353, 124 Stat. 3885 (2011).
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implement a food safety system that includes hazard analysis and risk-based
preventive controls (HARPC).456 Further, any facility that manufactures,
processes, packs, or holds food for consumption—including one that is
HARPC-exempt—must comply with cGMP for food.457
C. Medical Cannabis in Dietary Supplements
Dietary supplements are considered a type of food, but they are
defined separately in the FDCA and subject to slightly different rules.
As a result, there is a narrow path forward for marketing dietary
supplements containing cannabis constituents.458 There are at least
four significant constraints to keep in mind.
First, a dietary supplement cannot lawfully contain either
dronabinol or CBD. The FDCA imposes a “drug exclusion” for dietary
supplements, just as it does for conventional foods.459 A substance
cannot be classified as a “dietary supplement” if it has been approved
as a new drug or if it has been authorized for investigation as a new
drug, the clinical trials have started, and the trials are public
knowledge.460 The FDA already takes the position that this exclusion
means THC and CBD cannot be added to dietary supplements.461
There are options for avoiding the exclusion rule similar to those

456. 21 C.F.R. § 117.126; Current Good Manufacturing Practice, Hazard Analysis,
and Risk-Based Preventive Controls for Human Food, 80 Fed. Reg. 55,908, 55,911
(Sept. 17, 2015) (to be codified in 21 C.F.R.). This entails analyzing the hazards,
designing and implementing the controls, monitoring the effectiveness of the
controls, maintaining records of the monitoring, and establishing corrective actions
for problems, which must be documented. A small company that marketed its
cannabis-containing conventional food directly to consumers could qualify for an
exemption and modified HARCP requirements. 21 C.F.R. § 117.5(a).
457. 80 Fed. Reg. at 55,911; 21 C.F.R. §§ 117.10–117.110. To give another example,
if the FDA has issued a standard of identity for the food in question, the cannabisderived constituent could not be added to the food unless doing so was permitted by
the applicable standard of identity. 21 U.S.C. § 343(g).
458. Dietary supplements may contain herbs or botanicals, as well as concentrates,
metabolites, constituents, or extracts of herbs or botanicals, among other things. 21 U.S.C.
§ 321(ff). Cannabinoids would presumably qualify as extracts of an herb or other botanical.
459. § 321(ff)(3)(B).
460. Id.
461. Marijuana Q&A, supra note 410. It has sent numerous warning letters to
companies marketing cannabidiol in supposed dietary supplements, citing this
provision. See Warning Letters and Test Results for Cannabidiol-Related Products, FDA,
https://www.fda.gov/newsevents/publichealthfocus/ucm484109 (last updated Nov.
2, 2017) (providing examples of FDA warning letters sent out in 2017 regarding the
marketing of products containing CBD).
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discussed in the last part of this Article.462 For example, if the substance
was marketed in dietary supplement or food form before the drug was
approved or the trials started, the drug exclusion rule does not apply.463
The agency does not think this exception applies, but it has invited
evidence and arguments to the contrary.464 Other cannabis constituents,
however, could presumably be presented in dietary supplements. There
may also be room to argue that the agency’s claim about “THC” is
overbroad because it has approved only dronabinol (9-THC).
Today, numerous companies sell hemp extracts that contain CBD,
in interstate commerce.465 These products are positioned as dietary
supplements and marketed illegally, as the FDA has explained in
various Warning Letters.466 For instance, the agency issued a Warning
Letter in October 2017 to Stanley Brothers Social Enterprises, which
operates as “CW Hemp” and markets “Charlotte’s Web” through the
internet.467 The FDA’s letter took the position that certain claims on
the website (e.g., claiming the product’s “anti-tumoral” and “anticancer” benefits) rendered Charlotte’s Web a “new drug” which may
not be shipped in interstate commerce without an approved
application.468 The company appears to have removed the drug claims
from its website and promotional materials, focusing instead, for
instance, on “a sense of calm and focus.”469 As of August 2018,
however, it is still distributing Charlotte’s Web in interstate
commerce.470 The company may be missing the second violation cited

462. See infra Part IV.
463. § 321(ff)(3)(B).
464. Marijuana Q&A, supra note 410.
CHARLOTTE’S
WEBTM
HEMP
EXTRACT,
465. See,
e.g.,
Shop
CBD,
https://www.cwhemp.com/all-charlottes-web-cannabinoid-hemp-cbd-supplements
(last visited Feb. 5, 2019).
466. The FDA issues a Warning Letter when it finds significant violations of the
statute, which it defines as “violations that may lead to enforcement action if not
promptly and adequately corrected.” FDA, REGULATORY PROCEDURES MANUAL § 4-1-1
(2018), https://www.fda.gov/downloads/iceci/compliancemanuals/regulatoryproc
eduresmanual/ucm074330.pdf.
467. Warning Letter from FDA to Stanley Brothers Social Enterprises, LLC (Oct.
31, 2017) [hereinafter Stanley Warning Letter], https://www.fda.gov/ICECI/
EnforcementActions/WarningLetters/2017/ucm583192. Charlotte’s Web is a type of
CBD manufactured by the Stanley Brothers. See Our Company, CHARLOTTE’S WEBTM HEMP
EXTRACT, https://investors.cwhemp.com/our-company/default.aspx (last visited Feb. 5, 2019).
468. Stanley Warning Letter, supra note 467, at 3.
469. Charlotte’s Web Benefits: What Charlotte’s Web Can Do For You, CHARLOTTE’S WEBTM
HEMP EXTRACT, https://www.cwhemp.com (last visited Feb. 5, 2019).
470. Id.
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in the Warning Letter because CBD has been the subject of new drug
clinical trials (and in fact is now the subject of an approved new drug),
and no company may distribute dietary supplements containing
CBD.471 In other words, either the disease claim or the presence of
CBD is sufficient to trigger enforcement action. A Warning Letter does
not commit the FDA to enforcement action, but the recent approval
of a new drug containing CBD (discussed in Part IV) could prompt the
agency to act without further notice.472
Second, any dietary supplement containing a non-excluded
cannabis constituent must be sold to consumers in a form intended for
ingestion.473 This means a tablet, capsule, powder, softgel, liquid, or
another ingestible form that is not represented as conventional food
or as a meal replacement.474 Further, no dietary supplement can be
represented for use as a conventional food or meal replacement.475
This precludes putting a cannabis constituent in a conventional food
(such as a brownie) that is then recharacterized as a dietary
supplement. It should be possible to market “edible” dietary
supplements containing cannabis constituents, but it is important to
avoid the appearance of a conventional food as well as the use of any
terms (such as “beverage”) in the labeling that would cause the FDA to
categorize the product represented as a conventional food.476 And
because a dietary supplement must be intended for ingestion, it is not
possible to present a cannabis-based product in a form that cannot be
ingested—such as an inhaler, gel, or patch—and characterize that
product as a dietary supplement.477

471. Stanley Warning Letter, supra note 467, at 2.
472. REGULATORY PROCEDURES MANUAL, supra note 466, § 4-1-1 (2018)
(“violations . . . may lead to enforcement”) (emphasis added); see also infra Part IV.
Indeed, after Congress removed hemp from the Controlled Substances Act in
December 2018, the FDA issued a statement noting the “proliferation” of products
containing cannabis-derived substances, reminding the public that it is unlawful to
market CBD in dietary supplements, and promising to take any enforcement action
needed. See Statement on Signing of the Agriculture Improvement Act, supra note 49.
473. See 21 U.S.C. § 321(ff)(2)(A)(i) (2012).
474. Id.; see also § 350(c)(1)(B); United States v. Ten Cartons, Ener-B Nasal Gel, 888
F. Supp. 381, 396 (E.D.N.Y. 1995).
475. § 321(ff)(2)(B).
476. See generally FDA, GUIDANCE FOR INDUSTRY: DISTINGUISHING LIQUID DIETARY
SUPPLEMENTS FROM BEVERAGES (2014), https://www.fda.gov/downloads/Food/Guid
anceRegulation/GuidanceDocumentsRegulatoryInformation/DietarySupplements/
UCM381220.pdf.
477. See 21 U.S.C. §§ 321(ff)(2)(A)(i), 350(c)(1)(B).
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Third, a company pursuing this strategy would probably need to
submit a premarket notification to the FDA with results from
premarket safety testing. This is because a cannabis constituent
(including a non-excluded cannabinoid) would probably be
considered a “new dietary ingredient.” If the substance had been
marketed in dietary supplements before October 15, 1994, it would not
be considered a new dietary ingredient.478 But the agency requires
rigorous documentation of prior marketing—such as business records,
mail-order catalogs, magazine advertisements, and sales contracts.479 It
is unlikely that sufficient evidence would exist for any substance
derived from cannabis, especially a cannabinoid other than
dronabinol and cannabidiol.480 Any other dietary ingredient—one
used in supplements for the first time after October 15, 1994—would
be considered a “new dietary ingredient.”481
Because a cannabis constituent would be a new dietary ingredient,
there would be two bases for marketing it in a dietary supplement. To
begin with, a company could market a dietary supplement containing
this new dietary ingredient if the dietary ingredient was previously
present in the food supply “as an article used for food in a form in
which the food has not been chemically altered.”482 The FDA
interprets this to mean the ingredient was marketed in the same
chemical form as a distinct conventional food or conventional food
ingredient.483 A new cannabis constituent (other than dronabinol or
CBD) would probably not satisfy this standard.
In the alternative, a company could market a dietary supplement
containing this new dietary ingredient if there was a “history of use or
other evidence of safety” establishing that, when used according to the
directions in its labeling, the ingredient will “reasonably be expected

478. 21 U.S.C. §§ 350b(a), 350b(d). Any dietary ingredient marketed prior to that
date is considered an “old” dietary ingredient and does not require a premarket
notification. But it must have been marketed as a dietary ingredient, meaning in or as
a dietary supplement. NDI GUIDANCE, supra note 408, at 14.
479. NDI GUIDANCE, supra note 408, at 17–18. The FDA also might not accept
evidence relating to illegal marketing.
480. The FDA would not consider an ingredient’s previous marketing as a
conventional food or marketing for non-food use as evidence that the substance was an
old dietary ingredient. Id. at 19. Changes in the manufacturing process since 1994 would
turn the dietary ingredient into a new dietary ingredient, if they altered the identity of
the ingredient or changed its properties or even its purity or impurities. Id. at 21.
481. 21 U.S.C. § 350b(d).
482. § 350b(a)(1).
483. NDI GUIDANCE, supra note 408, at 23, 25–26.
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to be safe.”484 This would allow the company to test its cannabinoid to
support its use as a dietary ingredient in a dietary supplement. In this
case, the company would submit a “new dietary ingredient
notification” (“NDI notification”) at least seventy-five days before it
planned to introduce the supplement to the market, providing the
basis for its conclusion that the supplement satisfies the statutory safety
standard.485 Although preparing an NDI notification is not as
expensive and time consuming as preparing a food additive petition
(let alone a new drug application), the burden is still significant.486
The company would need to provide detailed chemistry information
and a description of its manufacturing process, including analytical
testing and specifications used.487 For a botanical drug, the agency
would expect to see information about the conditions of propagation
and cultivation, as well as production methods. For an extract of a
botanical, the agency would require additional manufacturing
information (including, for instance, measures taken to control
adulterants such as pesticides and heavy metals). The amount of safety
data required from testing in animals and humans would depend on a
variety of considerations, such as whether the supplement was
intended for daily chronic or intermittent use, whether there was
documented historical use and the nature of that use, and the
information from that historical use.488 In the absence of any history,
the agency would generally require a battery of studies, some of which
could last up to two years.489
Fourth, a dietary supplement containing a cannabis constituent
could not be the subject of a disease claim or health claim. Any claim
that the supplement could mitigate, treat, prevent, or cure a disease
would render the supplement an unapproved new drug subject to
enforcement action.490 Also, as noted, the FDA may permit “health
claims” on dietary supplements if the standards for their inclusion are
satisfied.491 But the agency is unlikely even to consider a health claim
484. § 350b(a)(2).
485. Id. It is not necessary to wait for formal approval. Many companies wait for a “no
objection” letter, but it is legally permissible to wait for seventy-five days and then, in the absence
of a response from the agency, begin marketing. NDI GUIDANCE, supra note 408, at 50.
486. See generally NDI GUIDANCE, supra note 408, at 55–95 (describing what must be
included in the notification).
487. Id. at 55–56.
488. Id. at 67, 72.
489. Id. at 77.
490. See 21 U.S.C. §§ 321(g)(1), (p) (2012).
491. See supra note 440.
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for a cannabis constituent. It defines a health claim as one that
characterizes the relationship of a “substance” to a disease or healthrelated condition and defines a food “substance” as a specific food or
component of food.492 Whether the substance occurs naturally in food
or has been added, however, it must serve a traditional food purpose—
taste, aroma, or nutritive value (or a technical role such as
preservation)—at the levels necessary to justify the health claim.493
Cannabinoids are unlikely to satisfy this standard, although
terpenoids, flavonoids, and other cannabis constituents might have
nutritive value and qualify.
Taking these four limitations into account, there is a limited path
forward for dietary supplements. It should be possible to market a new
(non-dronabinol and non-CBD) cannabis constituent in an ingestible
form as a dietary supplement, provided that: (1) the product is not
represented as a conventional food, and (2) premarket safety testing
and premarket notification requirements have been satisfied.494 A
company could not make disease claims or health claims with respect
to a cannabinoid constituent, but it could possibly make
“structure/function” claims (and maybe, although this would require
the agency’s permission, which we view as unlikely, a health claim
grounded in nutritive value) for other cannabis constituents.495 Unlike
structure/function claims for conventional foods, structure/function
claims for dietary supplements need not be based on the nutritive
value of the supplement.496 The FDA does, however, carefully police
the line between permissible structure/function claims and
impermissible disease claims. For example, it would not be permissible
to refer to the symptom of a disease (such as pain associated with
arthritis), nor would it be permissible to suggest that the supplement
is a substitute for an approved drug. The agency would likely permit a
claim such as “helps to maintain a healthy appetite,” but it might not
permit a claim such as “helps to maintain a healthy appetite during
492. 21 C.F.R. §§ 101.14(a)(1)–(2) (2018).
493. Food Labeling; General Requirements for Health Claims for Food, 58 Fed.
Reg. 2,478, 2,480 (Jan. 6, 1993) (to be codified at 21 C.F.R. pts. 20 and 101).
494. See supra notes 463–93 and accompanying text.
495. Regulations on Statements Made for Dietary Supplements Concerning the
Effect of the Product on the Structure or Function of the Body, 65 Fed. Reg. 1,000,
1,000 (Jan. 6, 2000) (to be codified at 21 C.F.R. pt. 101) (adopting regulations
governing permissible structure/function claims for dietary supplements).
496. Food Labeling; Requirements for Nutrient Content Claims, Health Claims,
and Statements of Nutritional Support for Dietary Supplements, 62 Fed. Reg. 49,859,
49,860–61 (Sept. 23, 1997) (to be codified at 21 C.F.R. pt. 101).
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treatment for cancer.”497 Any structure/function claim would require
substantiation. The FDA applies the same standard as the Federal
Trade Commission, meaning it expects “competent and reliable
scientific evidence,” which it explains means “tests, analyses, research,
studies, or other evidence based on the expertise of professionals in
the relevant area, that has been conducted and evaluated in an objective
manner by persons qualified to do so, using procedures generally
accepted in the profession to yield accurate and reliable results.”498
D.

The Possibility of Non-Regulation, with Caveats

The preceding parts of this Article did not exhaust the possible ways
cannabis could be commercialized after descheduling. We note a few
additional possibilities below and explain how they would be handled
(if at all) by the FDA.499
First, the cannabis flower might simply be sold for recreational
smoking. Purely intrastate transactions (in which the cannabis is
grown, sold, and smoked within one state) would not trigger the FDA’s
jurisdiction.500 This is true even if the seller made claims about using
the cannabis to treat a disease or other health conditions.501 There is
a solid argument that interstate transactions of cannabis only for

497. The FDA’s regulations prohibit claims suggesting that a product “treats,
prevents, or mitigates adverse events associated with a therapy for a disease, if the
adverse events constitute disease.” 21 C.F.R. § 101.93(g)(2)(ix) (2018). The agency
gives the example of “helps individuals using antibiotics to maintain normal intestinal
flora” (impermissible disease claim) and “helps maintain healthy intestinal flora”
(permissible structure/function claim). 65 Fed. Reg. at 1,029. If the FDA concluded
loss of appetite (anorexia) were a medical condition, it would not permit the claim
described in the text.
498. Guidance for Industry: Substantiation for Dietary Supplement Claims Made Under
Section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act, FDA (Dec. 2008),
https://www.fda.gov/food/guidanceregulation/guidancedocumentsregulatoryinfor
mation/dietarysupplements/ucm073200.
499. Additional possibilities might be inclusion of cannabis or ingredients derived
from cannabis in animal drugs or animal food or feed. Some of the rules governing
animal food and drugs are similar to those applicable to human food and drugs, but
there are additional considerations. For instance, a food additive in animal feed can,
if there is a residue remaining in the edible tissue of the animal, become an indirect
food additive in human food, triggering the human food additive rules, which are
different from the food additive rules for animal feed.
500. 21 U.S.C. § 355(a) (2012) (“No person shall introduce or deliver for
introduction into interstate commerce any new drug, unless an approval . . . is effective
with respect to such drug.”).
501. §§ 331(a)–(d) (specifically limiting prohibited acts to those in interstate commerce).
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recreational smoking also would not trigger the FDA’s jurisdiction.502
But if the seller (in interstate commerce) made claims about treating
a disease or about affecting the structure or functioning of the body,
the FDA would deem the cannabis a drug.503 Thus, claims that smoking
the cannabis would promote relaxation, mitigate insomnia, reduce
anxiety, or maintain the appetite would turn the cannabis into a
regulated drug. In the absence of these claims, the agency might try
to assert its drug authorities on the theory that the product’s design or
the circumstances surrounding its use demonstrated its intended use
as a drug.504 But doing so would be controversial.
Second, the same analytical framework would apply if a cannabis oil
were marketed as a consumer product—for instance an essential oil
sold for aromatherapy or with a vaporizer that can generate a mist for
inhaling. Such a product would not qualify as a dietary supplement
because it is not intended for ingestion.505 For FDA purposes, it is
either a drug or it is nothing. If the product is associated with a disease
claim or a structure/function claim and moves in interstate commerce,
then the FDA will treat it as a drug—whether it appears in a soap,
lotion, massage oil, or bottle for vaporizing. The agency does not
prioritize enforcement with respect to structure/function claims (such
as “helps you sleep”) on essential oils like lavender because the risk to
consumers is negligible. But its calculus would change for a cannabis

502. The FDA would have jurisdiction only if the intended use of the cannabis
triggered the agency’s drug authorities under § 201(p). And intended use usually turns
on claims made in labeling, advertising, and other promotion. See supra Section III.A.
503. See § 321(g) (defining “drug”).
504. See infra Section IV.A (discussing the government’s reasoning that nitrous
oxide balloons distributed at a rock concert constituted “drugs” due to the
circumstances surrounding their distribution). The FDA might also try to rely simply
on the company’s knowledge that consumers use its product for medical purposes. See
21 C.F.R. § 201.128 (2018) (“But if a manufacturer knows, or has knowledge of facts
that would give him notice, that a drug introduced into interstate commerce by him is
to be used for conditions, purposes, or uses other than the ones for which he offers it,
he is required to provide adequate labeling for such a drug which accords with such
other uses to which the article is to be put.”). The “knowledge prong” of the intended
use regulation has been controversial for more than sixty years, however. It faces
substantial opposition from regulated industries, and it is seldom used (at least, not
without other evidence as well). E.g., Medical Information Working Group Citizen
Petition, No. FDA-2013-P-1079, at 17–19 (Sept. 3, 2013), http://www.miwg.org/sites/
default/files/7%20MIWG%20Citizen%20Petition%20%282013%29%2C%20Docket
%20No%20FDA-2013-P-1079.pdf.
505. See 21 U.S.C. § 321(ff)(2)(A)(i) (defining “dietary supplement” as “a product
that is intended for ingestion”).
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constituent product that actually affected the functioning of the body.
The agency would likely take enforcement action if the manufacturer
made drug claims. It is also possible the agency would find an intended
drug use even without claims—based on the company’s knowledge of
actual use in the market or perhaps its design.506
Third, a company might place a cannabis constituent in a cream or
lotion (or another similar topically applied product) and position the
product as a cosmetic. An item is a “cosmetic” for FDA purposes if it is
intended for “cleansing, beautifying, promoting attractiveness, or
altering the appearance” or if it is a component of such an item.507
Cosmetics are less heavily-regulated than food and drugs.508 As always,
any disease or structure/function claim would turn this item into a
drug, even if the item also satisfied the definition of cosmetic.509 Thus,
a skin oil with a cannabis extract would be regulated as a cosmetic and
as a drug if the labeling made a disease claim. But if the company
made no claims about the presence of the cannabis constituent and
genuinely marketed the product for cosmetic purposes, the agency
might leave the company alone.510 This could change if the cannabis
constituent had an impact on the structure or function of the body; for
instance, if it was systemically absorbed and biologically active.511 The
FDA has occasionally asserted that it could infer a supposed cosmetic’s
intended drug use from its active ingredients.512
506. 21 C.F.R. § 201.128; see also supra note 406 and accompanying text.
507. 21 U.S.C. § 321(i).
508. The FDCA prohibits various acts relating to cosmetic misbranding and
adulteration, which allow the agency to take enforcement action in a variety of
situations, including when a cosmetic contains a “deleterious substance which may
render it injurious” when used as directed. § 361(a).
509. See supra notes 435–37 and accompanying text.
510. If a company simply removed the drug claims from its product and attempted
to position the resulting product as a cosmetic, without correcting consumer
impressions and perhaps even with disclaimers, FDA might still find a drug intended
use. See United States v. Undetermined Quantities of an Article of Drug Labeled as
“Exachol,” 716 F. Supp. 787, 791 (S.D.N.Y. 1989) (“Courts have recognized that where
years later customers purchase a product in reliance on the therapeutic claims of the
previous literature marketed with that product, the court may use such literature to
determine the intent in marketing the product despite a later disclaimer”); see also
Zettler, supra note 249, at 1958 n.143.
511. For a discussion of FDA regulation of structure/function claims, see supra
notes 435–37 and accompanying text.
512. E.g., Warning Letter from FDA to Lifetech Resources LLC (Apr. 18, 2011),
https://wayback.archive-it.org/7993/20170111100914/http:/www.fda.gov/ICECI/E
nforcementActions/WarningLetters/2011/ucm251951.htm
(stating
that
the
“presence of the prostaglandin analog . . . along with appearance claims such as
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Finally, a company might add cannabis to a currently-marketed
tobacco product or add a cannabis extract to that tobacco product—
for instance, a cigarette. In this case, the cannabis (or extract) would
be considered a tobacco additive.513 The tobacco product itself, now
modified with a new additive, would be considered a “new tobacco
product” subject to a premarket approval requirement unless an
exemption applied.514 Separately, the FDCA provides that once an
item satisfies the definition of “tobacco product,” it cannot be sold in
combination with any other product regulated under the FDCA.515 Put
another way, dual classification (as a tobacco product and a new drug,
for instance) is not permissible. This provision would be triggered if the
company made any claims about the new ingredient that triggered a
different FDA regulatory authority.516 The FDA gives the example of
adding a mouthwash (which might be a drug or a cosmetic) to the
ingredients of a cigarette and identifying the cigarette as containing
mouthwash.517 Moreover, the definition of “tobacco product” excludes
“an article that is a drug” under § 201 of the FDCA.518 As a result, if a
company added cannabis or an extract to a cigarette and made
structure/function claims, the product in question would be deemed a
“drug” rather than a “tobacco product,” and would be a new drug
marketed illegally without an approved NDA. Indeed, the FDA might
infer a drug intended use on the basis of the additive’s identity and actual
use of the product—even in the absence of claims—with the same result.

‘enhance the appearance of your lashes and brows’ . . indicate that your products are
intended to affect the structure or function of the body”); Cosmetic Products
Containing Certain Hormone Ingredients; Notice of Proposed Rulemaking, 58 Fed.
Reg. 47,611, 47 611 (Sept. 9, 1993) (to be codified at 21 C.F.R. pts. 700 and 701)
(proposing a rule that would declare any cosmetic product containing more than a
specified amount of pregnenolone acetate or progesterone was an unapproved new
drug regardless of claims made).
513. 21 U.S.C. § 387(1).
514. §§ 387j(a)(1)–(2).
515. § 321(rr).
516. § 321(rr)(4).
517. FDA, DRAFT GUIDANCE FOR INDUSTRY AND FDA STAFF: THE SCOPE OF THE
PROHIBITION AGAINST MARKETING A TOBACCO PRODUCT IN COMBINATION WITH ANOTHER
ARTICLE OR PRODUCT REGULATED UNDER THE FEDERAL FOOD, DRUG, AND COSMETIC ACT 4
(Sept. 30, 2009), https://www.fda.gov/downloads/TobaccoProducts/Labeling/Rules
RegulationsGuidance/UCM259896.pdf.
518. § 321(rr).
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Summary

Any product containing a cannabis constituent will be regulated as
a “new drug” by the FDA if the company responsible for the product
makes claims about its medical uses and if the product (or any
component of the product) crosses state lines. This will, in turn,
require the company to conduct a rigorous research program proving
the product’s safety and effectiveness before the product can be
launched in the market. There is no reasonable pathway forward for
conventional foods containing or comprising cannabis constituents if
those foods (or any of their ingredients) cross state lines, with the likely
sole exception of certain hemp seed ingredients that appear to be
GRAS. Any other cannabis constituent would need to be chemically
distinct from those already under clinical investigation or approved as
new drugs—such as dronabinol (synthetic 9-THC) and CBD—and
either GRAS or an approved food additive. It may be possible to
market a cannabis product in traditional dietary supplement form
(such as capsules) or another ingestible form (such as liquid drops)
but, again, only if the cannabis constituents chemically distinct from
those already under clinical investigation or approved as new drugs.
Permitted dietary supplements could require several years of
premarket safety testing and could not be marketed with medical
claims, but it should be possible to claim that they support the healthy
structure and functioning of the body. The FDA derives its jurisdiction
from statutory provisions, however, that expressly require the
movement of products in interstate commerce. This means the agency
will not regulate cannabis grown, sold, and consumed entirely within
the borders of a single state, even if that cannabis is sold with claims
about treatment of disease. So, too, with conventional foods and
dietary supplements. But if any ingredient (such as the gelatin used to
make a capsule for a dietary supplement) travels in interstate
commerce, the agency could—and likely would—assert its authority.
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IV. THREE PATHWAYS FOR FEDERAL LEGAL
MEDICAL CANNABIS FOLLOWING DESCHEDULING
Based on the analysis in Part III, the Authors believe that if cannabis
and THC are descheduled, there are three pathways forward under
FDA law for medical cannabis.
A.

Medical Cannabis Providers Engaged in Purely Intrastate Operations

The first pathway forward represents, in a sense, continuation of the
traditional medical cannabis industry—sale of whole plant-based
products, by small operations, to locally-based consumers. Cannabis
that is grown, sold, and used entirely within the borders of one state
will not fall within the FDA’s jurisdiction.519 This is true even if the
seller makes medical claims about the product and if those claims are
made in media, such as on the internet, that are accessible outside the
state.520 Not only does the FDA derive its power from the Commerce
Clause, but the FDCA is drafted even more narrowly.521 It is not
sufficient for the agency to find a connection with interstate
commerce; it generally must also find that a product or component of
the product traveled in interstate commerce.522
But there are reasons to be cautious about this pathway. To begin
with, if the FDA is concerned about the claims made or about the safety
of the product, it will strain to find a component that traveled in
interstate commerce. Any inactive ingredient will qualify.523 In
addition, the agency takes the position that sale of a product in one
state for consumer use in another state constitutes introduction of that
product into interstate commerce.524 This will include not only online
sales to residents of other states but in-person sales if the purchasers
cross state lines. Moreover, violation of the FDCA is a strict liability

519. See §§ 331(a)–(d) (specifically limiting prohibited acts to those in interstate commerce).
520. See generally § 331 (listing prohibited acts does not include making claims about
a product in the media).
521. U.S. CONST. art. I, § 8, cl. 3.
522. 21 U.S.C. § 331.
523. § 321(f) (defining food to include any article “used for components” of
another food); § 321(g) (defining a drug to include any “article intended for use as a
component” of another drug).
524. Thus, for instance, the agency has taken enforcement action against dairy
farms that sell raw milk (which cannot be sold in interstate commerce) to buyers
residing in other states. E.g., United States v. Organic Pastures Dairy Co., 708 F. Supp.
2d 1005 (E.D. Ca. 2010) (enjoining dairy that sold raw milk to out-of-state customers).
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offense;525 a seller’s ignorance of the purchaser’s out-of-state status
would presumably be irrelevant. This effectively places the burden on
the medical cannabis business to ensure that transactions are purely
intrastate.526 There is no real prospect for creative circumvention of
the intrastate requirement, for instance through a “buyer’s club.”527
The FDA is likely to view these as shams, much as it does interstate
“cow-share” arrangements, which are an attempt to circumvent the
prohibition on sale of raw milk in interstate commerce.528 Finally, the
fact that the FDA has no jurisdiction over medical cannabis does not

525. See United States v. Park, 421 U.S. 658 (1975) (affirming the conviction of an
individual unaware of the violation of law, following a jury instruction that stated “the
individual is or could be liable under the statute, even if he did not consciously do wrong”).
526. This does not mean that advertising and promotion cannot reach persons out
of state, including through the internet. After all, the availability of medical cannabis
in a state could prompt people to move into the state. The FDA does not derive its
statutory authority from the reach of advertising and promotion, but rather from the
movement of products (or their components) in commerce.
527. Members of a buyer’s club pay membership dues to the organization, which
provides items or services free of charge to its members. The theory is that without
purchasing transactions, shipments of products (such as a cannabis-derived drug or
raw milk) from a club to its members across state lines do not constitute shipment in
interstate commerce. The FDA rejects this theory, reasoning that the FDCA does not
“recognize an exception to . . . prohibited conduct based on the nature of the
contractual arrangement between the distributor and consumer.” E.g., Memorandum
in Support of Government’s Motion for Summary Judgment, United States v. Allgyer,
Civil Action No. 5:11CV02651 LS (Dec. 6, 2011), 2011 WL 7416103.
528. The sale of raw milk in one state for consumer use in another state constitutes
introduction of raw milk into interstate commerce, in violation of FDA regulations. See
21 C.F.R. § 1240.61(a) (2018). But more than half of the states in this country permit
the sale of raw milk directly to consumers. See State Milk Laws, NAT’L CONF. ST.
LEGISLATURES (Aug. 29, 2016), http://www.ncsl.org/research/agriculture-and-ruraldevelopment/raw-milk-2012. Dairy farms in states that have legalized the sale of raw
milk have attempted to avoid the prohibition on interstate shipments by establishing
“cow-share” arrangements, pursuant to which consumers combine resources to
purchase a cow. Some states permit (intrastate) cow sharing arrangements, but the
FDA views interstate cow sharing as a sham. Cf. United States v. Allgyer, No. 11-02651,
2012 WL 355261, at *3–5 (E.D. Pa. 2012) (enjoining a Pennsylvania dairy farm
operator from delivering raw milk to individuals in other states who joined a buyer’s
club that leased his cows). Some dairy farms instead establish “farm-share”
arrangements.
See Share Agreements:
Cowshares, Goatshare, Herdshares,
Farmshares, REALMILK.COM (Nov. 26, 2003), http://www.realmilk.com/herdshares/
share-agreements. In this case, the consumer shares ownership in the farm and
receives profits in the form of raw milk. The FDA would also view an interstate farm
sharing arrangement as a sham.
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mean that the product will be unregulated. States such as Washington
already regulate medical cannabis.529
B.

Development of Pharmaceutical Products Containing
Cannabis Constituents and Synthetic Cannabinoids

The second pathway forward takes the classical Western approach of
small molecule drug development for a product containing a cannabis
constituent or a synthetic cannabinoid. Indeed, the FDA has already
approved several new drugs containing synthetic cannabinoids as well
as one new drug containing CBD. These approvals shed some light on
what this second pathway might look like after descheduling.
1.

Synthetic cannabinoids
The pharmaceutical industry turned to synthetic cannabinoid
products in the early 1980s, perhaps in part because scheduling of
cannabis under the CSA made it difficult to secure botanical raw
materials for naturally-derived products. Unimed Pharmaceuticals,
later acquired by Solvay (now AbbVie), brought the first synthetic
cannabinoid to market.
Marinol capsules contain synthetic 9-THC, assigned the
nonproprietary (generic) name “dronabinol.”530
Each capsule
contains dronabinol dissolved in sesame oil with other inactive
ingredients.531 Oral delivery of dronabinol presented manufacturing
529. See, e.g., WASH. REV. CODE § 69.51.080 (2018).
530. The nomenclature conventions of the International Union of Pure and
Applied Chemistry (IUPAC) guide the generation of the chemical name for a drug.
Under the FDCA, every drug also has an “established” name, which is a shorter simpler
nonproprietary name and by convention appears in parenthesis after any brand name
(typically trademarked) the manufacturer may have adopted for its product. 21 U.S.C.
§ 352(e)(1) (2012); see also Use of Drug Name Terms Policy, FDA, https://www.fda.go
v/drugs/developmentapprovalprocess/formssubmissionrequirements/electronicsub
missions/datastandardsmanualmonographs/ucm071638 (last updated Oct. 3, 2014).
As a practical matter the established name is usually the drug’s “United States adopted
name” (USAN) assigned by the USAN Council, a small group of individuals that
includes a representative from the American Medical Association (AMA) as well as the
FDA. See USAN Council, AM. MED. ASS’N, https://www.ama-assn.org/about/unitedstates-adopted-names/usan-council (last visited Feb. 5, 2019); Designated Names;
Revocation of List of Official Names of Drugs, 49 Fed. Reg. 37,574 (Sept. 25, 1984) (to
be codified at 21 C.F.R. pt. 299). “THC” is an abbreviation for “tetrahydrocannabinol.”
Dronabinol is the established name for 9-THC.
531. MACK & JOY, supra note 81, at 202; see also FDA, MARINOL PACKAGE INSERT § 11
(Aug. 28, 2017), https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/0186
51s029lbl.pdf.

910

AMERICAN UNIVERSITY LAW REVIEW

[Vol. 68:823

and development challenges. For instance, only a small fraction of the
dronabinol present in a capsule reaches its target in the body, in part
because it is not water soluble.532 In addition, dronabinol takes effect
slowly, reaching its full effect in two to four hours after dosing.533
These issues have led researchers to explore other routes of
administration, including inhalation and sublingual products
(administered under the tongue).534 To date, however, this research
has not borne fruit.535 One complicating factor may have been that a
faster onset of action, though desirable from a therapeutic potential,
is associated with a higher potential for misuse.536
Approval and commercial launch of Marinol took an unusually long
time, but the factors driving delay would not affect a new cannabisderived drug after descheduling. The FDA initially approved Marinol
in May 1985 for “treatment of the nausea and vomiting associated with
cancer chemotherapy in patients who have failed to respond
adequately to conventional anti-emetic treatment.”537 The company
supported approval with pivotal effectiveness data from 454 cancer
patients who received a total of 750 courses of treatment.538 But the
FDA took nearly four years to approve the NDA.539 After Unimed filed
its NDA in June 1981, the agency took three years to issue an
approvable letter, which it subsequently rescinded.540 The agency did
not issue a final approval letter until the summer of 1985.541 Today, an

532. MACK & JOY, supra note 81, at 143.
533. Id. at 203.
534. Id. at 206.
535. See generally id. at 205–06.
536. Id.
537. Unimed’s Marinol Is Headed out of Group C and into the Marketplace, PINK SHEET
(Jun. 10, 1985) [hereinafter Marinol into the Marketplace], https://pink.pharmaintelli
gence.informa.com/PS008469/unimeds-marinol-is-headed-out-of-group-c-and-intothe-marketplace.
538. FDA, MARINOL LABEL, NDA 18-651/S-025 AND S-026 6 (June 21, 2006),
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018651s025s026lbl.pdf.
In these patients, the drug’s effectiveness varied, with the greatest benefit seen in
patients receiving cytotoxic therapy with MOPP for Hodgkin’s lymphoma and nonHodgkin’s lymphoma. Id.
539. Marinol into the Marketplace, supra note 537.
540. Unimed’s Marinol NDA Will Be Resubmitted, PINK SHEET (Nov. 12, 1984)
[hereinafter Marinol Resubmitted], https://pink.pharmaintelligence.informa.com/
PS007485/unimeds-marinol-nda-will-be-resubmitted.
541. Marinol into the Marketplace, supra note 537. While the NDA was pending, the
National Cancer Institute—which had been deeply involved in the development of
dronabinol by conducting or funding much of the preclinical and clinical work that
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NDA for a new cannabinoid would be subject to user fees and would
receive an “action date” for the FDA decision, typically eight or twelve
months from submission.542 The launch of Marinol was further
delayed when the DEA took an unusually long time to reschedule the
drug from Schedule I to Schedule II, but this would not be a
consideration if cannabis and THC were descheduled.543
Marinol has also faced challenges in the marketplace. The drug can
cause adverse psychiatric reactions, such as exacerbation of mania,
depression, and schizophrenia, and cognitive impairment.544 These
side effects are dose dependent and may be more common in elderly
patients, who are more likely to be undergoing cancer treatment in the
first instance.545 Other central nervous system adverse reactions
commonly noted in clinical trials have included paranoid reactions,
abnormal thinking, confusion, amnesia, depersonalization, and
hallucinations.546 Combined with the access restrictions inherent in
scheduling, these considerations may have limited the product’s sales for
its initial indication—treatment of nausea and vomiting due to
chemotherapy.547 Reglan (metoclopramide) was also approved for relief

supported approval—distributed the drug for free to more than 25,000 patients. MACK
& JOY, supra note 81, at 143–44; Marinol Resbumitted, supra note 540.
542. See 21 U.S.C. § 379h (2012). The FDA’s current goals are to act within ten
months of the sixty-day filing date for a standard application and within six months of
the sixty-day filing date for a priority application. FDA, PDUFA REAUTHORIZATION
PERFORMANCE GOALS AND PROCEDURES FISCAL YEARS 2018 THROUGH 2022 4
https://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/
UCM511438.pdf.
543. Roxane Will Begin Marketing Unimed’s Marinol in Early May, PINK SHEET (Apr. 7,
1986), https://pink.pharmaintelligence.informa.com/PS009947/roxane-will-beginmarketing-unimeds-marinol-in-early-may. The delay at DEA stemmed in part from a
related petition at the agency and the Administration’s initial plan, which was opposed
by the American Medical Association, to deem off-label prescribing a violation of the
Controlled Substances Act. DEA Schedule II Prescribing Limitations for Dronabinol, PINK
SHEET (Feb. 3, 1986), https://pink.pharmaintelligence.informa.com/PS009616/deaschedule-ii-prescribing-limitations-for-dronabinol; Marinol DEA Scheduling, PINK SHEET
(Dec. 16, 1985), https://pink.pharmaintelligence.informa.com/PS009414/MarinolDEA-scheduling.
544. MARINOL PACKAGE INSERT, supra note 531, § 5.1.
545. Id. §§ 5.1, 8.5; MACK & JOY, supra note 81, 143.
546. MARINOL PACKAGE INSERT, supra note 531, § 6.1.
547. MACK & JOY, supra note 81, at 144–45. Indeed, the company estimated that
rescheduling Marinol would increase sales 15 to 20 percent, and DEA did so in July
1999. Id.; see also Roxane/Unimed Marinol Now Refillable Following DEA Down-Scheduling,
PINK SHEET (July 12, 1999), https://pink.pharmaintelligence.informa.com/PS034
484/RoxaneUnimed-Marinol-Now-Refillable-Following-DEA-DownScheduling.
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of nausea and vomiting due to chemotherapy and remained the standard
of care despite significant side effects.548 And sales of Marinol for nausea
and vomiting declined after the FDA approved Zofran (ondansetron) in
January 1991 for essentially the same indication.549 Sales improved after
the FDA-approved Marinol in December 1992 for treatment of anorexia
associated with weight loss in patients with AIDS.550
The other synthetic cannabinoid faced challenges in the market as
well. The FDA approved Eli Lilly’s Cesamet (nabilone) at the end of
1985, the same year it approved Marinol.551 Nabilone is a synthetic
cannabinoid similar to 9-THC,552 and it was similarly approved for
treatment of nausea and vomiting associated with cancer
chemotherapy.553 Lilly withdrew the drug from the market in 1989 for
“commercial reasons,” but Valeant purchased the drug from Lilly in

548. Glaxo’s Zofran (Ondansetron) Approved for Prevention of Chemotherapy-Induced
Nausea and Vomiting with “1-B” Rating After 27-Month Review at FDA, PINK SHEET (Jan. 7,
1991), https://pink.pharmaintelligence.informa.com/ps018594/glaxos-zofran-ond
ansetron-approved-for-prevention-of-chemotherapyinduced-nausea-and-vomiting-with1b. The FDA had initially approved Reglan (for a different use) in 1979. Biocraft,
Quantum Pharmics and Colmed Labs Clear Metoclopramide Generics, PINK SHEET (Aug. 5,
1985), https://pink.pharmaintelligence.informa.com/PS008721/biocraft-quantumpharmics-and-colmed-labs-clear-metoclopramide-generics.
549. MACK & JOY, supra note 81, at 144.
550. Id. The new use was protected by seven years of orphan exclusivity. Id.; see also
21 U.S.C. § 360cc (2012) (providing seven years of exclusivity for an approved drug
that was designated under § 360bb for a rare disease or condition). Unimed supported
this new use with the results of a randomized, double-blind placebo-controlled study
involving treatment of 139 patients for six weeks. MARINOL PACKAGE INSERT, supra note
531, § 14.1; see also Unimed’s Marinol (Dronabinol) Gains Indication for Anorexia in AIDS
Patients, PINK SHEET (Jan. 4, 1993), https://pink.pharmaintelligence.informa.com
/PS021983/unimeds-marinol-dronabinol-gains-indication-for-anorexia-in-aids-patients.
551. Lilly’s Cesamet (Nabilone) Launch Awaits DEA Scheduling, PINK SHEET (Jan. 6,
1986) [hereinafter Cesamet Await Scheduling], https://pink.pharmaintelligence.
informa.com/PS009486/lillys-cesamet-nabilone-launch-awaits-dea-scheduling.
The
FDA took more than two years to approve the NDA. See id. (indicating an advisory
committee meeting in April 1983). Through a series of corporate transactions,
Cesamet is now marketed by Mylan. Cesamet, INFORMA: PHARMA INTELLIGENCE,
http://drugprofiles.informa.com/drug_profiles/5266-cesamet (last visited Feb. 5, 2019).
552. The structural formula for dronabinol is C21H30O2. See MARINOL PACKAGE
INSERT, supra note 531, § 11. The structural formula for nabilone is C24H36O3. Cesamet
Label, NDA 18-677/S-011, U.S. FOOD & DRUG ADMIN. 3 (May 15, 2006),
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018677s011lbl.pdf.
553. Cesamet Await Scheduling, supra note 551.
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2004 and relaunched in 2006.554 Its failure in the marketplace may
have been attributable to its narrow therapeutic window.555
Recently, the FDA approved a quasi-generic dronabinol in a new
dosage form. Generally, a generic drug must have the same route of
administration, dosage form, and strength as the innovative drug it
copies.556 The FDA has approved four generic dronabinol products
presented in oral capsules at the same strength as Marinol.557 Insys
Development Company chose to pursue an oral solution, however,
which it believed would allow it to “convert a large portion of the
market” from the generic dronabinol capsules to its product.558 The
FDA concluded a “human abuse liability study” would be needed,559
however, which meant the company could not use the generic
approval pathway. Thus Insys Development Company submitted its
application under a statutory provision that permitted the company to
rely on the Marinol NDA and add its own data.560 The company’s data
revealed that its oral solution had a higher potential for misuse, and
there were more psychiatric adverse events in the oral solution group
554. Valeant Returns Synthetic Cannabinoid to USA, PHARMATIMES (May 17, 2006),
http://www.pharmatimes.com/news/valeant_returns_synthetic_cannabinoid_to_usa
_996830. The FDA refused to approve the Valeant labeling until the company added
“class-related” safety information—regarding psychotomimetic effect—to the package
insert. Lee Szilagyi, Valeant Cesamet Slated to Hit Market in ‘Next Several Weeks,’ PINK SHEET
(May 16, 2006), https://pink.pharmaintelligence.informa.com/PS064159/ValeantCesamet-Slated-To-Hit-Market-In-Next-Several-Weeks?vid=Pharma&process.
555. Di Marzo, supra note 133, at 2.
556. 21 U.S.C. § 355(j)(2)(A)(iii) (2012).
557. See FDA, CTR. FOR DRUG EVALUATION & RES., ANDA No. 078292,
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process
&ApplNo=078292 (last visited Feb. 5, 2019); FDA, CTR. FOR DRUG EVALUATION & RES.,
ANDA No. 078501, https://www.accessdata.fda.gov/scripts/cder/daf/index.c
fm?event=overview.process&ApplNo=078501 (last visited Feb. 5, 2019); FDA, CTR. FOR
DRUG EVALUATION & RES., ANDA No. 079217, https://www.accessdata.fda.gov/scripts
/cder/daf/index.cfm?event=overview.process&ApplNo=079217 (last visited Feb. 5,
2019); FDA, CTR. FOR DRUG EVALUATION & RES., ANDA No. 201463,
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process
&ApplNo=201463 (last visited Feb. 5, 2019).
558. Bridget Silverman, Keeping Track: FDA Nixes Medicure’s Aggrastat for STEMI,
Approves Insys’ Syndros, PINK SHEET (July 10, 2016), https://pink.pharmaintelligence.
informa.com/PS118719/Keeping-Track-FDA-Nixes-Medicures-Aggrastat-For-STEMIApproves-Insys-Syndros.
559. FDA, CTR. FOR DRUG EVALUATION & RES., APPLICATION NO. 05525ORIG1S000,
CROSS DISCIPLINE TEAM LEADER REVIEW 5–6 (May 20, 2016) [hereinafter INSYS GENERIC
DRONABINOL TEAM LEADER REVIEW], https://www.accessdata.fda.gov/drugsatfda_
docs/nda/2016/205525Orig1s000CrossR.pdf.
560. See 21 U.S.C. § 355(b)(2).

914

AMERICAN UNIVERSITY LAW REVIEW

[Vol. 68:823

than in the oral capsule group.561 These findings could make the
agency more cautious about differences in dosage form and route of
administration as other companies move forward with cannabinoid
drug products. The FDA approved Syndros in July 2016, and DEA
scheduled the drug in March 2017.562 It is not clear whether the sales
have lived up to the company’s expectations.563
2.

Naturally derived CBD
On June 25, 2018, the FDA approved an NDA for Epidiolex® (CBD)
for the treatment of seizures associated with Lennox-Gastaut syndrome
(LGS) and Dravet syndrome (DS) in patients two years of age and
older.564 Both are extremely rare seizure disorders that can lead to
developmental delays and intellectual disabilities.565 Epidiolex’s
approval marked the first FDA approval of a new drug derived directly
from the cannabis plant and attracted attention in the popular press.566

561. INSYS GENERIC DRONABINOL TEAM LEADER REVIEW, supra note 559, at 52–53.
This led to placement in Schedule II instead of Schedule III. Id. at 53.
562. Schedules of Controlled Substances: Placement of FDA-Approved Products of
Oral Solutions Containing Dronabinol in Schedule II, 82 Fed. Reg. 14,815 (Mar. 23,
2017) (to be codified at 21 C.F.R. pt. 1308).
563. Initially, many insurer formularies did not include the drug. The company has
also faced unrelated legal challenges, including suits relating to its marketing of a
fentanyl spray and the arrest of its former Chief Executive Officer. See Todd Campbell,
Why this Marijuana Stock Crashed 18.5% in August, MOTLEY FOOL (Sept. 5, 2017, 9:31
AM),
https://www.fool.com/investing/2017/09/05/why-this-marijuana-stockcrashed-185-in-august.aspx. At the end of 2017 the company characterized the rollout of Syndros as “controlled,” and its first quarter 2018 reports indicated sales had
been flat. Insys Therapeutics Reports First Quarter 2018 Results, GLOBENEWSWIRE (May 8,
2018), https://globenewswire.com/news-release/2018/05/08/1498834/0/en/INS
YS-Therapeutics-Reports-First-Quarter-2018-Results.html; Insys Therapeutics Reports
Fourth Quarter and Full Year 2017 Results, FINANZEN.NET (Mar. 8, 2018),
https://www.finanzen.net/nachricht/aktien/insys-therapeutics-reports-fourth-quarte
r-and-full-year-2017-results-6020165.
564. FDA,
EPIDIOLEX
PACKAGE
INSERT
§1
(June
25,
2018),
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf.
565. Shelly B. DeAdder, The Legal Status of Cannabidiol Oil and the Need for
Congressional Action, 9 BIOTECHNOLOGY & PHARMACEUTICAL L. REV. 68, 68–69 (2016);
Michael Cipriano, Epidiolex Advisory Committee Appears to Be Covering U.S. FDA’s Bases, but
Liver Injury Concerns Persist, PINK SHEET (Apr. 17, 2018), https://pink.pharmaint
elligence.informa.com/PS122921/Epidiolex-Advisory-Committee-Appears-To-Be-Cov
ering-US-FDAs-Bases-But-Liver-Injury-Concerns-Persist.
566. See, e.g., Debra Goldschmidt & Susan Scutti, FDA Approves First Cannabis-Based
Drug, CNN (June 25, 2018, 2:02 PM), https://www.cnn.com/2018/06/25/health/fdaapproves-first-cannabis-drug-bn; John Hudak, Opinion, The FDA Just Opened the Door to
Transforming Marijuana Policy, WASH. POST (June 27, 2018), https://www.washingtonpo
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Although approving a drug derived from cannabis was
unprecedented, it is important to understand what the approval does
and does not represent. Because the FDA had already approved a drug
containing synthetic 9-THC and a drug containing a THC-like
ingredient, the primary significance of Epidiolex’s approval was the
natural, rather than synthetic, origins of the ingredients.567 Nor was it
new for the FDA to approve a drug with botanical origins. The agency
had approved numerous new drugs with highly-processed active
ingredients that derived from natural sources, as well as two botanical
NDAs made from less-processed botanical raw materials.568 The active
ingredient of Epidiolex is a highly purified extract produced from the
cannabis plant.569 The FDA did not deem this drug substance a
botanical.570 Consequently, it did not treat the application as a
botanical NDA, nor did it exercise the flexibility with respect to
chemistry, manufacturing, and controls that botanical drugs have
needed in the past.571 Thus, the precedent is not as significant as it
might seem at the surface.
In many respects, the Epidiolex application was unremarkable. CBD
shares almost none of the pharmacological features of dronabinol,572
and the FDA’s controlled substances staff concluded—on the basis of
preclinical and clinical data—that it does not have misuse potential.573
st.com/opinions/the-fda-just-opened-the-door-to-transforming-marijuana-policy/201
8/06/26/aeb9b628-7978-11e8-aeee-4d04c8ac6158; Matthew Perrone, Medical
Milestone: U.S. Oks Marijuana-Based Drug for Seizures, CHI. TRIBUNE (June 25, 2018, 4:19
PM), http://www.chicagotribune.com/business/ct-biz-fda-epidiolex-marijuana-seizu
re-drug-20180625-story.html.
567. See supra Section IV.B.1.
568. See supra Section III.A.2.
569. EPIDIOLEX PACKAGE INSERT, supra note 564, § 11.
570. FDA, CTR. FOR DRUG EVALUATION & RES., APPLICATION NO. 210365ORIG1S000,
SUMMARY REVIEW 9 (June 22, 2018), https://www.accessdata.fda.gov/drugsatfda_docs
/nda/2018/210365Orig1s000SumR.pdf (noting the FDA Office of Product Quality
described the drug “as a highly-purified drug substance from a plant source”).
571. See generally FDA, CTR. FOR DRUG EVALUATION & RES., APPLICATION NO.
210365ORIG1S000, PRODUCT QUALITY REVIEW(S) (June 4, 2018) [hereinafter EPIDIOLEX
PRODUCT QUALITY REVIEW(S)], https://www.accessdata.fda.gov/drugsatfda_docs/
nda/2018/210365Orig1s000ChemR.pdf.
572. FDA, PERIPHERAL & CENTRAL NERVOUS SYSTEM DRUGS ADVISORY COMM., FDA
ADVISORY COMMITTEE BRIEFING DOCUMENT 12 (Apr. 19, 2018) [hereinafter FDA
BRIEFING DOCUMENT], https://www.fda.gov/downloads/AdvisoryCommittees/Comm
itteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryC
ommittee/UCM604738.pdf.
573. FDA, PERIPHERAL & CENTRAL NERVOUS SYSTEM DRUGS ADVISORY COMM., FDA
BRIEFING DOCUMENT: NDA 210365 CANNABIDIOL 55 (Apr. 19, 2018) [hereinafter NDA
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It does not attach to cannabinoid receptors or other neural receptors
associated with misused drugs, and it did not induce overt behaviors
like those induced by drugs like dronabinol.574 The NDA contained
exactly what one would expect to see in any application for a drug
intended to treat a serious but rare condition.575 The applicant
demonstrated effectiveness through two randomized placebocontrolled studies in LGS and one single randomized placebocontrolled study in DS, together enrolling 516 patients.576 A signal of
drug-induced liver injury emerged in the clinical trials and expanded
access program, which necessitated a more detailed evaluation of liver
safety prior to approval.577 The reviewers found that administration of
the drug to the target population in controlled clinical trials, as well as
in the expanded access program, was causally associated with
elevations in liver enzymes consistent with drug-induced injury to liver
cells.578 Actual cases of severe hepatocellular injury, however, did not
occur.579 They were therefore unable to reach a conclusion on the risk
for chronic liver injury.580 The advisory committee voted unanimously
that the benefit-risk ratio of cannabidiol was favorable for treating

210365 BRIEFING DOCUMENT], https://www.fda.gov/downloads/AdvisoryCommittees
/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAd
visoryCommittee/UCM604736.pdf; see also supra notes 559–61 and accompanying text
(noting research that found potential for abuse in dronabinol oral solution).
574. NDA 210365 BRIEFING DOCUMENT, supra note 573.
575. The company also benefitted from fast-track status and rolling review. See FDA
BRIEFING DOCUMENT, supra note 572, at 42. Fast track is meant to “facilitate
development and expedite review of drugs to treat serious and life-threatening
conditions” so that drugs that meet unmet medical needs can more quickly reach
consumers. FDA, GUIDANCE FOR INDUSTRY: EXPEDITED PROGRAMS FOR SERIOUS
CONDITIONS—DRUGS AND BIOLOGICS 9 (2014), https://www.fda.gov/downloads/Drug
s/Guidances/UCM358301.pdf. The designation entitles the company to more
frequent meetings with the agency to discuss the development plan and may allow the
company to submit its application piecemeal as it completes each section (thus, a
“rolling” submission). Id. at 9–10. The FDA will review the pieces as they arrive, rather
than waiting for a complete application, which allows the applicant to address issues
earlier and should, in theory, allow for earlier approval. In this case, the agency agreed
to fast track designation in June 2014, agreed to the rolling submission in July 2016,
and received the final pieces of the NDA from the applicant in October 2017. FDA
BRIEFING DOCUMENT, supra note 572, at 42.
576. FDA BRIEFING DOCUMENT, supra note 572, at 43.
577. NDA 210365 BRIEFING DOCUMENT, supra note 573, at 7.
578. Id. at 51.
579. Id.
580. Id. at 52.
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seizures associated with LGS and DS,581 and the FDA approved the
NDA on June 25, 2018.582
Three aspects of this approval nevertheless hold lessons for other
companies. First, even though the Office of New Drug Products
concluded that the drug substance was not a botanical, it invited the
Botanical Review Team to provide a review of the quality control
process for the botanical raw material.583 Although this could have
been an anomaly, it is also possible BRT will be involved in review of
other drugs containing highly purified extracts from cannabis. As a
general rule, and as suggested in Part III, the BRT’s involvement will
work in an applicant’s favor as these reviewers are more familiar with
the complexity of botanically sources and more inclined to be
flexible.584 Further, the written memorandum from the review officer
reflects the team’s current understanding of the cannabis plant (as well
Among other things, the
as its history of medical use).585
memorandum acknowledges the “competing schools of thought on
cannabis taxonomy” and seems to adopt the monotypic (single species,
with subspecies) perspective.586 The memorandum, though brief, now
constitutes a sort of informal “precedent” within the agency, which
subsequent new applicants should review.
Second, a substantial expanded access program involved more active
patients than had enrolled in the pivotal trials.587 The FDA began to
581. FDA, CTR. FOR DRUG EVALUATION & RES., SUMMARY MINUTES OF THE PERIPHERAL
4 (Apr. 19, 2018),
https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials
/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM606745
.pdf. FDA’s advisory committees are composed of outside experts from the scientific
community, as well as industry and consumer representatives. What is an FDA Advisory
Committee?, FDA, https://www.fda.gov/AboutFDA/Transparency/Basics/ucm222191
(last visited Feb. 5, 2019). They provide the agency with independent advice on issues
relating to drugs, food, and other products, but their recommendations are not
binding on the agency. Id. See generally Erika Lietzan, Advisory Committees at FDA: The
Hinchey Amendment and “Conflict of Interest” Waivers, 39 J. HEALTH L. 415, 419–24 (2006)
(providing an overview of the development of FDA advisory committees).
582. FDA, CTR. FOR DRUG EVALUATION & RES., NDA APPROVAL: NDA 210365 (June
25, 2018), https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/210365
Orig1s000Ltr.pdf.
583. See EPIDIOLEX PRODUCT QUALITY REVIEW(S), supra note 571.
584. See Botanical Review Team (BRT), FDA, https://www.fda.gov/AboutFDA/Cente
rsOffices/OfficeofMedicalProductsandTobacco/CDER/ucm090946 (last visited Feb. 5, 2019).
585. EPIDIOLEX PRODUCT QUALITY REVIEW(S), supra note 571, at 8–10.
586. Id. at 9 (noting the polytypic (multi-species) perspective, a competing school of
thought).
587. FDA BRIEFING DOCUMENT, supra note 572, at 52–53.
AND CENTRAL NERVOUS SYSTEM DRUGS ADVISORY COMMITTEE MEETING
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authorize physician-initiated expanded access programs in May 2013,
more than a year before the company began its clinical trials.588
Although the company “exerted no control over these programs” (and
“site physicians were responsible for specific treatment plans and
actions”), it submitted, and the agency considered, the safety data as
part of new drug approval.589 These data related to “684 patients with
DS, LGS, and a variety of severe epilepsy conditions.”590 The adverse
events in the expanded access program were generally consistent with
those from the controlled trials, but interpretation of safety results
from expanded access is always complicated by the lack of controls and
the variability in investigators.591 Because cannabis-based drugs are
likely to be studied in a variety of serious and life-threatening
conditions, requests for expanded access are likely to be a feature of
many premarket programs, and the safety data from this use will be an
important part of the agency’s review of any resulting NDAs.592
Third, it is unclear how the approval of Epidiolex will affect
companies already marketing CBD, and the uncertainty points to one
of the most difficult challenges that companies and policymakers
would face if cannabis were descheduled. The FDCA does not permit
the marketing of a dietary supplement containing the active ingredient
of a new drug.593 So it is a federal crime to market dietary supplements
containing cannabidiol, and it was already a federal crime when GW
Pharmaceuticals was testing its product in clinical trials. The agency
has cited violation of the drug exclusion rule in warning letters to
companies marketing cannabidiol, and it specifically points to the
clinical trials of Epidiolex.594 But many of these products remain on
588. Id. at 12, 42–43. The company submitted its IND in March 2014 and started
clinical trials in October 2014. Id. at 42.
589. NDA 210365 BRIEFING DOCUMENT, supra note 573, at 14–15.
590. Id. at 33.
591. FDA BRIEFING DOCUMENT, supra note 572, at 99–100.
592. The new “Right to Try” law will not affect the FDA’s ability to consider the
safety data from expanded access programs, if the data are material to the benefit-risk
ratio of the drug. See Trickett Wendler, Frank Mongiello, Jordan McLinn, and
Matthew Bellina Right to Try Act of 2017, Pub. L. No. 115-176, 132 Stat. 1372 (codified
at 21 U.S.C. § 360bbb-0a (2012)). The Act provides that the FDA “may not use a
clinical outcome associated with the use of an eligible investigational drug pursuant to
this section” unless it finds that use of the clinical outcome “is critical to determining
the safety of the eligible investigational drug.” § 360bbb-0a(c)(1).
593. See supra Section III.C.
594. See Warning Letter from FDA to Green Roads of Florida LLC (Oct. 31, 2017),
https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2017/ucm58318
8; Warning Letter from FDA to Natural Alchemist (Oct. 31, 2017),
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the market. Epidiolex received orphan drug exclusivity, which
precludes the FDA from approving cannabidiol for the same uses for
seven years.595 This is intended to provide GW Pharmaceuticals an
opportunity to recoup its research and development costs in the
marketplace through exclusive sales.596 If the company loses sales to
inexpensive cannabidiol dietary supplements, however, it may not be
able to recoup the research and development costs.
The
manufacturers and distributors of the dietary supplements could not
make claims about treatment of seizures associated with LGS and DS,
but consumers could nevertheless purchase the products, particularly
if the price differential is substantial.597
GW Pharmaceuticals could reasonable urge the FDA to act against
unlawfully marketed dietary supplements, which compete directly with
its product and undermine its orphan exclusivity. But when KV
Pharmaceuticals effectively did the same thing—secured approval and
orphan exclusivity for a treatment that had previously been available
to patients in a cheap unapproved form and asked the FDA to take
action against the unapproved versions—outraged insurers, patients,
and physicians went to the Federal Trade Commission and Congress
for relief.598 So it is unclear whether the manufacturer of Epidiolex
will press the FDA to take action. The FDA might take more formal
action on its own initiative, but it would likely be concerned about the
same backlash.599 Perhaps the parents of children with DS and LGS

https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2017/ucm58320
5; Warning Letter from FDA to Stanley Brothers Social Enterprises, LLC (Oct. 31,
2017), https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2017/uc
m583192; Warning Letter from FDA to That’s Natural! Marketing & Consulting (Oct.
31, 2017), https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2017
/ucm583197.
595. See FDA, APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE
EVALUATIONS: 38TH EDITION A-11 (Cumulative Supp. 2018), https://www.fda.gov/
downloads/Drugs/InformationOnDrugs/UCM086233.pdf.
596. See 21 U.S.C. § 360aa(b) (noting “there is reason to believe that some
promising orphan drugs will not be developed unless changes are made . . . to provide
financial incentives to develop such drugs”).
597. See supra Section III.A.1 (explaining that a product will be deemed a drug if it
is associated with drug claims).
598. Cathy Kelly, Makena Pricing Prompts Multi-Pronged Appeals: FDA, FTC—Bayh
Dole?, PINK SHEET (Mar. 21, 2011), https://pink.pharmaintelligence.informa.com
/PS053233/Makena-Pricing-Prompts-MultiPronged-Appeals-FDA-FTC-ndash-BayhDole.
599. The agency is most likely to act if companies make claims that present a public
health risk, for instance, claims about treatment of serious or life-threatening
conditions that might cause patients to forego proven therapies. See, e.g.¸ Michael
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will prefer the assurance of safety and effectiveness that comes with
FDA approval, but others may not. Other companies considering
cannabis-based drug products will watch GW’s pricing and sales
closely. Whether these companies move forward will depend in part
on the complexity and burden of the NDA approval process for the
particular drug they are developing and on the likely market
conditions after approval. If cannabis is descheduled, these companies
will also need to consider the risk of investing hundreds of millions of
dollars into a new drug product only to find that their target patient
population self-medicates with recreational cannabis.
3.

Current conventional drug research and development
The descheduling of cannabis and THC could lead to a rapid growth
in research to develop new drugs from cannabis simply because
researchers would no longer struggle to obtain raw materials.600 A
review of the medical literature from 1948 through March 2015
uncovered twenty-eight randomized clinical trials for uses other than
those for which Marinol and Cesamet are approved, including chronic
pain, neuropathic pain, multiple sclerosis, Parkinson’s disease,
Crohn’s disease, amyotrophic lateral sclerosis (ALS), and neurogenic
symptoms.601 Today, a review of the Clinical Trial Registry on the
National Institutes of Health indicates more than a dozen ongoing
clinical trials examining the therapeutic potential of cannabis.602 The

Cipriano, Gottlieb: Epidiolex Approval Covers One Specific Cannabidiol Medication, Not
Marijuana, PINK SHEET (June 25, 2018), https://pink.pharmaintelligence.informa.
com/PS123363/Gottlieb-Epidiolex-Approval-Covers-One-Specific-Cannabidiol-Medic
ation-Not-Marijuana (quoting the FDA Commissioner saying that the agency will “prioritize
enforcement going forward” by focusing on situations where patients face “particularly
significant harm because there’s otherwise effective, available therapy for those patients”).
600. As discussed in Part I, researchers are currently limited to NIDA cannabis from
the University of Mississippi. See supra notes 161–65 and accompanying text. Many
trials on the NIH website are taking place in other countries, however, which may
enable them to use other strains depending on the laws in those countries.
ClinicalTrials.gov, U.S. NAT’L INST. HEALTH:
U.S. NAT’L LIBR. MED.,
https://clinicaltrials.gov/ct2/home (last visited Feb. 5, 2019) (listing, in a search for
“cannabis,” 294 studies completed or active studies outside of the United States).
601. Kevin P. Hill, Medical Marijuana for Treatment of Chronic Pain and Other Medical
and Psychiatric Problems: A Clinical Review, 313 J. AM. MED. ASS’N 2474, 2474 (2015).
602. See ClinicalTrials.gov, supra note 600. This search captured trials that are
currently recruiting or enrolling, or active but no longer recruiting. Id. The clinical
trial registry on the NIH website must include any clinical trial of a new drug that
occurs in the United States or under an IND (including under an IND but in a foreign
country) and that is not a phase 1 trial. 42 C.F.R. § 11.22 (2017). In practice, it

2019]THE SURPRISING REACH OF FDA REGULATION OF CANNABIS

921

ongoing trials generally focus on CBD and THC, presumably 9-THC,
rather than other cannabinoids.603 And, like the trials uncovered in
the historical literature review, current research focuses primarily on
treatment of pain or neurological or psychiatric conditions.604 For
instance, many are examining the effectiveness of cannabis-based
products in treating pain associated with cancer, low back pain, or
osteoarthritis of the knee.605 Some are considering use of cannabisbased products for treatment of Tourette Syndrome,606 tremor
associated with Parkinson’s Disease,607 and multiple sclerosis.608 Others

includes many phase 1 trials as well. This Article discusses the ongoing clinical trials
that relate to new therapeutic uses. Many other trials listed on the registry relate to
cannabis—for instance, examining its safety and pharmacology, and its effect on
driving, on sperm production, or breast milk. See ClinicalTrials.gov, supra note 600.
603. See ClinicalTrials.gov, supra note 600. Other cannabinoids are, however, being
studied. For example, Schrot and Hubbard reported in 2016 that a mixture of
cannabidiol and tetrahydrocannabivarin was being tested for treatment of diabetes
and metabolic syndrome. Richard J. Schrot & John R. Hubbard, Cannabinoids: Medical
Implications, 48 ANNALS OF MED. 128, 137 (2016).
604. See Hill, supra note 601.
605. See, e.g., NCT02460692, Trial of Dronabinol and Vaporized Cannabis in Neuropathic
Low Back Pain, CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/NCT0246
0692 (last updated Oct. 19, 2018) (describing a Phase 2 trial of vaporized cannabis or
dronabinol in patients with low back pain associated with nerve injury to determine
whether these drugs reduce spontaneous and evoked pain more than placebo);
NCT02324777, Cannabinoid Profile Investigation of Vapourized Cannabis in Patients with
Osteoarthritis of the Knee (CAPRI), CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct
2/show/NCT02324777 (last updated Apr. 5, 2018) (describing a Phase 2 trial of
vaporized finely ground herbal cannabis to asses analgesic dose response in patients
with osteoarthritis of the knee); NCT03339622, Safety and Efficacy of Smoked Cannabis for
Improving Quality of Life in Advanced Cancer Patients, CLINICALTRIALS.GOV,
https://clinicaltrials.gov/ct2/show/NCT03339622 (last updated Feb. 8, 2018)
(describing a Phase 3 trial of an inhaled cannabis product (dried pellet smoked with
a titanium pipe) to improve quality of life and reduce pain intensity in patients with
uncontrolled cancer pain and incurable malignancy).
606. See, e.g., NCT03247244, Safety and Efficacy of Cannabis in Tourette Syndrome,
CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/NCT03247244 (last updated
Oct. 19, 2018) (describing a Phase 2 trial considering the safety and effectiveness of
vaporized medical cannabis in treatment of adults with Tourette Syndrome).
607. See, e.g., NCT02818777, A Study of Tolerability and Efficacy of Cannabidiol on Tremor
in Parkinson’s Disease, CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show
/NCT02818777 (last updated Apr. 28, 2017) (describing a Phase 1/2 trial assessing
the tolerability and efficacy of cannabidiol oral solution in patients with tremor from
Parkinson’s Disease).
608. See, e.g., NCT03186664, The Role of Sativex® in Robotic-Rehabilitation (SARR),
CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/NCT03186664 (last updated
June 14, 2017) (detailing a trial of Sativex (nabiximols) to assess its role in improving
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are studying cannabis in treatment of psychiatric conditions such as
obsessive-compulsive disorder609 or post-traumatic stress disorder.610
Several trials are examining its use in treatment of agitation associated
with dementia,611 and one is considering oral cannabinoid formulations
in the treatment of behavioral problems in children and youth with
autism spectrum disorder.612
Where this research would lead, however, remains to be seen.
Descheduling will make it easier to develop drug candidates in the
laboratory and to conduct clinical trials. But much of the current
research is sponsored by academic researchers rather than
biopharmaceutical companies, and this could remain true after
descheduling. And in any case, whether the results would lead
experienced companies to invest in full blown premarket clinical

motor outcome when coupled with robotic neurehabilitation training in multiple
sclerosis patients).
609. See, e.g., NCT03274440, Effects of Marijuana on Symptoms of OCD (ECOS),
CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/NCT03274440 (last updated
Nov. 9, 2018) (discussing a Phase 1/2 trial of smoked marijuana in differing
concentrations of CBD and THC in patients with obsessive-compulsive disorder
(OCD)); NCT02911324, Cannabinoid Medication for Adults with OCD,
CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/NCT02911324 (last updated
Feb. 7, 2018) (explaining a Phase 1 /2 trial of nabilone in patients with OCD).
610. See, e.g., NCT02759185, Study of Four Different Potencies of Smoked Marijuana in 76
Veterans with PTSD, CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/
NCT02759185 (last updated Nov. 7, 2018) (describing a Phase 2 trial of smoked
cannabis in four variations with differing levels of THC and CBD in military veterans
with post-traumatic stress disorder (PTSD)); NCT02517424, Evaluating Safety and
Efficacy of Cannabis in Participants with Chronic Posttraumatic Stress Disorder,
CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/NCT02517424 (last updated
Apr. 18, 2018) (describing a Phase 2 trial of different potencies of vaporized cannabis
to evaluate its safety and effectiveness in treatment of chronic treatment-resistant posttraumatic stress disorder).
611. See, e.g., NCT03328676, The Effect of Cannabis on Dementia Related Agitation and
Aggression, CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/NCT03328676
(last updated Feb. 23, 2018) (reporting a Phase 2 trial of oral cannabis oil to investigate
its effectiveness and safety for treatment of subjects with agitation related to dementia);
NCT02351882, Safety and Efficacy of Nabilone in Alzheimer’s Disease, CLINICALTRIALS.GOV,
https://clinicaltrials.gov/ct2/show/NCT02351882 (last updated Aug. 10, 2018)
(evaluating a Phase 2/3 trial of nabilone to assess its safety and effectiveness in treating
agitation in patients with moderate to severe Alzheimer’s Disease).
612. See NCT02956226, Cannabinoids for Behavioral Problems in Children with ASD
(CBA), CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/NCT02956226 (last
updated Aug. 7, 2018) (describing a Phase 2 trial of two oral cannabinoid formulations
to assess their safety, tolerability, and effectiveness for behavioral problems in children
and youth with autism spectrum disorder).
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programs, in light of the likely challenges maintaining an exclusive
position in the marketplace to recover research and development
costs, remains to be seen.
C.

Dietary Supplements

The prospects for marketing medical cannabis in dietary
supplement form are more complex, and the pathway is riskier. It is a
misimpression that dietary supplements are mostly unregulated and
that labeling a product as a “supplement” is enough to mostly bypass
the FDA framework. The most important restriction is that no dietary
supplement may contain a constituent of cannabis that already appears
in an approved drug or in a drug that is the subject of clinical trials.
Although it is theoretically possible to avoid this by proving the
substance was marketed (overtly) in dietary supplements or food
earlier, the FDA takes such a conservative approach to this exception
that, in our view, pursuing the exception is unlikely to be productive.
A company that chose to move forward with another constituent (in
a dosage form for ingestion) would need to submit information and
data to satisfy the statutory safety standard. It would also need to wait
for seventy-five days or (if it was risk averse) wait for the agency to issue
a “no objection” letter. The catch, however, is that time is of the
essence; once a clinical trial of the same constituent has begun and is
made public, the dietary supplement route is legally foreclosed—even
if the supplement company is in the middle of its safety tests or waiting
for the FDA’s response. Once the seventy-five days lapse or the agency
issues a no objection letter, the company could market the dietary
supplement nationally, including with structure/function claims. But
the agency polices structure/function claims vigorously, and we
believe it would be especially vigilant with respect to cannabis-derived
dietary supplements. Finally, the full scope of the drug exclusion may
be the subject of some dispute with the agency. That CBD is excluded
is clear, but whether the FDA would attempt to treat all THCs as the
same for purposes of drug exclusion remains to be seen. The dietary
supplement pathway would be much less expensive than the new drug
pathway, but its availability is much less clear.
The competitive landscape for a dietary supplement would also be
very different. Although expensive to develop, an approved new drug
would benefit from exclusivity in the marketplace, because the FDA
would be precluded from approving generic copies for a time.
Depending on the disease being treated, the agency might also be
precluded from approving other versions that were not generic copies.
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A dietary supplement containing a constituent of cannabis, by way of
contrast, could very rapidly become one of many in the marketplace.
And without the ability to make disease-related claims, it could be
difficult for one company to differentiate its product from others.
CONCLUSION
After descheduling, all three pathways should be available for
medical cannabis products. The relative distribution of products
among these three pathways will turn on a variety of factors.613 Fully
exploring those factors and the likely distribution is beyond the scope
of this Article, but this Article makes a few preliminary observations
here based on the discussion in Parts III and IV.
Given the approval of Epidiolex, the Authors would expect smaller
pharmaceutical companies to explore the development of highly
purified cannabis constituents for rare diseases that are poorly treated
today. This will be particularly true if insurance coverage and
protection from competing drug approvals will ensure a profitably
exclusive market position for some time. The Authors also expect the
pharmaceutical pathway would be pursued for any cannabis
constituent that (based on preliminary research) seemed likely to be
highly effective, particularly for a chronic or common condition
because robust clinical evidence and the imprimatur of FDA approval
could lead in this scenario to blockbuster status.
At the same time, some patient groups and caregivers have a strong
preference for products that they perceive as more “natural” and
“holistic,” which is likely to maintain a market base for traditional
cannabis dispensaries. Thus, particularly in states that have legalized
medical marijuana and that have patient populations accustomed to
the availability of cannabis from dispensaries, intrastate-only medical
cannabis operations might flourish. Intrastate dispensaries might also
emerge in areas where consumers embrace complementary and
alternative medicine, as well as areas where consumers are more
suspicious of federal regulation.
Use of the dietary supplement pathway is harder to predict. It is
possible this pathway will be commercially advantageous only when
structure-function claims can be made. The challenge is that the
constituents must be new (not yet tested in drug trials), and yet claims
613. See, e.g., Lester Black, Legal Weed Isn’t the Boon Small Businesses Thought It Would
Be, FIVETHIRTYEIGHT (Dec. 29, 2017, 6:00 AM), https://fivethirtyeight.com/fea
tures/legal-weed-isnt-the-boon-small-businesses-thought-it-would-be.
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must be substantiated with competent and reliable scientific evidence.
Time to market will be of the essence, because of the drug exclusion rule,
so these dietary supplements may reach the market first without claims.
This pathway might be more common in situations where the physiological
benefits are uncertain. Concerns about the pricing of prescription drugs
and consumer preferences for self-medication with products perceived to
be more “natural” could also drive up usage of this pathway.

